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Transcription factors (TFs) control gene expression by binding to highly specific 
DNA sequences in gene regulatory regions. This TF binding is central to control myriad 
biological processes. Indeed, transcriptional dysregulation has been associated with many 
diseases such as autoimmune diseases and cancer. In this thesis, I studied the transcriptional 
regulation of cytokines and gene transcriptional dysregulation in cancer. Cytokines are 
small proteins produced by immune cells that play a key role in the development of the 
immune system and response to pathogens and inflammation. I mined three decades of 
research and developed a user-friendly database, CytReg, containing 843 human and 647 
mouse interactions between TFs and cytokines. I analyzed CytReg and integrated it with 
phenotypic and functional datasets to provide novel insights into the general principles that 
govern cytokine regulation. I also predicted novel cytokine promoter-TF interactions based 
on cytokine co-expression patterns and motif analysis, and studied the association of 
cytokine transcriptional dysregulation with disease. Transcriptional dysregulation can be 
caused by single nucleotide variants (SNVs) affecting TF binding sites (TFBS). Therefore, 
I created a database of altered TFBS (aTFBS-DB) by calculating the effect (gain/loss) of 
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all possible SNVs across the human genome for 741 TFs. I showed how the probabilities 
to gain or disrupt TFBSs in regulatory regions differ between the major TF families, and 
that cis-eQTL SNVs are more likely to perturb TFBSs than common SNVs in the human 
population. To further study the effect of somatic SNVs in TFBS, I used the aTFBS-DB to 
develop TF-aware burden test (TFABT), a novel algorithm to predict cancer driver SNVs 
in gene promoters. I applied the TFABT to the Pan-Cancer Analysis of Whole Genomes 
(PCAWG) cohort and identified 2,555 candidate driver SNVs across 20 cancer types. 
Further, I characterized these cancer drivers using functional and biophysical assay data 
from three cancer cell lines, demonstrating that most SNVs alter transcriptional activity 
and differentially recruit cofactors. Taken together, these studies can be used as a blueprint 
to study transcriptional mechanisms in specific cellular processes (i.e. cytokine expression) 
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Chapter 1. Introduction 
Transcription Factors and Gene Expression 
Transcription Factors (TFs) are a group of approximately 1,600 proteins that 
control gene expression by regulating transcription and their activity ultimately determines 
how cells function and respond to environmental cues (Lambert et al. 2018). The cellular 
processes TFs are involved with range from cell cycle progression to cellular 
differentiation and response to external stimuli. TFs regulate transcription by binding to 
highly specific short DNA sequences (6-12 bp) in regulatory regions such as gene 
promoters and enhancers (Wunderlich and Mirny 2009).  The DNA binding specificity of 
TFs is determined by their DNA binding domain (DBD), which has been used to group 
TFs with similar DBDs into TF families, such as nuclear receptors, C2H2 zinc fingers and 
homeodomains (Johnson and McKnight 1989; Vaquerizas et al. 2009). 
Several experimental methods have been developed to study TF binding 
specificities such as protein-binding microarrays (Berger et al. 2006), high-throughput 
systematic evolution of ligands exponential enrichment (Jolma et al. 2013), bacterial one-
hybrid (Meng, Brodsky, and Wolfe 2005), and chromatin immunoprecipitation sequencing 
(ChIP-seq) (Valouev et al. 2008b). These methods allow us to determine the motif of a TF, 
the nucleotide content in each DNA binding position, which can be used to predict the 
binding of a TF to a new DNA sequence. However, only around 60% of TFs have motifs 
characterized (Lambert et al. 2018) because experimental methods have limitations such 
as the expression, purification and post translational modifications of the TF, availability 




methods can only test one TF at a time). In addition, TFs may act in complexes and require 
interaction with co-factors in order to recruit (activate) or block (repress) RNA polymerase, 
leading to the expression or repression of its target gene (Shlyueva, Stampfel, and Stark 
2014; Spitz and Furlong 2012). Further, other factors influence TF binding to DNA such 
as chromatin accessibility, DNA methylation status, and DNA local and global topology 
(Shlyueva, Stampfel, and Stark 2014; Spitz and Furlong 2012). Even though these assays 
characterize motifs and can be used for binding predictions, they do not provide any 
functional information (i.e. gene activation/repression) and the majority of them are 
performed in-vitro. Therefore, functional assays such as reporter assays and integration of 
sequencing and transcriptomics data are required to determine how the TF binding to a 
gene regulatory affects its target gene expression in-vitro/in-vivo. 
 
Cytokine Dysregulation and Disease 
Cytokines are small proteins predominately produced by macrophages and helper 
T cells, among other immune cell types (J. M. Zhang and An 2007). Known cytokines 
range from 132 to 261 genes, as some lists include growth factors, hormones, or cytokine 
receptors (Wong et al. 2016; Al-Yahya et al. 2015; Kveler et al. 2018). Indeed, 133 have 
been compiled to be involved primarily in the immune system (Carrasco Pro et al. 2018). 
Cytokines may have autocrine, paracrine, or endocrine action in cell communication (J. M. 
Zhang and An 2007) and they play a key role in the development of the immune system as 
well as response to pathogens and inflammation (J. M. Zhang and An 2007; Medzhitov 




Cytokine expression dysregulation can be caused by mutations in gene regulatory 
regions (i.e. promoters, enhancers), changes in the TFs that regulate them, or changes in 
genes in related signaling pathways (Turner et al. 2014). This dysregulation has been 
associated with multiple diseases including autoimmune disorders, susceptibility and 
response to pathogens, and cancer (Carrasco Pro et al. 2018). For example, upregulation of 
IL-1 and IL-6 has been observed in chronic inflammatory and autoimmune disorders, 
including type I diabetes, rheumatoid arthritis, lupus nephritis, psoriasis and systemic 
sclerosis (Turner et al. 2014; Rosa et al. 2008; Kawaguchi, Hara, and Wright 1999). In 
addition, TNFa plays a central role in essential cellular functions, such as cell proliferation, 
apoptosis and necrosis (Turner et al. 2014; MacEwan 2002). However, its altered 
expression has been associated with rheumatoid arthritis (Arend and Dayer 1995), 
parkinson’s diasease (Mogi et al. 1994), and alzheimer’s disease (Holmes et al. 2009), 
among others. Further, overexpression of cytokines such as CCL2, CCL5, CCL7, IL-8, and 
CXC10 have been observed in bronchial biopsies of asthmatic patients and murine models 
(Miotto et al. 2001; Medoff et al. 2002). Finally, cytokines have been associated with 
cancer performing as growth factors (i.e. CXCL8 in melanoma, liver and pancreatic tumors) 
(Schadendorf et al. 1994; Miyamoto et al. 1998), angiogenic and angiostatic factors (i.e. 
CXCL8, CXCL10, CCL1, and CCL11) (Belperio et al. 2000; Bernardini et al. 2000; 
Salcedo et al. 2001), and playing a role in metastasis (i.e. CXCR4 and CXCR7 in breast 
cancer) (Müller et al. 2001). These vast implications of cytokines in disease require the 




describing their proper regulation as well as their dysregulation mechanisms in disease, 
which will ultimately lead to better disease diagnostics and therapeutics. 
 
 
Transcriptional Regulation and Disease 
Adapted from the following manuscript: 
1. Kok Ann Gan#, Sebastian Carrasco Pro#, Jared Allan Sewell, Juan Ignacio Fuxman 
Bass. Identification of single nucleotide non-coding driver mutations in cancer. 
Frontiers in genetics. 2018 Feb 2;9. doi: 10.3389/fgene.2018.00016. eCollection 
2018. 
# co-first authors 
Cancer initiation, progression, maintenance, and metastasis originate from somatic 
single nucleotide variants (SNVs), small insertions and deletions, structural variants, and 
epigenetic alterations (Helleday, Eshtad, and Nik-Zainal 2014a). In particular, recent 
whole-genome sequencing studies of tumor samples, through collaborative projects such 
as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium 
(ICGC), have identified millions of somatic SNVs associated with different types of 
cancers (McLendon et al. 2008; Weinstein et al. 2013; Nik-Zainal et al. 2016). Although, 
these projects and follow-up studies have been successful at identifying common sets of 
mutated genes and pathways across many cancer types, the functional role of most 
mutations detected remains to be determined. Indeed, the main challenge in analyzing the 




mutations that provide growth advantage to tumor cells) from passenger mutations (i.e., 
inert mutations that do not confer any growth advantages) (Khurana et al. 2016). This 
requires the integration of computational analyses that predict functional SNVs with 
experimental pipelines to validate and characterize those SNVs. 
Most studies have focused on characterizing the functional impact of SNVs on 
coding regions given that it is relatively straightforward to computationally predict how a 
protein sequence and/or structure will be affected by a missense, nonsense or frameshift 
mutation. However, the vast majority of SNVs identified in cancer samples reside in 
noncoding regions of the genome (Araya et al. 2016a). These noncoding SNVs can affect 
the binding of transcription factors (TFs), RNA-binding proteins (RBPs), and micro RNAs 
(miRNAs) (Figure 1.1) (Khurana et al. 2016). This in turn affects multiple gene regulatory 
functions including chromatin structure or accessibility, transcription, DNA methylation, 
splicing, as well as 5‘ and 3’ untranslated region (UTR) function, which ultimately 
increases or decreases the production, stability and translation efficiency of mRNA 





Figure 1.1 Noncoding cancer mutations affecting transcriptional and post-transcriptional 
regulation. Somatic mutations (present in tumor but not in matched normal tissue samples) can 
affect gene regulation by affecting the binding of a transcription factor (TF) to a regulatory region, 
the binding of RNA binding proteins (RBPs) or miRNAs to untranslated regions (UTRs) in the 
mRNAs, or affect normal splicing. TF – purple, RBP – orange, regulatory region – blue, UTR – 
green, coding region – yellow, SNV – red. 
Despite recent advances in the understanding of the downstream consequences of 
noncoding SNVs, it remains a challenge to identify noncoding driver mutations and the 
mechanisms through which they effect biological functions. First, as stated above, 
noncoding SNVs can affect multiple regulatory functions including transcription and post-
transcriptional regulation. Second, noncoding regions present higher mutations rates than 
coding regions, due to weaker selective pressure (Weinhold et al. 2014). As a result, 
parsing through a higher number of passenger mutations to find noncoding driver SNVs 
becomes a difficult statistical and computational task (Vogelstein et al. 2013). Third, it is 
challenging to computationally predict whether a noncoding SNV affects gene expression 
or mRNA stability because the logic involved in regulatory element function has not yet 
been fully elucidated. Thus, computational predictions of altered regulatory function need 
to be confirmed by extensive experimental validation using reporter assays, genome editing, 
measurement of endogenous gene expression, and/or chromatin immunoprecipitation.  
Early studies that identified noncoding driver SNVs compared the sequence of 
regulatory regions of candidate cancer-related genes between tumor and non-tumor 
samples in order to determine whether these mutations disrupt or create TF binding sites. 
For example, SNVs were identified in the GTAAC sequence within the first intron of MYC 
in samples from multiple patients with Burkitt lymphomas (Zajac-Kaye, Gelmann, and 




binding of a then unidentified TF. Since this early work, targeted studies have identified 
several mutations in regulatory regions, both in tumor samples and in patients with 
increased cancer incidence (Stenson et al. 2009).  
More recently, whole-genome sequencing of matched tumor and normal samples 
has enabled the identification of millions of SNVs. However, the identity of the SNVs 
responsible for driving cancer and those that constitute passenger mutations remains to be 
determined. Two pioneering studies showed that mutations present in the telomerase 
reverse transcriptase (TERT) promoter in tumor samples of patients with melanoma lead 
to increased TERT mRNA expression (S. Horn et al. 2013; Huang et al. 2013). These 
studies identified two independent C>T transitions, at around -100 bp from the TERT 
transcription starting site (TSS), that create a 11 bp nucleotide stretch containing a 
consensus binding site for E-twenty-six (ETS) TFs. Additionally, other mutations in the 
TERT promoter have been found in melanoma as well as in other cancer types such as 
ovarian, follicular thyroid, and meningiomas (Goutagny et al. 2014; S. Horn et al. 2013; T. 
Liu et al. 2014; R. C. Wu et al. 2014). More recently, mutations in the regulatory regions 
of other cancer-related genes have been identified, including recurrent mutations in the 
promoters of PLEKHS1, WDR74, SDHD, and FOXA1 that alter gene expression levels, 
TF binding and that are associated with poor prognosis (Fredriksson et al. 2014; Nik-Zainal 
et al. 2016; Rheinbay et al. 2017; Weinhold et al. 2014). Here, we present an overview of 
state-of-the-art approaches to computationally predict and functionally validate driver 




Computational approaches to identify noncoding SNVs 
 Computational approaches to predict functional SNVs within regulatory regions 
share a common general pipeline, including the identification of somatic SNVs, 
comparison with common germline variants, constraining the analysis to regulatory 
regions (in some cases, close to cancer-related genes), identification of mutational hotspots, 
and determining altered TF binding sites (Figure 1.2).  
 
Figure 1.2 Computational pipeline to prioritize somatic SNVs in regulatory elements. Whole-
genome sequencing (WGS) of matched tumor and normal samples are analyzed to identify somatic 
mutations. Identification of mutations within regulatory regions is performed by restricting 
analyses to promoter regions, generally defined around transcription start sites, and distal elements 




identify regions with increased mutational burden compared to background models based on 
mutational frequency in neighboring regions and/or regions with similar functional roles. 
Covariates such as replication timing or gene expression levels can be included to account for 
mutational heterogeneity across the genome. Motif analyses are performed to predict differential 
TF binding between SNV alleles. Prioritized noncoding SNVs are usually validated in functional 
assays. 
The identification of somatic SNVs requires comparing the genome sequences of 
tumor samples with matched normal tissue samples. This is a challenging task because 
somatic SNVs occur at low frequency in the genome (0.1 to 100 SNVs per megabase), 
which needs to be distinguished from errors derived from whole-genome sequencing and 
genome alignment pipelines (Alioto et al. 2015; M. S. Lawrence et al. 2013). Thus, most 
methods used to identify somatic SNVs require high sequencing depths (usually 30-300x) 
and paired-end reads, leading to elevated sequencing costs (Alioto et al. 2015). In addition, 
given that tumors are comprised by heterogeneous populations of cells, many functional 
SNVs may be present at a low frequency in patient samples (Carter et al. 2012; Nik-Zainal, 
Van Loo, et al. 2012). Therefore, while high-frequency SNVs can be identified provided 
that the sequencing depth is sufficient enough and that computational pipelines 
accommodate for sequence heterogeneity, low-frequency SNVs may require single-cell 
genome sequencing approaches (Eirew et al. 2015; Navin et al. 2011; Zong et al. 2012). 
Several computational methods have been developed to identify somatic SNVs, 
including: (1) those that separately call SNVs in tumor and normal samples and then 
identify tumor-specific SNVs by comparison, such as GATK (Depristo et al. 2011), 
GATKcan (Hsu et al. 2017), and EBCall (Shiraishi et al. 2013); and (2) those that 
concurrently analyze tumor-normal samples using heuristic methods or statistical models, 




(Saunders et al. 2012)  (Table 1). While the first type of methods models sequencing errors 
based on statistical parameters from the sequencing reads or from non-matched normal 
samples, the second type of methods compare matched tumor-normal samples to 
distinguish true mutations from sequencing errors. Even though these algorithms have been 
used as stand-alone methods to call SNVs, some studies have used a combination of 
methods for a “wisdom of the crowd” approach with the goal of increasing the confidence 
in the SNVs detected (Melton et al. 2015; Weinhold et al. 2014).  
 
Table 1.1. List of computational methods and databases to identify somatic SNVs, incorporate 
background models to predict functional noncoding SNVs, predict altered TF binding sites, and 
integrate with functional annotations. This list is not exhaustive, thus, the authors apologize for any 
method/database not referenced in this table. 
Hotspot analysis based on mutation frequency 
Among the millions of noncoding somatic SNVs identified in different cancers, 




experimentally test most of the SNVs identified, methods have been developed to prioritize 
which SNVs are more likely to be functional. A common approach to prioritize somatic 
SNVs is to determine genomic regions with high mutation frequency across different 
cancer samples. Given the billions of bases in the human genome, the thousands of 
mutations per cancer sample, and that we only have sequencing data for a few thousand 
tumors, the chances of detecting a significantly enriched mutation across cancers after 
multiple hypothesis testing correction is almost null.  
Currently, there are two complementary strategies, frequently used together, to 
increase the power to detect noncoding driver mutations. One strategy is to focus on DNA 
elements that are expected to have a regulatory function. For example, promoter regions 
are relatively easy to determine by selecting regions up- and downstream of transcription 
start sites, while distal elements are usually determined based on DNase hypersensitivity 
sites (DHSs) or histone marks such as H3K4me and H4K27ac (Figure 1.2) (Dunham et al. 
2012). Further, some studies constrain the analyses to the regulatory regions of cancer-
related genes such as those compiled in the Cancer Gene Census (Futreal et al. 2004). 
Overall, restricting the analysis to a set of regulatory regions reduces the search space for 
SNVs and, thus increases the power to detect driver mutations. 
 The second strategy is the identification of clusters of SNVs within short DNA 
windows, called hotspots, rather than single mutations (Figure 1.2). This reduces 
dimensionality and increases the frequency of SNVs within each DNA window leading to 
increased statistical power. The identification of these mutational hotspots across cancers 




distribution of SNV frequencies. These methods can be divided into local and global 
models, comparing the SNV frequencies to other windows in neighboring genomic regions 
or to functionally similar regions (e.g., other promoters or enhancers), respectively. The 
window size selection can vary widely between analysis, ranging from 50 bp  up to 500 kb 
(Fujimoto et al. 2016). While short windows provide higher resolution, allowing one to 
identify functional promoter or enhancer regions, they lead to low statistical power and 
thus many functional regions may be missed (Fujimoto et al. 2016). Long windows do not 
have the resolution to detect functional promoters or enhancers but allow for the 
identification of covariates, regional features associated with genomic heterogeneity in 
mutation frequency, such as replication timing and gene expression levels (Fujimoto et al. 
2016). Both types of methods can be integrated with one another to increase the chances 
of detecting driver mutations. For example, a recent study analyzing 863 human tumors 
has identified recurrent mutations in regulatory elements upstream of TERT, PLEKHS1, 
WDR74 and SDHD in different types of cancer by using 50 bp windows to find hotspots 
and regional recurrence approaches that take into account length and replication timing 
(Weinhold et al. 2014). 
  Although studies using low tumor sample numbers may be underpowered to 
identify hotspot regions, large samples sizes can also be challenging to analyze. This is 
because large sample sizes frequently lead to larger lists of potentially significant genes 
which in many cases do not have cancer-related functions, suggestive of a high false 
positive prediction rate (M. S. Lawrence et al. 2013). This stems from using background 




across genomic regions (M. S. Lawrence et al. 2013). Pipelines such as MutSigNC have 
been developed to correct for variation in mutation frequency by considering patient-
specific mutation rates, patient-specific sequencing coverage, information about regional 
mutation clustering, and using as background the mutation rates of promoters (Table 1) 
(Rheinbay et al. 2017). Other computational frameworks have also been used to also 
include distal elements in the analyses, including LARVA that incorporates background 
models for noncoding regions by integrating SNVs with a comprehensive set of noncoding 
functional elements based on DHSs and histone marks (Table 1) (Lochovsky et al. 2015). 
In addition, LARVA uses regional genomic features like replication timing allowing to 
better estimate local mutation rates and mutational hotspots.  
Further covariates can be included while modelling mutation frequencies. For 
instance, recent studies have shown that some breast tumors have mutations mediated by 
the alipoprotein B messenger RNA-editing enzyme catalytic (APOBEC) which have been 
found to occur in dense hypermutated regions in the genome (kataegis) (Alexandrov et al. 
2013; Nik-Zainal, Alexandrov, et al. 2012). These mutations share a sequence pattern 
(TCW, where W is A/T), which can be used to assign mutations a probability of being 
originated by APOBEC activity (Roberts et al. 2013), leading to a more conservative 
approach to call candidate mutations. This approach identified SNVs in breast cancer 
samples within the regulatory regions of FOXA1, RMRP, and NEAT1 that affect gene 
expression levels (Rheinbay et al. 2017). Alternatively, covariates can be avoided 
altogether by using a non-parametric, permutation-based approach such as MOAT, that 




background-mutation rate changes smoothly with genomic features (Table 1) (Lochovsky 
et al. 2015). The variety of co-existing computational approaches, background models, and 
covariates included in those models, highlights the challenges currently faced in identifying 
mutational hotspots associated with cancer. 
Prediction of noncoding SNVs with high functional impact 
Hotspot analyses allow for the prioritization of cancer driver candidate SNVs. 
However, to further narrow down the set of functional SNVs and predict the functional 
impact of these SNVs, location and sequence context of the mutations must be integrated 
with functional models of noncoding regions. One of the most widely used approaches to 
prioritize SNVs in regulatory regions involves the identification of TF binding sites created 
or disrupted by the mutations (Figure 1.2). These TF binding differences between SNV 
alleles can be predicted based on DNA specificities determined by protein-binding 
microarrays, SELEX, bacterial one-hybrid assays, or chromatin immunoprecipitation 
(ChIP) followed by next generation sequencing (ChIP-seq) (Jolma et al. 2013; Noyes et al. 
2008; Weirauch et al. 2014). Currently, DNA binding specificities have been determined 
for nearly half of human TFs, which are available in different repositories such CIS-BP, 
Jaspar, Uniprobe, and Transfac (Table 1) (Hume et al. 2015; Weirauch et al. 2014; Matys 
et al. 2003; Khan et al. 2018). Differences in TF binding between SNV alleles can be 
predicted using position weight matrices (PWMs), probabilistic representations of DNA 
binding specificities, and motif prediction algorithms such as FIMO (Grant, Bailey, and 
Noble 2011), MotifbreakR (Coetzee, Coetzee, and Hazelett 2015), BEEML-PBM (Hume 




Claeys et al. 2012) (Table 1). For example, MotifLocator, a tool to score how mutations 
affect wild-type TF binding sites, led to the identification of gain of binding sites for RB1, 
E2F1 and ETS to multiple promoter regions in tumor samples from TCGA (Kalender Atak 
et al. 2017). Similarly, mutations in the promoter of FOXA1, a known gene driver in breast 
cancer, were found to increase E2F binding using TFM-pvalue (Rheinbay et al. 2017). Loss 
of TF binding sites have also been widely associated with cancer. For example, many 
recurrent mutated regions in cancer genomes have been found to overlap with CTCF 
binding sites, showing a possible selection for these mutations (Katainen et al. 2015; 
Lochovsky et al. 2015; Piraino and Furney 2017). In addition, disruption of FOX TF 
binding sites in the BCL6 promoter have been reported in follicular lymphoma using an 
integrative approach that identifies functional regulatory mutation blocks (Batmanov et al. 
2017). Interestingly, both the creation and disruption of binding sites for the same TFs have 
been linked to cancer. For example, by integrating motif analyses with evolutionary 
conservation, creation of ETS binding sites were determined in the ANKRD53 promoter, 
while disruption of ETS binding sites were identified in the TAF11 and SDHD promoters 
(Weinhold et al. 2014). 
In addition, motif analyses can integrate functional annotations of regulatory 
sequences (including DHSs, histone marks, and sequence conservation) and TF expression 
levels such as those provided by the ENCODE, Roadmap Epigenomics, FANTOM, and 
GTEx Projects to constrain the analyses to TFs expressed and regulatory elements active 
in the tissues of interest (Andersson et al. 2014; Dunham et al. 2012; Lonsdale et al. 2013; 




RegulomeDB (Boyle et al. 2012) that considers functional annotations for the regulatory 
regions, and Funseq2 (Fu et al. 2014) that also considers sequence conservation across 
species and recurrence of somatic mutations in cancer (Table 1).  
Although motif analyses have been instrumental to predict altered TF binding, these 
methods are limited by the availability of high-quality PWMs and by the high false positive 
and false negative predictions rates of motif finding algorithms (Sewell and Fuxman Bass 
2017; Weirauch et al. 2014; Zia and Moses 2012). Indeed, motif analyses can rarely 
distinguish between different members of a TF family, and often miss the TF that 
differentially binds to SNV alleles (Weirauch et al. 2014). Thus, SNVs in regulatory 
regions predicted to be functional based on hotspot and motif analyses, need to be 
experimentally tested to determine whether these mutations actually affect TF binding. 
Experimental validation of differential TF binding between SNV alleles 
 Multiple complementary experimental methods can be used to determine TF 
binding including ChIP, electrophoretic mobility shift assays (EMSA), and enhanced yeast 
one-hybrid (eY1H) assays (Figure 1.3). ChIP has been successfully used to study 
differential TF binding between noncoding SNV alleles in vivo (Figure 1.3A). For example, 
several studies have identified mutations in the TERT promoter, such as G228A, that lead 
to the creation of de novo bind site for ETS factors (S. Horn et al. 2013; Huang et al. 2013). 
However, the identity of the specific ETS factor involved remained elusive until a recent 
study analyzing ChIP-seq data from the ENCODE Project (Dunham et al. 2012), identified 
GABPA as the TF that differentially binds and regulates TERT expression. In particular, 




the G228A mutation, specifically to the mutant allele, while other ETS factors did not show 
significant binding. Although ChIP is the method of choice to validate in vivo differential 
TF binding between alleles, this method requires a priori TF candidates as it can only test 
one TF at a time. Further, given that ChIP tests for in vivo TF binding, experiments need 
to be performed in cell lines harboring the mutations or using patient samples, which are 
frequently challenging to obtain.  
 
Figure 1.3 Overview of assays to measure differential TF binding between noncoding SNV 
alleles. (A) ChIP against a candidate TF can be performed in cells that are heterozygous for the 
SNV. Sequencing of the amplified regions (or allele-specific qPCR) can determine relative TF 
binding between wild-type (wt) and mutant (mut) alleles. Alternatively, ChIP-seq data can be 
analyzed to detect biases in the number of sequencing reads between alleles. The figure shows an 
example of loss of TF binding caused by a mutation. (B) EMSA can be performed to determine 
differential TF binding to oligonucleotides containing wild-type (wt) or mutant (mut) SNV alleles 
by using nuclear extracts (NE) followed by super-shifts using antibodies against the candidate TF 
(α-TF), or by incubating with extracts overexpressing the TF. (C) eY1H assays can test the binding 
of >1,000 TFs to wild-type and mutant allele sequences. In this assay, each DNA sequence is cloned 
upstream the HIS3 and LacZ reporters and integrated into the yeast genome. Interactions are tested 
by mating with yeast strains expressing different TFs in an arrayed format system. Differential TF 
interactions (highlighted in red) can be determined by comparing screening results between alleles. 
 
A recent study using enhanced yeast one-hybrid (eY1H) assays, a method that tests 
protein-DNA interactions in the milieu of the yeast nucleus, has increased the screening 




parallel, without the need for antibodies or patient samples (Figure 1.3C) (Fuxman Bass et 
al. 2015). Although this study has focused on germline variants associated with different 
genetic diseases, the experimental eY1H pipeline can also be used to evaluate somatic 
SNVs in cancer. Given that ChIP, EMSA and eY1H assays measure physical DNA binding, 
rather than regulatory activity, interactions identified by these methods need to be tested in 
human cell lines to determine the SNV impact on gene regulation by using transient 
reporter assays, or endogenous gene expression measurements following TF 
knockdown/knockout. 
Experimental validation of altered gene expression by SNVs 
 Driver mutations that affect regulatory regions are expected to affect the expression 
of a target gene. Functional validation assays such as those using luciferase reporters have 
been widely used to determine expression differences between noncoding SNV alleles 
(Figure 1.4A) (Denisova et al. 2015; Fuxman Bass et al. 2015; Huang et al. 2013; Rheinbay 
et al. 2017). In addition, reporter assays can be used to validate differential TF binding 
determined based on physical binding assays, by overexpressing or knocking down TF 
expression and measuring the impact on reporter activity driven by the wild-type or mutant 
regulatory sequences. Although useful for functional validation, reporter assays are 





Figure 1.4 Functional assays to measure altered gene expression and phenotypic parameters 
induced by SNVs in regulatory regions. (A) Reporter assays can be used to determine differential 
expression induced by wild-type and mutant regulatory elements in transiently transfected cells. (B) 
In MPRAs wild-type and mutant alleles for hundreds/thousands of noncoding SNVs can be tested 
in parallel for changes in transcriptional activity. ~200 bp sequences containing the SNVs are 
cloned upstream of an inert ORF and associated with random barcodes. Cells are then transfected 
with the pooled library, ORF-specific mRNA is isolated, and barcode tags are counted using next-
generation sequencing (NGS). By comparing the number of reads per allele in the mRNA and the 
plasmid populations, relative expression levels can be determined. (C) Functional validation and 
follow-up studies can be performed by determining differences in endogenous gene expression, 
proliferation, migration, and viability, among other assays, using cells engineered to carry the 
mutation. 
Recent studies using massively parallel reporter assays (MPRAs), a high-
throughput technology based on barcodes and next generation sequencing, have made 
progress in determining whether germline SNVs associated with genetic disorders affect 
transcriptional regulation (Figure 1.4B) (Melnikov et al. 2012; Tewhey et al. 2016; Ulirsch 
et al. 2016; Mogno, Kwasnieski, and Cohen 2013). In particular, differential transcriptional 
activity has been detected for hundreds of expression quantitative trait loci (eQTL) and 




expected that MPRAs will constitute an essential tool for identifying functional noncoding 
somatic SNVs. Although powerful, MPRAs are not free of caveats. For instance, current 
oligonucleotide synthesis pipelines only allow for a maximum DNA fragment length of 
~230 nucleotides. Thus, noncoding mutations are not usually tested within full length 
regulatory elements (that can be up to several kilobases), which may be hamper the ability 
of MPRAs to detect changes in gene expression. This limitation may be overcomed as 
pooled and arrayed oligonucleotide synthesis technologies are adapted to generate longer 
DNA sequences. Another limitation of MPRAs is that reporter activity is generally tested 
using episomal constructs, or randomly integrated lentiviral constructs, that do not reflect 
the endogenous genomic context where the noncoding mutations reside (Tewhey et al. 
2016; Ulirsch et al. 2016). Thus, the functional effect of many SNVs on target gene 
expression may be over or underestimated. Downstream validation studies in the 
appropriate genomic context can be conducted by introducing the SNV in the endogenous 
locus using genome editing technologies such as the CRISPR/Cas9 system, zinc finger 
nucleases, or transcription activator-like effector nucleases (Figure 1.4C) (Claussnitzer et 
al. 2014; Elkon and Agami 2017).  These studies, ultimately need to be followed-up using 
assays that demonstrate the biological significance of the SNVs in cancer by measuring 
different oncogenic properties such as invasion, proliferation, and viability (Figure 1.4C). 
SNVs affecting distal regulatory elements 
 Compared to promoters, dissecting the functional effects of mutations in distal 
regulatory elements such as enhancers is a more complex task as it is not trivial to 




identity of the target gene involved. This, and the fact that including distal elements in 
hotspot analyses increases the search space and reduces statistical power are the main 
reasons why most studies characterizing germline and somatic noncoding SNVs have 
focused on promoter regions (Rheinbay et al. 2017; Stenson et al. 2014).  
Several technologies have been used to identify promoter-enhancer pairs 
interacting through chromatin loops. These methods, that involve crosslinking and ligation 
of spatially closed genomic regions, such as Hi-C (Lieberman-Aiden et al. 2009) and 
chromatin conformation capture by paired-end tag sequencing (ChIA-Pet) (G. Li et al. 
2012), have been used to capture the potential regulatory effect of enhancer mutations. For 
example, a recent study found that a somatic SNV (C>T) four kilobases upstream of the 
transcriptional start site of the LMO1 oncogene generated a de novo binding site for the 
MYB TF in patients with T-cell acute lymphoblastic leukaemia (Yongsheng Li et al. 2017). 
A combination of ChIP-Seq of MYB, followed by ChIA-PET and luciferase assays 
revealed that this mutation induced the formation of an aberrant transcriptional enhancer 
complex leading to increased expression of the LMO1 oncogene. Thus, integration of 
chromatin interaction data can identify the gene targets of distal regulatory elements and 
determine how mutations in those elements affect looping interactions leading to changes 
in gene expression.  
Noncoding SNVs affecting post-transcriptional regulation 
 Noncoding mutations not only affect transcriptional regulation but can also affect 
other biological processes such as mRNA stability, translation efficiency or splicing. 




interactions with RNA-binding proteins and miRNAs (Figure 1.1) (Khurana et al. 2016). 
For example, mutations in the 5’UTR of RB1 alter UTR conformation and mRNA stability 
in retinoblastoma (Kutchko et al. 2015), while mutations in the 5’UTR of BRAC1 in breast 
cancer patients reduce translation efficiency (Signori et al. 2001; Wang et al. 2007). In 
addition, mutations in the 3’UTR of BRCA1 were found to introduce a functional miRNA-
103 target site in a breast cancer case leading to reduced BRAC1 levels (Brewster et al. 
2012). As with SNVs in transcriptional regulatory regions, the functional impact of UTR 
mutations need to be tested in experimental assays. Low-throughput reporter assays have 
been used to quantify differences in mRNA levels by cloning the relevant UTR regions 
upstream or downstream of the coding region of GFP or luciferase. More recently, 
massively parallel functional annotation of sequences from 3' UTRs (fast-UTR) has been 
developed, which was used to discover 87 novel cis-regulatory elements and measure the 
effects of known gene variations in 3’UTRs (Zhao et al. 2014).  
Mutations in the exon-intron boundaries, introns, and coding regions can affect 
splicing and lead to the upregulation oncogenic isoforms or the downregulation of tumor 
suppressor isoforms. Various cancer tumor suppressor genes such as TP53, ARID1A, 
PTEN, CHD1, MLL2, and PTCH1 were found to carry mutations in the exon-intron 
boundaries which led to intron retention (Jung et al. 2015; Supek et al. 2014). An intronic 
mutation in BRAF induces the expression of a splice variant that confers resistance to 
vemurafenib treatment in melanoma (Salton et al. 2015). These aberrant or cancer-specific 
isoforms are generally detected using short- and/or long-read mRNA sequencing, and are 




high-throughput assay formats (Cavelier et al. 2015; Gaildrat et al. 2010; Yongsheng Li et 
al. 2017; Rosenberg et al. 2015). 
Future perspectives 
 Recent studies have identified a handful of somatic SNVs in regulatory regions that 
affect TF binding and target gene expression. However, the number of functional 
noncoding SNVs associated with cancer is expected to be much higher given the low 
overlap between those reported in different studies, and given that noncoding SNVs seem 
to play an important role in disease based on the hundreds of functional noncoding SNVs 
identified in genome-wide association and genetic studies (Stenson et al. 2014). Advances 
in several areas will be needed to increase our ability to identify these driver mutations. 
First, larger numbers of tumor samples with available whole-genome sequence data are 
needed to increase statistical power in prediction algorithms. Second, more refined 
background models in hotspot analyses that take into account multiple covariates will help 
identify functional regulatory regions in cancer. Finally, improvements in motif analyses 
will be needed through the generation of PWMs for uncharacterized TFs and by identifying 
in silico parameters that can accurately predict differential TF binding between alleles.   
Another source of underestimation of noncoding driver SNVs stems from the 
hotspot analysis itself as it assumes that driver mutations in a particular regulatory region 
should be present in multiple patients. Given the hundreds of thousands of regulatory 
elements in the human genome we may be far from having a sample size sufficiently large 
to detect most functional SNVs. An alternative approach would be to lower the stringency 




using MPRAs to identify functional variants. Ultimately, a combination of computational 
and experimental methods along with new technical innovations will increase our ability 
to identify and characterize the mechanisms by which noncoding SNV drive cancer. 
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Dissertation aims  
The aims in this dissertation seek to develop novel algorithms and resources to aid 
in the analysis of transcriptional regulation in the context of cytokine expression and 
dysregulation of TFBS by SNVs. Together, these aims will show that we can predict and 
validate novel regulatory mechanisms for cytokines, determine the probabilities of creating 
and disrupting TFBS, and discover and validate cancer drivers in gene promoters. The three 




Aim 1. Determine the transcriptional regulation landscape of cytokines in mouse and 
human 
Aim 2. Predict genome-wide effects of single nucleotide variants in transcription factor 
binding 






Chapter 2. Global landscape of mouse and human cytokine transcriptional 
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Introduction 
 Cytokines comprise an array of polypeptides that are critical in the development of 
the immune system and in the regulation of immune and autoimmune responses (Griffith, 
Sokol, and Luster 2014). The published lists of human cytokines range from 132 to 261 
genes depending on whether growth factors, hormones, or the receptors of cytokine genes 
are included (Wong et al. 2016; Al-Yahya et al. 2015; Kveler et al. 2018). Here, we focus 
on 133 cytokine genes, with a primary role in the immune system, shared by different 
publications.  
Cytokine dysregulation is associated with myriad diseases including autoimmune 
disorders, susceptibility to infections, and cancer (Griffith, Sokol, and Luster 2014; Homey, 
Müller, and Zlotnik 2002; Netea et al. 2003; Neurath 2014; O’Shea, Ma, and Lipsky 2002). 
The expression of cytokine genes is primarily regulated at the transcriptional level through 
a combination of tissue-specific (TS) transcription factors (TFs) that control cytokine 




respond to signaling pathways activated by pathogen-derived ligands or endogenous 
inflammatory mediators (Murphy and Reiner 2002; Medzhitov and Horng 2009). Although 
cytokine transcriptional regulation has been studied for more than three decades, including 
hallmark models of transcriptional regulation such as the IFNB1 enhanceosome (Thanos 
and Maniatis 1995), we currently lack a comprehensive view of the gene regulatory 
network (GRN) involved in controlling cytokine gene expression.  
Several databases have been generated that annotate protein-DNA interactions 
(PDIs). InnateDB reports interactions between TFs and immune-related genes retrieved 
from different databases such as PubMed and IntAct, a subset of which have been manually 
curated (Breuer et al. 2013). TRRUST reports interactions involving immune and non-
immune genes (Han et al. 2015), obtained by data mining and curating article abstracts 
from Pubmed. However, the overlap between these databases is generally low (20% 
overlap for cytokine genes), suggesting that they may be incomplete and/or may contain 
misannotated PDIs. This limits our understanding of the combinatorics involved in 
cytokine transcriptional regulation, especially in terms of the balance between TS and PSA 
TFs regulating each cytokine gene, the cooperativity and plasticity in cytokine regulation, 
and the relationship between TF connectivity and immune phenotype/disease.  
Here, we mine through three decades of research to generate a comprehensive and user-
friendly database, CytReg (http://cytreg.bu.edu), comprising 843 human and 647 mouse 
interactions between TF and cytokine genes. We analyze this cytokine GRN and integrate 
it with phenotypic and functional datasets to provide novel insights into the general 




connectivity in the cytokine GRN and immune phenotype. We observe that the balance 
between PSA and TS TFs is shifted towards PSA TFs for interferons and pro-inflammatory 
cytokines and we provide a model for cooperative and plastic recruitment of cofactors to 
cytokine promoters. Using this cytokine GRN, we also provide a blueprint for further 
studies of cytokine misregulation in disease and identify novel TF-disease associations. 
Finally, we discuss biases and the completeness of the literature-derived cytokine GRN, 
and provide predictions for novel interactions which we validate using enhanced yeast one-
hybrid (eY1H) and reporter assays in human cells. 
Materials and Methods 
Generation of CytReg 
 
To obtain a comprehensive list of physical and regulatory PDIs between TFs and 
cytokine genes we mined the XML files from ~26 million articles available in Medline on 
July 10th 2017, using NBCI’s e-utilities python implementation, for studies mentioning a 
cytokine, a TF, and an experimental assay. Three broad categories of assays (chromatin 
immunoprecipitation, electrophoretic mobility shift assays, and functional assays), 1431 
TFs, and 133 cytokines were considered. Alternative names for TFs and cytokines were 
obtained from the HUGO Gene Nomenclature Committee (www.genenames.org) and 
curated from the literature. Alternative spellings for names that include Greek letters or 
hyphens were also considered in the data mining.  
The resulting 6,878 articles, together with 815 articles annotated in databases such 
as TRRUST (Han et al. 2015) and InnateDB (Breuer et al. 2013), were manually curated 




generated containing, for each mined interaction, the TF and cytokine HGNC names, the 
TF and cytokine names used in the paper, the type of assay, and the PubMed ID of the 
paper. Curation was performed based on the entire publication, rather than the abstract 
alone, because in some cases, PDIs reported in the abstract were based on indirect evidence 
and in other cases many PDIs identified were only reported in the body of the publication 
or in the figures. In addition to validating or rejecting mined PDIs, curators annotated the 
species, the functional activity (activating or repressing) if reported, and additional PDIs 
absent in the mined list but present in the body of the paper. Each PDI was curated by two 
independent researchers, and disagreements were resolved by a third senior curator. The 
resulting database contains 1,552 PDIs (843 in human, 647 in mouse, and 62 from other 
species) for which we annotated the assay used and the regulatory activity identified. To 
visualize this complex cytokine GRN we developed CytReg (https://cytreg.bu.edu), a web 
tool where PDIs can be browsed by species, TFs, cytokines, assay types, and TF expression 
patterns across different cell-types. In addition, links are provided to Uniprot entries 
(http://www.uniprot.org) for cytokine and TF genes, and to PubMed articles for the PDIs. 
Determination of the level of evidence for PDIs 
 
We classified PDIs as high or low evidence of being direct regulatory interactions. 
PDIs detected by a functional assay (e.g., reporter assays and TF knockdown) and an assay 
measuring direct binding (e.g., chromatin immunoprecipitation and in vitro binding assays) 
were classified as high evidence. PDIs detected by only one type of assay were classified 




Determination of the relationship between TF connectivity and gene expression 
 
The median transcript per million (TPM) expression levels in 20 immune cell-types 
for TFs with different connectivity in the human cytokine GRN was determined based on 
expression data published by the Blueprint Epigenome Consortium (Stunnenberg et al. 
2016) (http://dcc.blueprint-epigenome.eu). In addition, an expression enrichment score in 
immune tissues compared to non-immune tissues was determined based on data from 32 
tissues from the Expression Atlas (https://www.ebi.ac.uk/gxa/experiments/E-MTAB-
2836). Briefly, a pseudocount of 1 was added to all the expression data to reduce the noise 
from low abundant transcripts. Then, the expression of a TF in a tissue was divided by the 
average expression of the TF across the 32 tissues to obtain an expression enrichment score. 
Finally, the average enrichment score per TF was determined for the five immune tissues 
(lymph node, bone marrow, spleen, tonsils, and appendix) and for the remaining 27 non-
immune tissues in the dataset. 
Associations between TFs and immune phenotypes and diseases 
 
The association between TFs and immune phenotypes was determined based on 
phenotypes in knockout mice reported by the Mouse Genome Informatics database 
(www.informatics.jax.org) as of January 12th 2018. Thirty different terms including 
different immune cells, antibody isotypes, cytokines, inflammation, and immune tissues 
were used to determine whether a reported phenotype should be classified as immune-
associated. 
Association between TFs and immune disorders (including autoimmune diseases 




2013 release and from genome-wide association studies (GWAS) downloaded on July 27th 
2017 from the NHGRI-EBI Catalog (MacArthur et al. 2017; Stenson et al. 2014). 
TF enrichment in PDIs with cytokines expressed in different immune cell types 
 
For each TF, we compared the proportion of cytokine targets corresponding to 
cytokines expressed in a specific immune cell type, to the proportion of the remaining 
cytokine targets. A proportion comparison test was used to determine a p-value and a 
Benjamini- Hochberg adjusted p-value to account for multiple hypothesis testing. 
Pathogen/stress-activated and tissue specific TFs 
 
PSA TFs were determined from the literature based on their ability to be activated 
or responsive to signaling pathways triggered by pathogen-associated molecular patterns 
and/or stress signals (e.g., oxidative stress, heat shock, and danger-associated molecular 
patterns). Tissue specific TFs were determined by calculating a tissue-specificity score 
(TSPS) based on expression data from 34 different tissues and cells as previously described 
(Ravasi et al. 2010): 
𝑇𝑆𝑃𝑆 = 	&𝑝(. 𝑙𝑜𝑔-(
𝑝(
𝑝 ) 
where pi corresponds to the ratio between the expression level in a tissue and the sum of 
the expression levels across all 34 tissues; and p corresponds to the expected ratio under 
the assumption of equal expression across all tissues. TFs were considered tissue-specific 
(TS) if their TSPS ≥ 0.7, a threshold selected based on the bimodal distribution of TSPS 
across all TFs. TFs for which a TSPS could not be calculated because of unavailable 




Determination of TF inflammatory scores 
 
For each TF, an inflammatory score (IS) was determined as the difference between 
the percentage of PDIs with canonical pro-inflammatory cytokines (IL1A, IL1B, IL12A, 
IL12B, IL18, TNF, IFNG, CSF2, CXCL8, and IL6), and the percentage of PDIs with anti-
inflammatory cytokines (IL10, IL11, IL13, IL19, IL1RN, IL24, IL37, IL4, IL5, CXCL17, 
TGFB1, TGFB2, and TGFB3). For TFs with IS ≥ 0.5 or IS ≤ -0.5 we determined the 
percentage that have a pro- or anti-inflammatory role, or a role in differentiation based of 
phenotypes in knockout mice (www.informatics.jax.org). 
TF-disease association 
 
For each disease (asthma, systemic lupus erythematosus, inflammatory bowel 
disease, type 2 diabetes, rheumatoid arthritis, tuberculosis infection, and cytomegalovirus 
infection) the Expression Atlas (www.ebi.ac.uk) was searched for cytokines upregulated 
in the disease state, using a cut-off of 2-fold induction. TFs enriched in regulating the 
upregulated cytokines were determined from the human cytokine GRN using the Fisher’s 
exact test. Multiple hypothesis testing was corrected by calculating the Benjamini-
Hochberg adjusted p-value and using an FDR threshold of 0.1. The resulting TF-disease 
associations were plotted using a Circos plot (http://mkweb.bcgsc.ca/tableviewer/).  
TF and cytokine association with autoimmune diseases 
 
TFs and cytokines associated with different autoimmune diseases were obtained 
from the Human Gene Mutation Database 2013 release, and from GWAS downloaded on 




The union of gene-disease associations between both databases was considered. Crohn’s 
disease and ulcerative colitis were grouped with inflammatory bowel disease. This list 
includes coding and noncoding variants, and thus variants that affect protein function or 
expression levels. Of note, this list of gene-disease associations is not comprehensive as it 
only includes associations identified in genetic studies (i.e., does not consider 
environmental or epistatic factors that affect cytokine expression). Significance for 
enrichment of shared autoimmune diseases between interacting TFs and cytokines was 
determined by comparing to 1,000 randomized versions of the human cytokine GRN. 
Network randomization was performed by edge switching as previously described 
(Martinez et al. 2008). 
TF-drug associations 
 
TF-drug associations and information regarding drug function were obtained from 
Drugbank (Wishart et al. 2018). Agonists and activators were grouped as agonists, 
antagonist and inhibitors were grouped as antagonists. For each cytokine, the number of 
TFs targetable by agonists or antagonists was determined. 
Prediction of novel PDIs in the human cytokine GRN 
 
To predict novel PDIs in the human cytokine GRN, for each TF, SEEK (Q. Zhu et 
al. 2015) was used to search for the top 100 genes co-expressed with the known cytokine 
targets of the selected TF across more than 5,000 expression profiling datasets. Then, for 
each cytokine within those 100 genes, the presence of binding sites for the selected TF in 




the Scan DNA sequence tool in CIS-BP (http://cisbp.ccbr.utoronto.ca/), the PWM-
Logodds algorithm, and a stringent threshold of ten (Weirauch et al. 2014). Enrichment for 
human PDI predictions reported in mouse was determined by calculating an odds ratio and 
statistical significance was calculated using the Chi-square test. The 1,066 predicted 
interactions were classified according to confidence: high (two or more TF binding sites 
and evidence of interaction in the mouse cytokine GRN), medium (two or more TF binding 
sites but absent from the mouse cytokine GRN, or less than two binding sites but presence 
in the mouse cytokine GRN), and low (one binding site and absent from the mouse cytokine 
GRN).  
Enhanced yeast one-hybrid (eY1H) assays 
 
eY1H assays were used to detect interactions between TFs and cytokine gene 
promoters (Reece-Hoyes, Barutcu, et al. 2011; Reece-Hoyes, Diallo, et al. 2011). This 
method involves two components: a ‘DNA-bait’ such as cytokine gene promoter, and a 
‘TF-prey’. The DNA-bait is cloned upstream of two reporter genes (LacZ and HIS3) and 
both constructs are integrated into the yeast genome (Fuxman Bass, Reece-Hoyes, and 
Walhout 2016a; 2016b). The DNA-bait strains generated are then mated with yeast strains 
expressing TFs fused to the yeast Gal4 activation domain (AD), and if the TF binds the 
regulatory region, the AD moiety activates the reporter genes. Reporter gene activity is 
measured by the conversion of colorless X-gal to a blue compound, and by the ability of 
the yeast to grow on media lacking histidine and to overcome the addition of 3-amino-
triazole (3AT), a competitive inhibitor of the His3 enzyme. Each interaction was tested in 




transcription start site) of cytokine genes were generated as previously described (Fuxman 
Bass, Reece-Hoyes, and Walhout 2016b; Fuxman Bass et al. 2015). The promoter regions 
of CXCL10, CXCL8, CXCL3, CCL4, and CCL20 were screened for REL binding, while 
promoter regions for IL17A, IL17F, and IL26 were screened for RORC binding. To 
identify TFs that interact with the promoters of CCL27 and CCL4L2, the CCL27 and 
CCL4L2 DNA-bait strains were screened against an array of 1,086 human TFs (Fuxman 
Bass et al. 2015). 
Motif analysis 
 
Binding of REL, RORC, RBPJ, TFAP2A/B, PPARG, ATF3, EBF1, ZIC1/3, 
GCM1, and WT1 were predicted using CIS-BP via the Scan DNA sequence tool, using the 
PWM-LogOdds method and a stringent threshold of ten (Weirauch et al. 2014). Motif 
analyses were performed on the same 2 kb regions upstream of the transcription start sites 
used to perform the eY1H assays. 
Transient transfections and luciferase assays 
 
HEK293T cells were plated in 96-well opaque plates (~1 x 104 cells/well) 24 hours 
prior to transfection in 100 µl DMEM + 10% FBS + 1% Antibiotic-Antimycotic 100X. 
DNA-bait luciferase reporter clones were generated by cloning the cytokine promoter 
regions upstream of the firefly luciferase into a Gateway compatible vector generated from 
pGL4.23[luc2/minP] (Fuxman Bass et al. 2015). TF-prey clones were generated by 
Gateway cloning the TF into a vector derived from pEZY3 (Addgene) to generate fusions 




with Lipofectamine 3000 (Invitrogen) according to the manufacturer’s protocol using 20 
ng of the DNA-bait luciferase reporter vector, 80 ng of the TF-pEZY3-VP160 vector, and 
10 ng of renilla luciferase control vector. The empty pEZY3-VP160 vector co-transfected 
with the recombinant firefly luciferase plasmid was used as a negative control. 48 hours 
after transfection, firefly and renilla luciferase activities were measured using the Dual-Glo 
Luciferase Assay System (Promega) according to the manufacturer’s protocol. Non-
transfected cells were used to subtract background luciferase activities, and then firefly 
luciferase activity were normalized to renilla luciferase activity. 
Code availability 
 




Statistical analyzes were performed using GraphPad Prism Version 7.01, Excel 
2016, or VassarStats (http://vassarstats.net). All tests performed were two-tailed tests. 
Software used to generate the figures 
 
Box, bar, histogram, and correlation plots were generated using GraphPad Prism 
Version 7.01. Heatmaps were generated using matrix2png (https://matrix2png.msl.ubc.ca/). 
Networks were generated using Cytoscape Version 3.2.1 (http://www.cytoscape.org/).  
Results 





To obtain a comprehensive cytokine GRN, we systematically mined ~26 million 
articles in Medline for studies mentioning at least one of 133 cytokines, one of 1,431 TFs, 
and an experimental assay (Figure 2.1A). The resulting 6,878 articles, and 815 additional 
articles referenced in TRRUST (Han et al. 2015) and InnateDB (Breuer et al. 2013), were 
then manually curated to determine whether experimental evidence for the physical and 
regulatory PDIs was provided. This resulted in a list of 1,552 PDIs (843 in human, 647 in 
mouse, and 62 in other species), for which we annotated the assay used and the regulatory 
activity identified (Figure 2.1A). To visualize this GRN we developed a database, CytReg 
(https://cytreg.bu.edu), where users can browse PDIs by species, TF, cytokine, assay type, 
and TF expression patterns (Figure 2.1B). Links are provided to Uniprot entries for TFs 
and cytokines, and to PubMed articles reporting the PDIs (Figure 2.1C). Finally, the 
selected PDIs can be visualized as networks showing the TFs, cytokines, and the types of 





Figure 2.1 Differentially Generation of CytReg. (A) Pipeline used for the text mining and article 
curation to determine literature-based PDIs between TFs and cytokine genes. (B) Search page of 
CytReg where PDIs can be browsed by TF, cytokine, species, assay type, and TF expression levels 
(mRNA and protein) in different immune cells. (C) Results page indicating the interacting 
cytokines and TFs, the types of assays used to determine the PDIs, whether the interaction is 
activating or repressing, and the Pubmed IDs of the publications referencing the PDIs. Links are 
provided to UniProt entries for cytokines and TFs, and to Pubmed for the references. The 
interactions can be downloaded as a CSV file or visualized as a network graph. (D) Network 
visualization of the selected PDIs. Nodes represent cytokines and TFs, edges represent the type of 
interaction (activating, repressing, bifunctional, or physical). Nodes can be moved to re-arrange the 
network. (E) Overlap of PDIs in CytReg and those annotated in InnateDB and TRRUST. (F) 





























Activating, repressing, and bifunctional
interactions are based on functional
assays. Physical interactions are those
determined by ChIP or in vitro binding
assays, but not functional assays.














































direct regulatory activity (by a functional assay and an in vitro or in vivo binding assay) or low 
evidence (by one type of assay). 
CytReg contains an additional 371 human and 264 mouse PDIs compared to 
TRRUST and InnateDB (Figure 2.1E). We also removed 243 PDIs annotated in TRRUST 
and InnateDB when: a) the article did not provide direct experimental evidence for the PDI, 
b) the TF interacted with the regulatory region of a cytokine receptor rather than that of a 
cytokine, or c) the cytokine regulated the activation pathway of a TF rather than the TF 
regulating a cytokine. Altogether, CytReg greatly expands the PDIs annotated in other 
databases and removes misannotated PDIs. 
Although multiple PDIs are shared between human and mouse, 69% of human and 
60% of mouse PDIs are species-specific (Figure 2.1F). This low overlap is not likely 
related to a lack of confidence in the interactions because a similar proportion of 
interactions found in one or both species were classified as high confidence based on 
evidence from functional (e.g., reporters assays and TF knockdowns experiments) and in 
vivo or in vitro binding assays (chromatin immunoprecipitation -ChIP- and electrophoretic 
mobility shift assays –EMSAs, respectively) (Figure 2.1G). More likely, this low overlap 
is related to literature bias and incompleteness of the GRN, or to different modes of 
regulation between mouse and human as has been previously reported (Schmidt et al. 
2010). Indeed, we found that PDIs reported early on in one species were more frequently 
detected in the other species than PDIs reported more recently. For example, 71% of mouse 
PDIs reported on or before the year 2000 are also reported in human, while only 21% of 




literature biases may play an important role in the differences in annotated PDIs between 
species.   
Most interactions were reported by at least two of three types of experimental 
assays: binding assays (e.g., EMSA and pull down assays), ChIP, and functional assays 
(Figure 2.2A and B). Human PDIs detected by all three types of assays were more 
frequently also detected in mouse (and viceversa) compared to PDIs detected by one or 
two types of assays (Figure S1A and B). The types of assays used to determine PDIs has 
changed over time, with papers in the 1990s focusing on binding and functional assays 
while papers in the 2010s focusing on ChIP and functional assays, reflecting the increased 





Figure 2.2 Distribution of experimental methods used to determine PDIs. (A, B) Number of 
PDIs in the human (A) and mouse (B) cytokine GRNs per assay type and the number of PDIs 
annotated in the mouse and human GRNs, respectively. Filled circles – PDIs involving the assay. 
(C, D) Number of PDIs in the human (C) and mouse (D) cytokine GRNs per assay type over time. 
 
Association between TF connectivity and immune phenotype 
 
As observed in other GRNs, a few TFs and cytokines are responsible for most PDIs 
in the cytokine GRN (Figure 2.3A and B, and Figure 2.4A and B) (Luscombe et al. 2004; 
Deplancke et al. 2006). For example, 12% of the TFs are responsible for more than 50% 




the PDIs in the human cytokine GRN (Figure 2.3A). Similarly, 8% of the cytokines, 
including the highly studied CXCL8, IL6, and TNF, are involved in more than 50% of the 
PDIs (Figure 2.3B). We obtained similar distributions for the mouse cytokine GRN (Figure 
2.4A and B). These lopsided distributions in the number of PDIs can be explained by a 
more central role of some TFs and cytokines in the GRN, but also by research biases as 
discussed below. 
 
Figure 2.3 Relationship between TF connectivity and phenotype in the human cytokine GRN. 
(A) Number of cytokine targets per TF (TF degree) in the human cytokine GRN ordered by TF 
degree rank. (B) Number of interacting TFs per cytokine (cytokine degree) in the human cytokine 
GRN ordered by cytokine degree rank. (C) Median expression as transcripts per million (TPM) 
across human immune cells obtained from the Blueprint Epigenome Consortium for TFs displaying 
different numbers of cytokine targets. (D) Expression enrichment in human immune tissues versus 
non-immune tissues for TFs with varying numbers of cytokine targets. Each box spans from the 
first to the third quartile, the horizontal lines inside the boxes indicate the median value and the 
whiskers indicate minimum and maximum values. Statistical significance determined using two-
tailed Wilcoxon matched-pair ranked sign test. (E) Fraction of TFs in the human cytokine GRN 
with annotated immune phenotypes when knocked out in mice (MGI), or associated with immune 
disorders in the Human Gene Mutation Database (HGMD) or in genome-wide association studies 
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We found that TFs that interact with multiple cytokine genes show higher 
expression levels in immune cells (Figure 2.3C) and higher expression enrichment in 
immune tissues (such as the spleen, bone marrow, and lymph nodes) compared to TFs that 
interact with only a few or no cytokine genes (Figure 2.3D). Further, highly connected TFs 
are frequently PSA TFs (e.g., 71% of TFs with ten or more cytokine targets are PSA 
compared to 9% for TFs with one cytokine target) consistent with their function in immune 
responses. More importantly, highly connected TFs are more frequently associated with 
immune phenotypes in knockout mouse studies, and with immune disorders as reported in 
the human gene mutation database (HGMD) and in GWAS compared to low connected 
TFs (Figure 2.3E and Figure 2.4C) (MacArthur et al. 2017; Stenson et al. 2014; Eppig et 
al. 2017). For example, the highly connected TF IRF5 is associated with multiple 
autoimmune diseases, including multiple sclerosis and systemic lupus erythematosus 
(SLE), and leads to low type-I interferon, TNF and IL6 production in knockout mice 
(MacArthur et al. 2017; Stenson et al. 2014; Eppig et al. 2017). Conversely, the low 
connected TFs HMGA2, NDS2, and HMBOX1, to our knowledge, have not yet been 
associated with immune phenotypes or diseases. Overall, these observations highlight the 
association between TF connectivity and disease, consistent with previous findings in a 





Figure 2.4 Relationship between TF connectivity and phenotype in the mouse cytokine GRN. 
(A) Number of cytokine targets per TF (TF degree) in the mouse cytokine GRN ordered by TF 
degree rank. (B) Number of interacting TFs per cytokine (cytokine degree) in the mouse cytokine 
GRN ordered by cytokine degree rank. (C) Fraction of TFs in the mouse cytokine GRN with 
annotated immune phenotypes when knocked out in mice (MGI), or associated with immune 
disorders in the Human Gene Mutation Database (HGMD) or in genome-wide association studies 
(GWAS) based on the number of cytokine targets. 
 
Cytokine regulation by different types of TFs 
 
Different cell types express different sets of cytokines in response to pathogen- or 
cell-mediated cues. For each immune cell type, we determined the TFs enriched in 
binding/regulating the cytokines expressed in the given cell type. As expected, several 
master regulator TFs are enriched, including TBX21 (T-bet) in Th1 cells, GATA3 and 
STAT6 in Th2 cells, RORC in Th17 cells, and SPI1 (PU.1) and CEBPA in monocytes. 
Additionally, several PSA TFs, such as RELA/NFKB1, are enriched in Th1 cells, 
monocytes, myeloid dendritic cells, eosinophils, and neutrophils, consistent with these 
cells producing pro-inflammatory cytokines upon activation; while IRF1/3/5/7 are 
enriched in B cells and plasmacytoid dendritic cells, producers of type-I interferons in 




Highly connected TFs in the cytokine GRN usually belong to the Ig-like plexins 
transcription factor (IPT/TIG/p53 - including NF-κB and NF-AT TFs), activator protein 1 
(AP-1), interferon regulatory factor (IRF), and signal transducer and activator of 
transcription (STAT) families, which are known to play prominent roles in immune cell 
differentiation and immune responses (Holloway, Rao, and Shannon 2002; Taniguchi et 
al. 2001; Rao, Luo, and Hogan 1997; Peltz 1997). These TF families are highly enriched 
in the cytokine GRN compared to the GRN reported in TRRUST (Han et al. 2015), a 
literature-derived network not constrained to cytokine genes (Figure 2.5A and Figure 2.6A 
and B). Furthermore, most PSA TFs are enriched in the cytokine GRN compared to the 
GRN reported in TRRUST, consistent with many cytokine genes being upregulated in 
response to pathogens or stress conditions (Figure 2.5B). 
 
Figure 2.5 Cytokine regulation by different types of TFs. (A, B) Correlation between the 
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annotated in TRRUST, for different TF families (A) or for pathogen- or stress-activated (PSA) TFs 
(B). (C) Average fraction of PSA and tissue-specific (TS) TFs for cytokines expressed in different 
cell types. (D) Fraction of PSA and TS TFs for different classes of cytokines. Correlation 
determined by Pearson correlation coefficient. (E) Inflammatory score (IS) for each TF based on 
the fraction of PDIs with pro- and anti-inflammatory cytokines. (F) Percentage of TFs with pro-
inflammatory, anti-inflammatory, and differentiation or other functions based on mouse knockout 
phenotypes. p = 0.009 by Fisher’s exact test. 
Cytokines are expressed in a highly tissue- and condition-specific manner. This is 
achieved by a specific combination of receptors and signaling pathways present in each 
cell type, and through the cooperation between PSA and TS TFs (Holloway, Rao, and 
Shannon 2002). To study the role of PSA and TS TFs in cytokine regulation, for each 
cytokine we determined the fraction of TFs that respond to pathogen/stress signals (e.g., 
NF-κB, AP-1 and IRFs) and the fraction of TS TFs determined based on each TF’s gene 
expression variability across tissues. Our analysis revealed that cytokines expressed in 
plasmacytoid dendritic cells, M1 macrophages, Th1 cells, and myeloid dendritic cells are 
primarily regulated by PSA TFs, whereas cytokines expressed NK cells, basophils, mast 
cells, Th2 cells, Th17 cells, and eosinophils are also regulated by several TS TFs (Figure 
2.5C). This is consistent with reports of the former cell types expressing multiple canonical 
pro-inflammatory cytokines and/or interferons, which are induced by pathogen-associated 
molecular patterns or danger signals from inflammatory microenvironments. Indeed, 
further analysis revealed that interferons and pro-inflammatory cytokines are regulated by 
broadly-expressed PSA TFs, whereas anti-inflammatory cytokines are regulated by both 





Figure 2.6 TF families present in the mouse and human cytokine GRNs. (A) Correlation 
between the percentage of PDIs involving a TF in the mouse cytokine GRN versus a global mouse 
GRN annotated in TRRUST. (B) Distribution of TF families in the human and mouse cytokine 
GRNs compared to those annotated in the TRRUST database. 
Different TFs have predominantly pro- or anti-inflammatory functions. Thus, for 
each TF, we determined an inflammatory score (IS) based on the preference of binding to 
pro- versus anti-inflammatory cytokine gene targets (Figure 2.5E). TFs with an IS>0.5 
more frequently had a pro-inflammatory function, while TFs with IS<-0.5 more frequently 
had an anti-inflammatory function based on knockout mouse phenotypes (Figure 2.5F, p = 
0.009 by Fisher’s exact test). Although the dysregulation of other targets is likely involved, 
these analyses suggest that the cytokine targets of a TF can be important drivers of immune 
phenotypes. 
GRN integration with TF-cofactor interactions 
 
Different cell types express different sets of cytokines in response to pathogen- or 
cell-mediated cues. For each immune TFs regulate gene expression by recruiting co-
activators and co-repressors that interact with the transcriptional machinery or mediator 




2006; Rolland et al. 2014). Based on literature-derived protein-protein interactions reported 
in Lit-BM-13 (Rolland et al. 2014), we found that the TFs that bind/regulate cytokine genes 
interact with numerous cofactors, including multiple co-activators such as EP300, 
CREBBP, and nuclear co-activators 1-3 and 6 (Figure 2.7A). This is not surprising given 
that ~80% of the regulatory PDIs in CytReg are activating and involve potent 
transcriptional activators such NF-κB and AP-1. Nevertheless, several activating TFs also 
interact with co-repressors which can inhibit TF function until triggered by signaling 





Figure 2.7 Cooperativity and plasticity in cytokine regulation.  (A) Protein-protein interaction 
network from Lit-BM-13 between cofactors and TFs in the human cytokine GRN. Ellipses – TFs, 
diamonds – cofactors. Node size indicates the number of cytokine targets (for TFs) in the cytokine 
GRN, and the number of protein-protein interactions with TFs (for cofactors). Only cofactors with 
five or more protein-protein interactions are shown. (B, C) Number of TFs (shades of grey) 
interacting with each human cytokine gene that interact with the different cofactors (B) or the 
different domains of EP300/CREBBP (C). (D, E) Fraction of cofactor (D) or EP300/CREBBP 
domain (E) protein-protein interactions (shades of red) involving PSA or TS TFs. Only cytokines 
and cofactors with five or more interactions are shown. Co-activators are shown in red font, co-
repressors in blue font, and bifunctional cofactors in purple font. 
In general, each cofactor interacts with multiple TFs that bind/regulate each 
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cooperativity to recruit cofactors to regulatory regions as has been reported for the 
cooperative recruitment of EP300 by RELA, IRFs, JUN, and HMGA1 to the IFNB1 
enhanceosome (Thanos and Maniatis 1995). Alternatively, cofactor binding to multiple 
TFs may also be associated with regulatory plasticity by which cofactors can be recruited 
by different sets of TFs to modulate cytokine gene expression in different cell types or 
conditions. To evaluate these possibilities, we focused on the histone acetyltansferases 
EP300/CREBBP, which play key roles in immune regulation and differentiation, and 
whose protein-protein interactions with TFs have been mapped to their different domains 
(Freedman et al. 2002; Hottiger and Nabel 2000). We found that, for cytokines for which 
multiple PDIs have been determined, the set of TFs that bind/regulate that cytokine gene 
collectively interact with multiple domains of EP300/CREBBP (Figure 2.7C). This may 
lead to a cooperative recruitment of EP300/CREBBP to regulatory regions, as has been 
observed for the IFNB1, TNF, and IL6 genes (Thanos and Maniatis 1995; Berghe et al. 
1999; Tsytsykova and Goldfeld 2002). This is also consistent with the observation that, 
even for cytokines with multiple annotated PDIs, the mutation of a single TF binding site 
or the inhibition of a single TF can lead to a dramatic effect on gene expression (Tsai et al. 
2000; Melnikov et al. 2012). Interestingly, for each cytokine, several TFs can also interact 
with the same domain of EP300/CREBBP (Figure 2.7C). Although this may contribute to 
a cooperative recruitment of EP300/CREBBP, it may also increase regulatory plasticity in 
different cell types and/or under different stimuli by allowing different TF combinations to 




lead to EP300/CREBBP recruitment to the TNF enhanceosome, however, through different 
sets of TFs (Tsytsykova and Goldfeld 2002).  
Some cofactors such as MAPK8, BRCA1, MDM2 and COPS5 preferentially 
interact with PSA TFs, consistent with their reported function in inflammation and stress 
responses, and associated immune phenotype in knockout mice (Figure 2.7D) (Eppig et al. 
2017). Other cofactors such as NCOR1/2, NCOA1/2/3/6, RB1, NRIP1, SRC and MED1 
interact primarily with TS TFs such as nuclear hormone receptors (Rolland et al. 2014) 
(25416956). Interestingly, different domains of EP300/CREBBP interact preferentially 
with PSA or TS TFs: for example, CH1, KIX and Q/I interact mostly with PSA TFs, 
whereas RID and CH3 interact mostly with TS TFs (Figure 2.7E). Altogether, this suggests 
that PSA and TS TFs cooperate in recruiting EP300/CREBBP through different domains 
to induce cytokine expression under the right stimuli and in the appropriate cell types. In 
addition, functional redundancy between different PSA TFs may allow for the activation 
of cytokine expression under different conditions. For example, the PSA TFs HIF1A and 
NF-κB, both of which interact with the CH1 domain of EP300/CREBBP, can 
independently induce CXCL8 expression (Kim et al. 2006). Overall, these findings are 
consistent with a model that contains aspects of both the enhanceosome (i.e., cooperative 
TF binding is required for regulatory activity) and billboard (i.e., TFs independently 
regulate gene expression) models of gene regulation, where only certain combinations of 
TFs present in particular cells or conditions can induce gene expression (Spitz and Furlong 
2012). Each cytokine, depending on their regulatory flexibility, may be closer to one model 




The cytokine GRN as a blueprint to study disease 
 
Cytokine expression is widely dysregulated in immune disorders and infection. 
This is driven by the activation of multiple signaling pathways that result in TF activation 
leading to the concomitant regulation of target cytokines. To explore these TF-disease 
relationships, we leveraged the human cytokine GRN to identify TFs enriched in regulating 
the cytokines overexpressed in different autoimmune diseases, Mycobacterium 
tuberculosis infection, and cytomegalovirus infection. We identified 46 TF-disease 
associations between 25 TFs and seven diseases, many of which are known (Figure 2.8A). 
For example, different subunits of NF-κB were associated with all the diseases evaluated, 
consistent with the ubiquitous role of NF-κB in inflammation (T. D. Gilmore and 
Herscovitch 2006). Other TF-disease associations identified were more specific. For 
instance, IRFs and ATF2 (in addition to NF-κB) were associated with cytomegalovirus 
infection which is consistent with these TFs being activated by viral pathogens through 
pattern recognition receptors (Navarro et al. 1998; Browne and Shenk 2003; Le et al. 2008). 
STAT1 and STAT2 were also associated with cytomegalovirus infection, in this case, 
likely through the activation of signaling pathways driven by the autocrine/paracrine 
secretion of type-I and type-II interferons induced by IRF and NF-κB activation. In 
addition, we identified an association between STAT6 and SLE, consistent with STAT6 
deficiency being associated with a better prognosis in mouse models of SLE (Singh et al. 
2003; Jacob et al. 2003), and with STAT6 polymorphisms being associated with SLE in 




XBP1, and HSF1 with inflammatory bowel disease further validating our analyses (Tanaka 
et al. 2007; Kaser et al. 2008; Goodman et al. 2016; Brattsand and Linden 1996). 
 
Figure 2.8 Association of the cytokine GRN with human diseases. (A) Circos plot connecting 
diseases with TFs based on enrichment of the TFs in regulating cytokines upregulated in the 
indicated disease. Ribbon width is proportional to the percentage of cytokines upregulated in the 
indicated disease that are regulated by the indicated TF. (B) GRN connecting interacting TFs and 
human cytokine genes associated with autoimmune disorders. Edges connect interacting cytokine-
TF pairs. Edge color indicates that the interacting cytokine and TF are associated with the same 
disease based on HGMD and GWAS. (C) The human cytokine GRN was randomized 1,000 times 
by edge switching and the number of TF-cytokine-disease sets in each randomized network was 
calculated. The number under the histogram peak indicates the average overlap in the randomized 
networks. The red arrow indicates the observed overlap in the real network. Statistical significance 
determined based on z-score calculation. (D) GRN connecting cytokines with TFs that can be 

































































































































































































































antagonists, or both, respectively. Oval size corresponds to the number of approved drugs targeting 
a TF. Rectangles indicate cytokine genes. Rectangle size is proportional to the number of druggable 
TFs per cytokine. 
More importantly, we found previously uncharacterized TF-disease associations. 
For example, we identified an association BCL6 and SLE (Figure 2.8A). A mouse model 
of SLE (Def6 and SWAP70 double knockout) showed increased BCL6 protein expression 
(Yi et al. 2017). However, the role of BCL6 in cytokine dysregulation in SLE has not been 
established. Our analyses, suggest that the increased BCL6 levels may be associated with 
increased levels of CCL1/2/7/8/13 observed in SLE. We also identified a previously 
uncharacterized association between ETS2 and cytokine upregulation in M. tuberculosis 
infected macrophages (Figure 2.8A). ETS2 is an activator that is upregulated 5.7 fold (p = 
3.6 x 10-7) in macrophages infected with M. tuberculosis for 48 hs (E-MEXP-3521). This 
increased ETS2 expression, together with ETS2 activation through the MAPK pathway 
(McCarthy et al. 1997), may contribute to cytokine upregulation in M. tuberculosis 
infection. Interestingly, the association between ETS2 and M. tuberculosis infection would 
not have been predicted only based on PDIs from InnateDB and TRRUST. Further, using 
PDIs from these previous databases we only predicted 21 TF-disease associations, most of 
them included within the 46 associations predicted based on CytReg, while missing 
multiple known associations such as those between NF-κB subunits and autoimmune 
diseases (Figure 2.9). Overall, our analyses predicted novel TF-disease associations which 
are consistent with known TF functions. Further studies are required to determine the 





Figure 2.9 Gene expression of Berry et al. (2010) 86-gene signature in TB and LTBI subjects 
from a South Indian population. Circos plot connecting diseases with TFs based on enrichment 
of the TFs in regulating cytokines upregulated in the indicated disease. Ribbon width is proportional 
to the percentage of cytokines upregulated in the indicated disease that are regulated by the 
indicated TF. The left plot is based on PDIs from the union of TRRUST and InnateDB, the right 
plot is based on PDIs from CytReg (as in Figure 2.8A). 
Mutations in multiple TFs have been associated with immune disorders such as 
autoimmune diseases (MacArthur et al. 2017; Stenson et al. 2014). The role of TFs in 
autoimmunity is likely related to the dysregulation of immune genes, in particular 
cytokines, as they play a central role in immune responses and tolerance (Neurath 2014; 
O’Shea, Ma, and Lipsky 2002). Indeed, mutations in many cytokine genes have been 
associated with autoimmunity (MacArthur et al. 2017; Stenson et al. 2014). We considered 
the cytokines and TFs that have been associated with autoimmune diseases in GWAS and 
HGMD, and found that many TF-cytokine gene pairs that interact in the cytokine GRN 
have been associated with the same autoimmune disease (Figure 2.8B). For example, we 




arthritis, atopic dermatitis/psoriasis, and SLE (Figure 2.8B). Overall, the number of TF-
cytokine pairs associated with the same autoimmune disease is higher than that determined 
in randomized networks derived from the human cytokine GRN (Figure 2.8C). These TF-
cytokine pairs identified may constitute different regulatory axes by which TFs lead to the 
disease. For example, AHR activation is protective in inflammatory bowel disease, partly 
due to increased IL10 expression (Goettel et al. 2016). Interestingly, the association 
between AHR, IL10, and inflammatory bowel disease, together with 19 other TF-cytokine-
disease associations was absent in predictions based on PDIs from the union of TRRUST 
and InnateDB. Altogether, the network depicted in Figure 5B constitutes a blueprint to 
study other regulatory axes in autoimmunity. 
Targeting cytokine activity is a widely used therapeutic approach for multiple 
autoimmune and inflammatory diseases (Wishart et al. 2018; Chan and Carter 2010). 
However, only ~15% of cytokines can currently be directly targeted with approved small 
molecules or specific antibodies, as reported in Drugbank (Wishart et al. 2018). An 
alternative strategy is to modulate cytokine production by activating or repressing TF 
regulatory pathways or by using TF agonists or antagonists (Wishart et al. 2018; T. D. 
Gilmore and Herscovitch 2006; O’Keefe et al. 1992). Although the use of antibodies is a 
more specific therapeutic approach to inhibit cytokine activity, antibodies cannot be used 
in many cases because: 1) approved antibodies blocking cytokine activity are only 
available for nine cytokines, 2) a therapeutic strategy may require the concomitant 
modulation of multiple cytokines, or 3) a strategy may require the induction of cytokine 




inhibition. In these cases, modulation of cytokine expression by targeting TFs may provide 
an effective alternative approach.  
Many cytokines can potentially be targeted using drugs against their interacting TFs 
(or the signaling pathways that activate those TFs). Indeed, multiple TF agonists and 
antagonists have been approved as therapeutics, including 17 TFs with targets in the human 
cytokine GRN (Figure 2.8D). Combined, these TFs, which include nuclear hormone 
receptors, NF-κB, and AP-1, can potentially target 59 cytokine genes, most of which are 
dysregulated in disease.  Targeting these TFs can increase or decrease cytokine expression 
depending on the TF regulatory function and on the drug’s agonist or antagonist activity. 
For example, IL10 expression can be induced using AHR agonists as a protective 
mechanism in inflammatory bowel disease, or repressed by an endogenous VDR agonist 
(calcitriol) during pregnancy to enhance responses to microbial infections (Goettel et al. 
2016; Barrera et al. 2012). Ultimately, multiple factors need to be considered including the 
off-target effect of the drugs, the number of other genes whose expression may be affected 
by targeting a particular TF, and how the modulation of TF activity may propagate to other 
immune and non-immune functions. 
Completeness of the cytokine GRN 
 
Although great progress has been made in the last three decades identifying novel 
PDIs, the cytokine GRN is far from complete. Indeed, we observed that the size of the 
cytokine GRN and the number of TFs involved have increased at a constant rate suggesting 
that novel PDIs remain to be identified (Figure 2.10A and Figure 2.11A).  Importantly, the 




immune phenotypes or diseases has remained constant suggesting that the GRN continues 
to grow towards immune-relevant interactions (Figure 2.10B and Figure 2.11B).  
 
Figure 2.10 Completeness of the human cytokine GRN. (A) Number of annotated PDIs, TFs, 
and cytokines in the human cytokine GRN over time. (B) Fraction of TFs in the human cytokine 
GRN with annotated immune phenotypes when knocked out in mice (MGI) or associated to 
immune disorders in genome-wide association studies (GWAS) and in the Human Gene Mutation 
Figure 6
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Database (HGMD) over time. (C, D) Number of PDIs per TF (C) or per cytokine (D) in the human 
cytokine GRN over time. (E, F) Correlation between the number of PDIs in the human cytokine 
GRN and the number of publications per TF (E) or per cytokine (F) reported in Medline. (G, I) 
PDIs with the promoters of CCL27 (G) or CCL4L2 (I) were analyzed by eY1H assays. Each 
interaction was tested in quadruplicate. The qualitative strength of PDIs detected by eY1H 
compared to AD-vector control are indicated as –, +, ++, and +++ corresponding to no, weak, 
medium, and strong interaction, respectively. Motif location for the indicated TFs in the promoters 
of CCL27 and CCL4L2 are shown. (H, J) Luciferase assays to validate interactions between the 
promoters of CCL27 (H) or CCL4L2 (J) and the indicated TFs. HEK293T cells were co-transfected 
with reporter plasmids containing the cytokine promoter region (2 kb) cloned upstream of the 
firefly luciferase reporter gene, and expression vectors for the indicated TFs (fused to the activation 
domain 10xVP16). After 48 h, cells were harvested and luciferase assays were performed. Relative 
luciferase activity is plotted as fold change compared to cells co-transfected with the vector control 
(1.0). Experiments were performed 3-4 times in three replicates. Individual data points represent 
the average of the three replicates, the average of all experiments is indicated by the black line. 
*p<0.05 by one-tailed Student’s t-test with Benjamini-Hochberg correction. 
Future growth of the cytokine GRN is not expected to be uniform for all TFs and 
cytokines. Indeed, the number of PDIs seems to have saturated for some TFs such as 
RELA, NFKB1, and FOS, while other TFs such as SPI1 and MAFK do not show signs of 
saturation (Figure 2.10C and Figure 2.11C). The number of PDIs for some well-studied 
cytokines such as CCL5 have also plateaued, while new PDIs are still being identified for 






Figure 2.11 Completeness of the mouse cytokine GRN.  (A) Number of annotated PDIs, TFs, 
and cytokines in the mouse cytokine GRN over time. (B) Fraction of TFs in the mouse cytokine 
GRN with annotated immune phenotypes when knocked out in mice (MGI) or associated to 
immune disorders in genome-wide association studies (GWAS) and in the Human Gene Mutation 
Database (HGMD) over time. (C, D) Number of PDIs per TF (C) or per cytokine (D) in the mouse 
cytokine GRN over time. (E, F) Correlation between the number of PDIs in the mouse cytokine 
GRN and the number of publications per TF (E) or per cytokine (F) reported in Medline. 
Correlation determined by Spearman’s rank correlation coefficient. (G, H) Correlation between the 
number of PDIs per TF (out degree) (G) or per cytokine (in degree) (H) in the human and mouse 
cytokine GRNs. 
We also observed a bias towards highly studied TFs and cytokines as we detected 
a strong correlation between the number of publications in Medline associated with a 
cytokine or TF and the number of PDIs in the cytokine GRN (Figure 2.10E and F; and 




pleiotropic functions and thus, are more frequently studied. However, more than 200 TFs 
absent in the cytokine GRN lead to an immune phenotype when knocked out in mice, many 
of which are associated with alterations in cytokine expression (Eppig et al. 2017). This 
suggests that many TFs are absent from the cytokine GRN and that many PDIs involving 
infrequently studied TFs are missing.  
Similarly, highly studied cytokines are involved in more PDIs (Figure 2.10F and 
Figure 2.11F). Although we cannot rule out the possibility that highly studied cytokines 
have more pleiotropic roles and are regulated by different TFs in different cells and 
conditions, this alone cannot explain that there are no PDIs reported for 30% of the 
cytokines. Further, if there is a strong selective pressure to have multiple modes of 
regulation for certain cytokines, we would expect the mouse and human cytokine orthologs 
to be regulated by a similar number of TFs, but this is frequently not the case 
(Supplementary Figure 2.11G and H). What is more likely is that highly studied cytokines 
such as TNF and CXCL8 have more PDIs because they have been studied in more cell 
types and conditions. To test this hypothesis, we performed eY1H assays to evaluate the 
binding of 1,086 human TFs to the promoters of CCL27 and CCL4L2, two under-studied 
cytokines absent from the GRN (Figure 2.10G and I). We detected seven interactions with 
the CCL27 promoter involving TFAP2A/B/E, KLF7, ZNF18, PPARG, and RBPJ (Figure 
2.10G). Motif analyses for TFs with available position weight matrices (TFAP2A/B, 
PPARG, and RBPJ) identified multiple TF binding sites in the CCL27 promoter. We 
evaluated the seven eY1H interactions by luciferase assays in HEK293T cells, all of which 




cells, is also absent from CytReg showing that novel TFs in the cytokine GRN remain to 
be identified. We also detected 13 TF interactions with the promoter of CCL4L2 using 
eY1H assays (Figure 2.10I). Multiple TF binding sites were found in the promoter of 
CCL4L2 for most of the TFs for which a position weight matrix was available. We tested 
the 13 eY1H interactions by luciferase assays in HEK293T cells, nine of which validated 
(Figure 2.10J). Interestingly, ATF3 is known to regulate CCL4, a close paralog of CCL4L2 
(M. Zhu et al. 2014). Further, CCL4L2 is produced by multiple cell types including 
monocytes, B cells, T cells, fibroblasts, endothelial, and epithelial cells, while ATF3, 
EBF3, REL, ZBTB10, ZNF710, WT1, TFAP2A, and TFAP2E are also expressed in one 
or more of these cell types (C. Wu et al. 2016) . Overall, this shows that novel interactions 
can be detected for cytokines and TFs that have been poorly characterized. 
Prediction of novel PDIs in the cytokine GRN 
 
Different cell types express different sets of cytokines in response to pathogen- or 
cell-mediated cues. To predict novel PDIs in the human cytokine GRN, we leveraged the 
observation that co-expressed genes tend to share interactions with similar TFs (Fuxman 
Bass et al. 2015; Marco et al. 2009). Thus, for each TF with at least two PDIs in the human 
cytokine GRN, we searched for other cytokines co-expressed with the known target 
cytokines across more than 5,000 expression profiling datasets using SEEK (Q. Zhu et al. 
2015). Potential targets were then filtered by the presence of the corresponding TF binding 
site in the promoter region (2 kb upstream of the transcription start site) determined using 
CIS-BP (Weirauch et al. 2014). The 1,066 predicted PDIs, were enriched in orthologous 




10-20 by Chi-square test). Predictions were classified as high, medium, or low confidence 
based on the number of TF binding sites for the corresponding TF and the presence of the 
interaction in mouse (Figure 2.12A). As expected, there is a strong correlation between the 
TF degree for known and for known plus predicted interactions, although this correlation 
is not perfect (Figure 2.12B). Importantly, adding the predicted interactions, maintained or 
even improved the correlation between TF degree and expression enrichment in immune 
tissues, presence of immune phenotype in mouse, and association with immune disorders 
in GWAS and HGMD (Figure 2.12C). Overall, this suggests that our predictions are 





Figure 2.12 Prediction of novel PDIs in the human cytokine GRN. (A) Novel PDI predictions 
based on co-expression between cytokines and known cytokine targets of each TF (determined 
using the SEEK database), and motifs analysis. Prediction confidence, as defined in the methods 
section, is shown. (B) Correlation between the number of cytokine targets (TF degree) for known 
PDIs and known + predicted PDIs. Correlation determined by Spearman’s rank correlation 
coefficient. (C) Correlation between TF degree for known (K) or known + predicted (K+P) PDIs 
and expression enrichment score (EES) in immune tissues, mouse immune phenotype (MGI), and 
human immune disorders in GWAS and HGMD. Correlation and significance determined by 
Spearman’s rank correlation coefficient. (D, G) Top predicted cytokine targets of RORC (D) and 
REL (G). The co-expression rank among all genes and among cytokines is shown. CXCL8 is a 
known target of REL, while IL17A is a known target of RORC. (E, H) Enhanced yeast one-hybrid 
assays testing PDIs between the indicated human cytokine promoters and RORC (E) and REL (H). 
AD-vector corresponds to empty vector. The qualitative strength of PDIs compared to AD-vector 
control are indicated as –, +, ++, and +++ corresponding to no, weak, medium, and strong 
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region. (F, I) Luciferase assays in HEK293T cells co-transfected with reporter plasmids containing 
the indicated cytokine promoter region (2 kb) cloned upstream of the firefly luciferase reporter 
gene, and expression vectors for RORC (F) or REL (I) (fused to the activation domain 10xVP16). 
After 48 h, cells were harvested and luciferase assays were performed. Relative luciferase activity 
is plotted as fold change compared to cells co-transfected with the vector control (1.0). Experiments 
were performed 3-4 times in three replicates. Individual data points represent the average of the 
three replicates, the average of all experiments is indicated by the black line. *p<0.05 by one-tailed 
Student’s t-test with Benjamini-Hochberg correction. 
Using this platform, we predicted IL26 and IL17F to be novel potential targets of 
RORC, whose RORγt isoform is a master regulator of Th17 cell differentiation and 
function (Figure 2.12D) (Ivanov et al. 2006). The interaction between RORC and IL17F, a 
paralog of the known RORC target IL17A, was reported in mouse (X. O. Yang et al. 2008) 
but, to our knowledge, not in human. IL26 is a key cytokine involved in immune cell 
priming, antibacterial immunity, and autoimmune diseases produced by RORγt expressing 
Th17 cells, but not previously shown to be directly regulated by RORγt (Manel, Unutmaz, 
and Littman 2008; Stephen-Victor, Fickenscher, and Bayry 2016). We validated these two 
novel predicted PDIs using eY1H assays, motif analyses, and luciferase assays in 
HEK293T cells showing even stronger activity than the well-known RORC-IL17A 
interaction (Figure 2.12E and F). Overall, this suggests that RORC directly regulates 
multiple Th17 cytokines. 
Using a similar approach, we found that CCL4, CXCL3, CCL20, and CXCL10 are 
among the most highly correlated cytokines to the known targets of the well-studied TF 
REL, and that their promoters have multiple binding sites for REL (Figure 2.12G and H). 
Interestingly, these cytokines are known to be regulated by other subunits of NF-κB but, 
to our knowledge, not by REL. We validated these predicted interactions using eY1H 




four novel targets of REL, a TF associated with autoimmune disorders, are also associated 
with and/or upregulated in autoimmune disorders (Meagher et al. 2007; Klein et al. 2004; 
Karin and Razon 2018; Hirota et al. 2007; Thomas D. Gilmore and Gerondakis 2011). 
Overall, this shows that by integrating the PDIs annotated in CytReg with co-expression 
data we can expand the current cytokine GRN. Additionally, our predictions provide a 
blueprint for further studies in cytokine regulation. 
Discussion 
 
In the present study, we mined ~26 million articles in Medline, of which we curated 
more than 7,000 articles, to generate comprehensive mouse and human cytokine GRNs 
comprising 843 and 647 PDIs, respectively. We created a user-friendly database 
(https://cytreg.bu.edu) where PDIs can be easily browsed by TF, cytokine, species, assay 
type, and TF expression patterns, and visualized as networks. Overall, CytReg is 2- to 3-
fold more complete than other databases such as InnateDB and TRRUST (Breuer et al. 
2013; Han et al. 2015). Using this comprehensive database, we were able to obtain novel 
insights into the principles involved in cytokine regulation, perform comparative analyses 
between mouse and human GRNs, and make functional predictions which were not 
previously possible with other databases.  
By analyzing the cytokine GRN, we found that highly connected TFs are more 
highly expressed in immune cells and more frequently associated with immune phenotypes 
and diseases compared to low connected TFs. This is consistent with previous reports 
correlating network connectivity and phenotype, both in protein-protein and protein-DNA 




Interestingly, we found that this correlation is specific to immune diseases as TFs 
associated with non-immune diseases do not display a high connectivity in the cytokine 
GRN (not shown). Overall, this suggests that the link between TF connectivity and 
phenotype may be a local feature of GRNs where connectivity to functionally related 
targets, rather than the entire GRN, dictates the type of phenotypes or diseases a TF is 
associated with. For example, REL which is highly connected in CytReg, but not in 
TRRUST, has been associated with rheumatoid arthritis, psoriasis, and Hodgkin's 
lymphoma but not with diseases unrelated to the immune system (MacArthur et al. 2017). 
Our analysis of the combinatorics of the TFs that regulate each cytokine gene 
illustrates the complexity in cytokine transcriptional regulation. We observed that pro- and 
anti-inflammatory cytokines are regulated by a different balance between PSA and TS TFs, 
but ultimately a combination of both types of TFs may be required for cofactor recruitment 
to induce cytokine expression in the appropriate cells and conditions. This cooperativity 
between PSA and TS TFs, together with cell type specific expression patterns of surface 
receptors and signaling molecules, may ultimately be responsible for the tight control of 
cytokine expression in immune responses. The cooperative relationship between TFs may 
also explain the deleterious effects of several disease-associated single nucleotide variants 
(SNVs) and engineered mutations in the promoters and enhancers of cytokine genes, as 
affecting the binding of a single TF may result in the loss of cooperativity and lead to gene 
misregulation (Melnikov et al. 2012; Wei et al. 2011; Tu et al. 2013). For example, using 
massively parallel reporter assays it was recently shown that ~60% of all possible 




infected cells (Melnikov et al. 2012). Remarkably, most of the substitutions that did not 
affect activity were located outside of known TF binding sites or led to an alternative 
binding site for the same TF. 
Our analyses also suggest a potential plasticity between TFs in cofactor 
recruitment, given that frequently multiple TFs that regulate a cytokine gene can interact 
with the same domain of EP300/CREBBP. Fine-mapping TF interactions with protein 
domains of other cofactors will indicate whether this is a unique feature of 
EP300/CREBBP. Further, a comprehensive functional characterization of different 
substitutions in cytokine promoters may determine whether the substitutions that affect the 
binding of potentially redundant TFs are generally more benign than those affecting the 
binding of cooperative TFs. However, the converse can also be true as this plasticity may 
be required for proper cytokine expression in different cell types and conditions.  
CytReg is the most comprehensive cytokine GRN to-date, significantly increasing 
the number of annotated PDIs compared to previous databases, yet CytReg is not fully 
complete. First, articles that do not mention interactions within the information available 
in Medline will be missed and will not have been curated. Second, CytReg is incomplete 
because multiple PDIs remain to be evaluated and characterized. Indeed, by performing 
eY1H and luciferase reporter assays, we found interactions involving cytokines (CCL27 
and CCL4L2) and TFs (e.g., ZNF18, ZBTB10, KLF17, EBF3, and ZNF710) that are absent 
from CytReg. Further, by leveraging CytReg, co-expression data, and motif analyses we 
predicted 1,066 PDIs in the human cytokine GRN, a subset of which we validated by eY1H 




may carry genomic variants in noncoding regulatory regions of cytokine genes or in TF 
coding sequences that lead to different TF-cytokine interactions. Indeed, several disease-
associated SNVs have been identified in the promoters of cytokine genes that result in the 
gain or loss of PDIs that may be absent in CytReg (Fuxman Bass et al. 2015; Nickel et al. 
2000; Sánchez et al. 2009; Knight et al. 1999). For example, a SNV in the proximal 
promoter of CCL5 that is associated with atopic dermatitis leads to a gain of PDI with 
GATA2 (Fuxman Bass et al. 2015; Nickel et al. 2000). Finally, CytReg catalogues PDIs 
as binary interactions between TFs and cytokine genes. However, the number of binding 
sites for each TF, their strength, spacing, and orientation are key for appropriate gene 
expression (Spitz and Furlong 2012; Smith et al. 2013). With a few exceptions (e.g., the 
IFNB1 and the TNF enhanceosomes), this regulatory logic is currently unknown, and thus 
cannot be annotated (Thanos and Maniatis 1995; Tsytsykova and Goldfeld 2002). 
Ultimately, the integration of different high-throughput and unbiased approaches, 
population-wide studies of regulatory variation, and in-depth functional characterizations 
of the regulatory logic will lead to a more comprehensive picture of cytokine regulation in 
different cell types, conditions, and individuals. 
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Chapter 3. Prediction of genome-wide effects of single nucleotide variants on 
transcription factor binding 
Adapted from the following manuscript: 
1. Sebastian Carrasco Pro, Katia Bulekova, Brian Gregor, Adam Labadorf, Juan 
Ignacio Fuxman Bass. 2020. Prediction of genome-wide effects of single 
nucleotide variants on transcription factor binding. In preparation. 
Introduction 
 Changes in gene expression caused by single nucleotide variants (SNVs) residing 
in transcriptional control regions have been shown to cause phenotypic changes which may 
be adaptive or lead to disease (Maurano et al. 2012; 2015; Hindorff et al. 2009). The 
mechanisms of action of these SNVs include alterations in the binding of transcription 
factors (TFs), in the recruitment of RNA Polymerase II, in nucleosome positioning, and in 
DNA modifications. Among these, the creation and disruption of TF binding sites (TFBSs) 
is likely the main mechanism by which SNVs affect gene expression (Maurano et al. 2015). 
Experimental methods to determine changes in TFBSs driven by SNVs include 
electrophoretic mobility shift assays (EMSA), chromatin immunoprecipitation followed by 
sequencing (ChIP-seq), and enhanced-yeast one-hybrid (eY1H) assays (Gan et al. 2018). 
EMSA is a very low-throughput assay that tests one or few TFs and DNA sequences at a 
time, and requires TF purification or anti-TF-specific antibodies. ChIP can be used to study 
differential TF recruitment by SNVs, but can only be tested one TF at time, is limited by 
the availability of high-quality anti-TF antibodies, and more importantly, requires cells 




SNV by testing the full repertoire of TFs, but can only test one SNV per experiment. Thus, 
current experimental methods are limited by the amount of SNVs and TFs they are able to 
test in a single experiment. Due to these limitations, prediction algorithms based on 
experimentally determined motifs have been developed for high-throughput prediction of 
altered TF binding by SNVs. 
TFs binding preferences to DNA sequences, represented by position weight 
matrices (PWMs), have been used to predict the likelihood that a TF binds a DNA sequence 
of interest. These computational methods, that scan DNA regions to predict TFBSs, include 
FIMO (Grant, Bailey, and Noble 2011), RSAT (Thomas-Chollier et al. 2011), Clover (Frith 
et al. 2004), and ENCODE DREAM Challenge derived methods (Quang and Xie 2019; 
Keilwagen, Posch, and Grau 2019), among others. In addition, methods have been 
developed to predict the impact of SNVs in TF binding, where scores of the mutated and 
reference DNA sequences are compared (Coetzee, Coetzee, and Hazelett 2015; Fu et al. 
2014; Weirauch et al. 2014; Boyle et al. 2012; Rentzsch et al. 2019; Movva et al. 2019). 
These methods have been used to predict the effect on TF binding of disease-associated 
SNVs such as those identified in genome-wide association and genetic studies (Xu and 
Taylor 2009; Tak and Farnham 2015; Schaub et al. 2012), and somatic mutations observed 
in tumor samples (Rheinbay et al. 2017; Yiu Chan et al. 2019; Rheinbay et al. 2020; Law 
et al. 2019). Furthermore, databases assessing the effect of known SNVs in the human 
population in gain/loss of TFBSs have been used to obtain insights into the effect of human 
variation on TF binding (Boyle et al. 2012; Shin et al. 2019; Kumar, Ambrosini, and Bucher 




mutations, on TF binding has not yet been determined. In this regard, a recent study 
evaluated the impact of tri-nucleotide cancer mutational signatures on TFBSs (Yiu Chan 
et al. 2019). This study calculated the differential probabilities of gain and loss of TFBSs 
corresponding to each TF for each mutational signature based on calculating the effect of 
SNVs across DNA k-mers found in the human genome. However, this method precludes 
identifying the sets of TFBSs that are poised to be gained and lost by SNVs as it assumes 
a uniform distribution of k-mers across the human genome. 
Here, we generated a database of genome-wide altered TFBSs by in silico mutating 
all possible SNVs in every position in the human genome and determining gain and loss of 
TFBSs for 1898 PWMs corresponding to 741 human TFs. Using this resource, we show 
that the probability to gain (gainability) or disrupt (disruptability) a TFBS in gene 
regulatory regions widely differ between different TFs and TF families. We also show that 
functional cis-eQTL SNVs are more likely to perturb TFBSs than common SNVs in the 
human population. Interestingly, the difference in disruptability is driven both by a higher 
probability of SNVs residing within TFBSs and a lower probability of retaining existing 
TFBSs by cis-eQTL versus population-wide SNVs. Finally, we show that somatic 
mutations in different cancer-types have differential effects on TFBSs between TF families 
and discuss how these profiles are related to distinct cancer mechanisms. Altogether, this 
database provides blueprint to study the impact of SNVs associated with genetic variation 
and cancer on TF binding. 
Materials and Methods 





To predict the effect of all possible SNVs in the human genome on TF binding, for 
each possible SNV and each TF with available PWMs, we calculated the binding score for 
the reference and alternate SNV alleles. We downloaded 1898 PWMs corresponding to 
741 human TFs from CIS-BP (Weirauch et al. 2014) on April 3 2018 and their respective 
TF family. Given a PWM of length n and a genomic position (hs37d5 from the 1000 
Genome Project), for each of the 2n-1 DNA sequences on each strand of length n that 
overlap with the genomic position, we calculated a TF binding score using the function:  
 
where s is a genomic sequence of length n, M is the PWM with n columns and each column 
in M contains the frequency of each nucleotide in each position i = 1,…,n, and bsi is the 
background frequency of nucleotide si (assuming a uniform distribution). The highest score 
obtained for the 4n-2 sequences was assigned as the binding score corresponding to the 
PWM for the reference or alternate SNV alleles. Significant scores were selected and 
reported based on TFM-p-value (Touzet and Varré 2007) score thresholds determined 
using a significance level of a = 10-4. This method was applied for each reference position 
and the three possible alternate SNVs for the complete genome (hs37d5) to create the 
altered TFBS database, a genome-wide catalogue of predicted SNV-PWM effects. A 
custom program was written in C and CUDA to generate the dataset 
(https://github.com/fuxmanlab/altered_TFBS). The program was executed on Nvidia 
GPUs that are available on the Boston University Shared Computing Cluster (SCC). The 
6.1Tb dataset was stored in a compressed Parquet format on a 320-core Hadoop cluster 










that is also part of the SCC. In addition, a query system was developed using Python and 
PySpark that was run on the BU Hadoop cluster.  The query system was used to search 
either a set of SNVs from a variant calling format (VCF) file (e.g., population-wide SNVs 
or somatic mutations), or all possible SNVs from genomic regions in BED files (e.g., 
promoter or DNase hypersitive site (DHS) regions). In both cases, the query reports the 
PWM scores for each reference/alternate genomic position pair where at least one of the 
alleles has a significant score for the given PWM. As an example, a query consisting of the 
human promoter coordinates from a BED file took about 60 minutes to complete on the 
Hadoop cluster. 
Genomic region definitions 
 
The hs37d5 human genome, downloaded from the Sanger Institute (November 2, 
2018), was used as reference. Promoters were defined as regions from -2000 bp to +250 
bp from all transcription start sites (TSSs) from protein coding genes available at 
GENCODE 19 version (June 14, 2018) (Harrow et al. 2012). We used the R package 
IRanges (M. Lawrence et al. 2013) and BEDTools (Quinlan and Hall 2010) to extract 
promoter coordinates and DNA sequences. DHS genomic coordinates were obtained by 
taking the union of DHS regions from all samples of the Roadmap Epigenomics Mapping 
Consortium (July 31, 2019) (Chadwick 2012). 
Generation of reference parameters for altered TF binding in genomic regions 
 
SNVs may affect TF binding by either creating or disrupting TFBSs. Therefore, we 




disruptability. Gainability was defined as the ratio between the number of SNVs that lead 
to gain of TFBSs and the total number of SNVs that are not located within existing TFBS 
for the given PWM. This corresponds to the probability of creating a TFBS for a given 
PWM for the set of SNVs analyzed assuming equal likelihood of nucleotide changes. 
Disruptability was defined as the ratio between the number of SNVs that disrupt a TFBS 
and the total number of possible SNVs. This corresponds to the probability of a SNV 
disrupting an existing TFBS for a given PWM assuming equal likelihood of nucleotide 
changes. Disruptability can be divided into two components: hitability, which is the 
probability of a random SNV residing within a TFBS corresponding to the PWM; and 
robustness, which is the probability of a SNV that resides within a TFBS to retain the TFBS. 
Thus, disruptability corresponds to the hitability multiplied by 1 – robustness of a PWM. 
In the case of TFs with multiple PWMs, we used the median score across PWMs as the 
representative one for each parameter. The four parameters (gainability, disruptability, 
hitability, and robustness) was calculated for each TF for the human genome, promoters, 
and DHS regions. 
Analysis of parameter scores for population-wide and cis-eQTL SNVs 
 
To predict the effect Population-wide SNVs were downloaded from the 1000 
Genomes Project (Auton et al. 2015) in vcf format (October 1, 2019). BEDTools intersect 
function was used to select SNVs in promoters or DHS regions. Gainability, disruptability, 
hitability, and robustness scores were calculated as described above. For DHS regions, we 
calculated the correlation of each population-wide TF score against their population-wide 




mutational frequency of each of the twelve types of SNV changes in the 1000 Genomes 
Project set (see below). In addition, we downloaded finely mapped cis-eQTL SNVs from 
GTEx (Aguet et al. 2017) (October 10 2020) reported by CaVEMaN (Brown et al. 2017) 
and DAPG (Wen, Pique-Regi, and Luca 2017) methods. BEDTools intersect function and 
a custom R script were used to obtain unique cis-eQTL SNVs located in promoter and DHS 
regions that were identified by both cis-eQTL prediction algorithms. Then, gainability, 
disruptability, hitability, and robustness scores were calculated for the cis-eQTL SNVs. To 
determine whether the altered TF binding parameters were different than expected by 
chance between population-wide and cis-eQTL SNVs, we subtracted the individual scores 
for each TF to the reference set generated from a random sampling model (see below) to 
calculate Dscores for gainability, disruptability, hitability, and robustness. 
Estimation of a population-wide SNV-specific reference set of TFBS parameters 
 
A reference set of scores for gainability, disruptability, hitability, and robustness 
was generated for the population-wide and cis-eQTL analysis. One million randomly 
selected SNVs were selected matching the frequency of the twelve possible mutations from 
the population-wide SNVs located in DHS regions. One hundred random samples were 
generated and the four parameters per sample were calculated for each PWM as previously 
discussed. Finally, the population-wide derived reference set for each parameter 
correspond to the average values for each PWM across the one hundred random samples. 





Somatic SNVs were obtained from 2,658 whole genome sequenced samples from 
the PCAWG cohort across 20 cancer types (Rheinbay et al. 2020). For each cancer type, 
we combined the SNVs across its associated samples and generated a unique set of SNVs 
per cancer type. BEDTools intersect function was used to extract SNVs in DHS regions 
for each cancer type. The observed gainability, disruptability, hitability, and robustness 
scores were calculated for each TF and were subtracted by their corresponding score from 
the reference set of all possible SNVs in DHS regions. This resulted in Dscores for each 
PWM-cancer type combination. We also calculated the median Dscore for each TF family 
and generated heatmaps in Prism version 8.3.1. Furthermore, we calculated the observed 
Dscores for gainability and disruptability for the 741 TFs for individual samples having 
more than 5,000 SNVs located in DHSs. Heatmaps comparing Dscores for individual 
samples and TFs were generated using the R package ComplexHeatmap (Gu, Eils, and 
Schlesner 2016). Finally, we downloaded SNVs caused by UV-light (Kucab et al. 2019) 
and these SNVs were filtered to obtain Dscores for each parameter in DHS regions as 
described for the PCAWG analysis. We calculated the correlation of the UV-light derived 




Custom R scripts and Prism were used for statistical analysis. Correlation tests were 
performed using the Pearson correlation coefficient and group comparisons were 





Estimating the effects of SNVs in creating and disrupting TFBS 
 
To predict the effect of each possible SNV in transcriptional control regions on TF 
binding, we focused DHS regions, which are generally associated with transcriptionally 
active or poised genomic regions. We calculated binding scores for 1,898 PWMs available 
in CIS-BP (Weirauch et al. 2014) corresponding to 741 human TFs, for each reference and 
alternative allele. For each PWM-SNV combination, we determined whether the 
alternative allele created or disrupted a TFBS. Then, we defined two parameters: 
‘gainability’ as the probability of a random SNV creating a binding site for a given TF, and 
‘disruptability’ as the probability of a random SNV disrupting an existing binding site for 
a given TF (Figures 3.1A-B). We also determined the gainability and disruptability scores 
genome-wide, and contrasted to that of DHS and gene promoter regions. We detected a 
wide range of distributions of gainability and disruptability scores for different TFs 
spanning five orders of magnitude which highly anti-correlated with the information 
content of the PWMs. We found a strong correlation for both scores between the different 
genomic regions suggesting that there is no clear a priori preference for random mutations 
to lead to gain or disrupt TFBSs both for regulatory regions and the whole genome. 
Interestingly, we found a higher disruptability for AP-1 TFs (e.g., FOS, FOSL1, FOSL2, 
JUN, JUNB, JUND), TAL1, and NFE2 in DHSs than in promoter regions, consistent with 
previous findings that these TFs are enriched in enhancer regions (Gerstein et al. 2012; 




regions, consistent with known roles of SP factors in regulating RNA Pol II recruitment to 
core promoters and regulating transcriptional activity. 
 
Figure 3.1 Prediction of the effect of SNVs on TF binding in DHSs. (A-D) The distribution of 
gainability (A), disruptability (B), hitability (C), and robustness (D) in DHSs were calculated for 
all TFs with available motifs in CIS-BP and binned by TF family. Significant differences for each 
parameter between a TF family and all TFs were calculated using a Mann-Whitney U test. * p < 
0.05. (E) The correlation between each of the four parameters was estimated using the Pearson 
correlation coefficient. 
TFs from the same DNA binding domain (DBD) family often have similar DNA 
binding preferences, in particular for certain families such as homeodomains, ETS factors, 
bHLH factors, and nuclear receptors, and are frequently different between TFs from 
different families (Weirauch et al. 2014). Thus, we expected different TF families to differ 
in gainability and disruptability scores. Indeed, we observed that homeodomain and 
forkhead TFs have a higher gainability than other TFs whereas bZIP, ZF-C2H2, nuclear 




for disruptability of these TF families (Figure 3.1B), suggesting that homeodomains and 
forkhead TFs are more likely to be rewired by SNVs than other TF families. This is likely 
due to the short homeodomain and forkhead TF motifs, as we observed that gainability and 
disruptability are overall anti-correlated with motif length and information content. 
The likelihood of SNVs disrupting TFBSs for a TF is influenced by two parameters: 
1) hitability (i.e., the probability of a SNV residing within an existing TFBS), and 2) 
robustness (i.e., the chance that a SNV in a TFBS for such TF would not affect TF binding). 
In this way, disruptability is equal to the product of hitability and 1 – robustness. Of these 
two parameters, hitability has a larger impact on the difference in disruptability between 
TFs as it spans five orders of magnitude compared to robustness which spans only one 
order of magnitude (Figure 3.1C-D). Interestingly, although hitability, gainability, and 
disruptability are all highly correlated with each other (Figure 3.1E), in part driven by the 
information content of the PWMs, robustness is lowly correlated with these parameters 
(Figure 3.1E). Further, contrary to the other parameters, robustness is correlated to the 
information content per base in the PWM which has low variantion between TFs, rather 
than the total information content. 
Evidence of noncoding selection in population-wide SNVs 
 
The human population displays high variability in genome sequence with close to 
100 million SNVs being reported (Auton et al. 2015). Most of these SNVs reside in 
noncoding regions of the genome potentially creating or disrupting TFBSs (Maurano et al. 
2012; 2015; Hindorff et al. 2009). The vast majority of these SNVs are expected to be 




SNVs present in the population would be depleted in those that alter TF binding, as changes 
in gene expression are expected to be evolutionarily constrained. To study the effect of 
population-wide genetic variation on TF binding, we analyzed SNVs from the 1000 
Genomes Project (Auton et al. 2015) located in DHS regions and determined gainability, 
disruptability, hitability, and robustness scores for each TF. We compared these parameters 
to a reference set derived from a random sampling of mutations based on the mutational 
frequency of each of the twelve types of SNV changes in the 1000 Genomes Project set. 
Interestingly, 89.2% of the TFs show a significantly higher gainability score than the 
reference (Figure 3.2A). In contrast, 66.8% of the TFs show a significantly lower 
disruptability for the population-wide SNVs (Figure 3.2B). These results suggest a 
selection of population-wide SNVs against disrupting existing TFBSs and a positive 





Figure 3.2 Differential parameter scores for population-wide and cis-eQTL SNVs. (A-D) 
Correlation between scores derived from SNVs from the 1000 Genomes Project (1000 genomes) 
and the average of 100 random sets of 1,000,000 SNVs (reference) for gainability (A), 
disruptability (B), hitability (C), and robustness (D). Correlation was determined by the Pearson 
correlation coefficient. Significantly enriched (red) and depleted (blue) TFs are highlighted. (E-H) 
Dscores (observed in set – reference) for each parameter for all TFs and specific TF families for 
population-wide and cis-eQTL SNVs. Significant differences between the population-wide and cis-
eQTL scores were determined by a Mann-Whitney U test. * p < 0.05. 
We further calculated the hitability and robustness scores for population-wide 




Strikingly, we found that even though hitability is similar between population-wide SNVs 
and the reference (Figure 3.2C), population-wide SNVs show higher values for robustness 
for 81.6% of TFs (Figure 3.2D). These results suggest that the negative selection towards 
TFBS disruption in population-wide SNVs is mainly driven by the selection for SNVs that, 
even though they may reside within existing TFBSs, they do not perturb TF binding. 
cis-eQTL SNVs display a high likelihood to create and disrupt TFBSs 
 
Previous studies on cis expression quantitative trait loci (cis-eQTLs) have identified 
functional sets of SNVs in transcriptional control regions associated with changes in target 
gene expression (Aguet et al. 2017). We compared the scores of cis-eQTL and population-
wide SNVs for each parameter in this study to the reference score obtained from a random 
sampling to generate Dscores (SNV group - reference). We found high Dgainability and 
Ddisruptability scores for all TF families in the cis-eQTL SNV set compared to the Dscores 
for the population-wide set (Figure 3.2E-F). This suggests that cis-eQTLs are enriched in 
SNVs that create or disrupt TFBSs which likely contributes to their effect in differential 
gene expression. We further investigated the effects on cis-eQTLs disruptability and found 
that cis-eQTL SNVs lead to higher Dhitability and lower Drobustness scores than 
population-wide SNVs (Figure 3.2G-H). These findings suggest that the increased 
disruptability by cis-eQTLs SNVs is due to both an increase in SNVs being located in 
existing TFBSs and by affecting bases with higher information content within those 
TFBSs. 





Cancer is characterized by the presence of somatic SNVs in tumors, more than 90% 
of which reside in noncoding regions of the genome (Araya et al. 2016b). It has been shown 
that different cancer-types display different mutational signatures driven by different 
mutation and DNA repair mechanisms (Alexandrov et al. 2013; 2020). Given the DNA 
binding specificity differences between TFs, we hypothesized that mutational signatures 
specific to different cancer-types may affect TFBSs differentially across TF families. To 
investigate this hypothesis, we selected SNVs located in DHS regions from 20 cancer types 
from 2,658 tumor samples from the Pan-Cancer Analysis of Whole Genomes (PCAWG) 
Consortium (Campbell et al. 2020) and calculated, for each TF, its Dgainability, 
Ddisruptability, Dhitability and Drobustness scores relative to the reference scores in DHSs.  
 We found higher Dgainability scores for forkhead and Sox families across many 
cancer-types (Figure 3.3A), with the highest enrichment in colon/rectum cancer. This is 
consistent with studies showing that the forkhead TFs FOXO3 and FOXA1, which have a 
2 and 2.4-fold increase in gainability in colon/rectum cancer respectively, promote colon 
cancer proliferation (Gao et al. 2019). Similarly, overexpression of FOXJ1 has been linked 
to progression of colorectal cancer by promoting translocation of b-catenin (K. Liu, Fan, 
and Wu 2017). Sox TFs are also associated with cancer, including SOX11 that shows a 
1.5-fold increase in gainability in breast cancer and that has been correlated with breast 
cancer growth and invasion (Shepherd et al. 2016). Overall, these results support a positive 





Figure 3.3 Effect of cancer somatic mutations on TFBSs. (A-D) Median Dscores for each TF 
family and cancer-type combination for gainability (A), disruptability (B), hitability (C), and 
robustness (D). (E-F) Motifs logos for NFATC4 (E) and ELF4 (F) and impact of melanoma 
mutational signatures on the gain and disruption of the corresponding motifs. 
Other associations for Dgainability scores between TF families and cancer-types 
are more specific. For example, we found gain of homeodomain TFBSs to be highly 
enriched in colon cancer (Figure 3.3A). Indeed, HOXA3, a homeodomain TF that shows a 
1.5-fold increase in gainability, has been shown to promote colon/rectum cancer (X. Zhang 
et al. 2018). Other TFs from the homeodomain subfamilies HOXB and HOXD have also 
been found to be up-regulated in cancer (S. Yang et al. 2018; de Bessa Garcia et al. 2020), 




respectively. Furthermore, skin cancer shows an enrichment in gain of rel TFBSs, which 
is mainly driven by the NFAT subfamily. In particular, NFATC3 (3.8-fold increase in 
gainability) is highly expressed in skin cancer and is associated with cell transformation 
and tumor growth in this cancer type (Xiao et al. 2017). Conversely, we found a depletion 
to gain TFBSs from the bHLH, bZIP, and ZF-C2H2 families in skin cancer. In particular, 
we found that all of CREB TFs from the bZIP family show a negative Dgainability in skin 
cancer, where these TFs have been reported to inhibit tumor growth and metastasis (Xie et 
al. 1997). In addition, ZBTB7A, a ZF-C2H2 TF with a 2.3-fold decrease in gainability in 
skin cancer, suppresses melanoma metastasis (X. S. Liu et al. 2015).  
In contrast to Dgainability, we found negative Ddisruptability scores for forkhead, 
homeodomain, nuclear receptor, rel, sox and T-box families across most of the 20 cancer 
types analyzed (Figure 3.3B). These results suggest a negative selection towards disrupting 
TFBSs for these families. Contrary to what we observed for population-wide SNVs where 
the reduced Ddisruptability was associated to an increase in Drobustness, the reduced 
disruption for cancer mutations is associated with both an increase Drobustness and a 
reduced Dhitability, suggesting negative selection (Figure 3.3C-D). The only exceptions 
having a higher Ddisruptability score correspond to rel and ETS TFs in skin cancer, many 
of which have been associated with melanoma. This is consistent with the frequency of 
triplets matching the mutational signatures of melanomas (TCNàTTN and CCNàCTN) 
(Alexandrov et al. 2020) within motifs of rel factors such as NFATC4 (Figure 3.3E) and 




mutations lead to a net increase in TF binding sites for forkhead, homeodomain, nuclear 
receptor, rel, sox and T-box families.  
Different tumors, even from the same cancer-type, can have different mutational 
signatures. Thus, we determined the Dgainability and Ddisruptability profile for 162 highly 
mutated tumors (>5,000 SNVs in DHSs) across 741 TFs. We observed a similar overall 
clustering pattern across tumors (Figure 3.4A-B). Interestingly, all highly mutated skin 
cancer samples clustered together showing a similar pattern of gain and loss of TFBSs. 
This pattern is highly correlated to that of SNVs introduced by treating cell lines with UV 
light (Dgainability, r=0.75, p-value<2x10-16 and Ddisruptability, r=0.78, p-value<2x10-
16) (Figure 3.4C-D), consistent with UV light being a major mutational driver of skin 
cancer SNVs. Surprisingly, colon/rectum tumor show two subtypes, where one subtype 
shows depletion of bZIP, bHLH and C2H2 zinc finger TFs and an enrichment of 
homeodomain TFs and the other subtype shows the opposite profile for both Dgainability 





Figure 3.4 Effect of cancer somatic mutations in individual cancers on Dgainability and 
Ddisruptability. (A-B) For cancer samples with at least 5,000 SNVs in DHS regions, we 
determined for each TF the Dgainability (A) and Ddisruptability (B) scores. Samples were 
clustered using hierarchical clustering, and TF were clustered by TF families. Cancer-types are 
indicated at the top and TF families are indicated at the right of each heatmap, respectively. (C-D) 
Correlation between UV-light-derived Dgainability (C) and Ddisruptability (D) scores for each TF 




In this study, we generated a comprehensive database of altered TFBSs by mutating 




disruptability, hitability, and robustness scores for 741 TFs across the genome, promoters, 
and DHS regions. We found differences in gainability and disruptability scores between 
TF families. Interestingly, we found lower gainability and disruptability values for bZIP, 
C2H2 ZF, nuclear receptors, and T-box, showing that binding sites for these TF families 
are less likely to be affected by SNVs. In contrast, forkhead and homeodomain display 
higher scores for both gainability and disruptability, suggesting a higher rewiring potential 
of the gene regulatory networks controlled by these TFs. Whether in vivo binding site 
occupancy for these TFs is actually rewired across evolution or between individuals in the 
human population, remains to be determined. 
We showed that functional cis-eQTL SNVs are more likely to perturb TFBSs than 
common SNVs in the human population. In addition, we observed that somatic mutations 
in cancer have differential effects on TFBSs for multiple TF families and discuss how these 
profiles are related to distinct cancer mechanisms. Altogether, this database provides 
blueprint to study the impact of SNVs on genetic variation and cancer. In addition, our 
results can be implemented further in methods to identify functional SNVs in sequencing 
data, as our estimated probabilities can be used as background probabilities to compare 
germline or somatic mutations associated with disease in a given cohort. 
By comparing the genome-wide gainability and disruptability to the respective gene 
regulatory regions, we found that score for different genomic regions are highly correlated. 
This suggests that SNVs are likely to affect TFBSs across the genome in a similar manner, 
independent of the genomic function. We hypothesize that the difference between genome-




govern TF binding to transcriptional control region rather than the TFBSs themselves. 
These include factors such as the proximity, co-occurrence, and orientation of TFBSs, as 
well as cooperative or competitive binding/regulation between TFs (Spitz and Furlong 
2012; Claussnitzer et al. 2014).  
By analyzing the parameter patterns of population-wide SNVs we showed that 89% 
of TFs showed increased gainability. However, this increase is significantly lower to the 
higher gainability values found in cis-eQTLs SNVs that correspond to expression 
perturbing SNVs. In contrast, 67% of TFs showed a decrease in disruptability by the 
population-wide SNVs, whereas the cis-eQTL SNVs displayed an increase in disruptability 
scores. Interestingly, this difference is driven by two factors: a higher likelihood of cis-
eQTL SNVs to reside within a TFBS and a higher likelihood of population-wide SNVs that 
land in a TFBS to retain it. These results can be explained by most population-wide SNVs 
being neutral, not affecting gene expression; however, there is a tendency for positive 
selection of gain of TFBSs and negative selection for loss of TFBSs. This suggests a higher 
selective pressure to maintain existing TFBSs which function together with other TFs 
within specific cis regulatory logics, while gain of TFBSs can provide evolutionary 
plasticity.  
To our knowledge, this is the first database that predicts the effect of all possible 
SNVs on TF binding. The database of genome-wide altered TFBSs generated in this study 
and the gainability, disruptability, hitability and robustness parameters calculated for each 
TF provide a powerful resource to predict the effect of SNVs on TF binding and provide a 




SNVs present in specific patient cohorts. Other applications of this resource include 
studying the potential of repetitive elements as latent reservoirs of TFBSs and uncovering 
the role of other disease associated SNV sets and carcinogen signatures. Ultimately, the 
integration of other datasets such as i TF dimer motif specificities, TF motifs in the context 
of nucleosomal DNA (F. Zhu et al. 2018), and the inclusion of new TF motifs as they 
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Chapter 4. Discovery and characterization of cancer driver mutations in gene 
promoters 
Adapted from the following manuscripts: 
1. Carrasco Pro S, Bray D, Hook HJ, Yin M, Bulekova K, Gregor B, Labadorf A, 
Tewhey R, Siggers T, Fuxman Bass JI, 2020. Discovery and characterization of 
cancer driver mutations in gene promoters. In preparation. 
Introduction 
Cancer initiation and progression often originates from environmentally induced or 
spontaneous mutations, and/or inherited genomic variants that increase cancer risk 
(Alexandrov et al. 2013; Helleday, Eshtad, and Nik-Zainal 2014b; Ding et al. 2018). Large 
scale projects such as the Cancer Genome Atlas (TCGA) and the International Genome 
Consortium (ICGC) have identified millions of somatic SNVs in tumors(Weinstein et al. 
2013; Hudson et al. 2010). However, in most cases, it is not known whether these mutations 
affect any cellular function, confer growth advantage, and are causally implicated in cancer 
development (Pon and Marra 2015). This is because only a few cancer driver mutations are 
needed to drive tumor initiation and growth and these mutations have to be distinguished 
from thousands of passenger mutations (Pon and Marra 2015). The vast majority of these 
cancer drivers have been identified in coding regions. Even though more than 90% of 
somatic SNVs are located in noncoding regions, only a handful of noncoding cancer drivers 
have been identified (Khurana et al. 2016).  
Noncoding variants (NCVs) may affect the binding of transcription factors (TFs) 




example, TERT overexpression is a major contributor to cancer and has been shown to be 
caused by NCVs in its promoter that create Ets factors binding sites (Susanne Horn et al. 
2013; Huang et al. 2013; Shrestha et al. 2019). Other examples of characterized noncoding 
cancer drivers include NCVs in the promoters of FOXA1, HES1, SDHD, PLEKSH, among 
others (Weinhold et al. 2014; Rheinbay et al. 2017; Piraino and Furney 2017). Further, the 
analysis of 2,568 cancer whole genome samples from the Pan-Cancer Analysis of Whole 
Genomes (PCAWG) predicted driver NCVs in the promoters of 9 genes and estimated 96 
potential driver NCVs gene promoters within this cohort (Rheinbay et al. 2020). Whether 
this is due to a limited contribution of NCVs to cancer or to limitations of current 
approaches to predict NCV drivers remains to be determined. 
Computational methods to predict driver NCVs, collectively called mutational 
burden tests, are based on determining an increased mutational rate (MR) in cis-regulatory 
elements (CREs) compared to a background mutational rate (BMR) (H. Li 2011; 
Martincorena et al. 2017; Shuai et al. 2020; Lanzós et al. 2017; Lochovsky et al. 2015; M. 
S. Lawrence et al. 2014; Nik-Zainal et al. 2016; Juul et al. 2017; Hornshøj et al. 2018). 
These methods consider different parameters to estimate the BMR such as cancer-specific 
mutational signatures, sequence conservation, functional annotations, and mutational rates 
in neighboring regions or other “similar” genomic regions. In addition, other covariates 
may be used such as replication timing, expression levels, and motif analysis. These 
mutational burden tests have only identified a handful of drivers NCVs given that most 
NCVs are passenger and that the BMR is locus specific (Rheinbay et al. 2020). Thus, 




predictive power of these methods. Given the reduced number of predicted driver NCVs, 
studies have used low-throughput methods for experimental validation such as report 
assays, EMSAs, and allelic imbalance in gene expression or TF binding.  
Here, we developed a novel TF-aware burden test (TFABT) based on the 
hypothesis that creating (or disrupting) a TFBS at different positions within a gene 
promoter is likely to lead to similar effects on target gene expression. It has been reported 
that TF binding sites in promoters and enhancers frequently occur in homotypic clusters 
and regulate gene expression through cooperative and non-cooperative mechanisms. This 
TFABT identifies promoters containing a higher than expected number of mutations across 
patients that create/disrupt a specific TFBS in a CRE using a binomial test. We predicted 
2,555 cancer driver NCVs in the promoters of 813 genes across 20 cancer types. These 
genes are enriched in cancer-related genes, essential genes, and their expression levels are 
associated with cancer prognosis. More importantly, we validated 765 NCVs using 
massively parallel reporter assays (MPRAs) and observed a similar validation rate to 
known drivers. Finally, we found that 604 NCVs show differential cofactor recruitment by 
comprehensive assessment of complex assembly at DNA elements (CASCADE).  
Materials and Methods 
Altered transcription factor binding predictions 
 
To predict the effect of all possible SNVs in the human genome on TF binding, for 
each possible SNV and each TF with available PWMs, we determined the binding score 
corresponding to the reference and SNV sequences. We downloaded 1898 position weight 




et al. 2014) and their corresponding TF family. Given a PWM of length n and a genomic 
position (hs37d5 from the 1000 Genome Project), for each of the 2n-1 DNA sequences on 
each strand of length n that overlap with the genomic position, we determined a TF binding 
score using the function:  
 
where s is a genomic sequence of length n, M is the PWM with n columns and each 
column in M contains the frequency of each nucleotide in each position i=1,…,n, and bsi 
is the background frequency of nucleotide si (we assume a uniform distribution). The 
highest score obtained for the 4n-2 sequences was assigned as the binding score 
corresponding to the PWM for the reference or alternate SNV alleles. Significant scores 
were selected and reported based on TFM-p-value (Touzet and Varré 2007) score 
thresholds determined using a significance level a=10-4. This method was applied for each 
reference position and the three possible SNVs for the complete genome (hs37d5) to create 
the altered TFBS database, a genome-wide catalogue of SNV-TF effects. Custom C scripts 
were developed to generate this dataset using GPUs and the data was stored in the Hadoop 
servers at Boston University (www.github.com/fuxmanlab/altered_TFBS). 
ChIP-seq allelic imbalance analysis 
 
To estimate optimal threshold(s) of motif scores differences for a given PWM 
between a reference allele and SNV allele to predict allelic imbalance in TF binding, we 
used available ChIP-seq experimental data. ChIP-seq experiment FASTQ files were 
downloaded from the ENCODE Project (Davis et al. 2018) for 14 datasets (55 experiments) 










performed in cell lines with normal karyotype (Table 4.1). The files were aligned using 
BWA (H. Li and Durbin 2009) and pre-processed using standard GATK methodology 
(Depristo et al. 2011). Variant calling was performed on the aligned BAM files using 
GATK Variant Discovery pipeline (Depristo et al. 2011) and BCF Tools (H. Li 2011). The 
intersection of variants from both tools was used to extract the allele read counts for each 
variant. Allelic imbalance analysis was performed for heterozygous positions in promoters 
for each experiment. A binomial test was used to identify SNV located in positions were 





Motif_ID TF_Name Family_Name cell_line encode_experiment_id
M4465_1.02 MAX bHLH GM12878 ENCSR000DZF
M4596_1.02 MAX bHLH HUVEC ENCSR000EEZ
M4481_1.02 USF2 bHLH GM12878 ENCSR000DZU
M4479_1.02 TCF12 bHLH GM12878 ENCSR000BGZ
M4513_1.02 TCF12 bHLH H1-hESC ENCSR000BIT
M4480_1.02 USF1 bHLH GM12878 ENCSR000BGI
M4514_1.02 USF1 bHLH H1-hESC ENCSR000BIU
M4464_1.02 JUND bZIP GM12878 ENCSR000DYS
M4452_1.02 BATF bZIP GM12878 ENCSR000BGT
M4500_1.02 ATF3 bZIP H1-hESC ENCSR000BKC
M4501_1.02 JUN bZIP H1-hESC ENCSR000ECA
M4591_1.02 JUN bZIP HUVEC ENCSR000EFA
M4483_1.02 ZEB1 C2H2 ZF GM12878 ENCSR000BND
M4469_1.02 REST C2H2 ZF GM12878 ENCSR000BQS
M4508_1.02 REST C2H2 ZF H1-hESC ENCSR000BHM
M4482_1.02 YY1 C2H2 ZF GM12878 ENCSR000BNP
M4516_1.02 YY1 C2H2 ZF H1-hESC ENCSR000BKD
M4430_1.02 CTCF C2H2 ZF AG04449 ENCSR000DPG
M4431_1.02 CTCF C2H2 ZF AG04450 ENCSR000DPM
M4433_1.02 CTCF C2H2 ZF AG09319 ENCSR000DPS
M4436_1.02 CTCF C2H2 ZF BJ ENCSR000DQI
M4455_1.02 CTCF C2H2 ZF GM12878 ENCSR000AKB
M4456_1.02 CTCF C2H2 ZF GM12878 ENCSR000DZN
M4457_1.02 CTCF C2H2 ZF GM12878 ENCSR000DKV
M4458_1.02 CTCF C2H2 ZF GM12878 ENCSR000DRZ
M4517_1.02 CTCF C2H2 ZF HA-sp ENCSR000DSU
M4518_1.02 CTCF C2H2 ZF HBMEC ENCSR000DTA
M4521_1.02 CTCF C2H2 ZF HEEpiC ENCSR000DTR
M4580_1.02 CTCF C2H2 ZF HMEC ENCSR000DUS
M4583_1.02 CTCF C2H2 ZF HPAF ENCSR000DUX
M4585_1.02 CTCF C2H2 ZF HRE ENCSR000DVH
M4586_1.02 CTCF C2H2 ZF HRPEpiC ENCSR000DVI
M4588_1.02 CTCF C2H2 ZF HSMMtube ENCSR000ANS
M4593_1.02 CTCF C2H2 ZF HUVEC ENCSR000DLW
M4647_1.02 CTCF C2H2 ZF NH-A ENCSR000AOO
M4648_1.02 CTCF C2H2 ZF NHDF-Ad ENCSR000APM
M4651_1.02 CTCF C2H2 ZF NHLF ENCSR000ANO
M4654_1.02 CTCF C2H2 ZF Osteobl ENCSR000APF
M4659_1.02 CTCF C2H2 ZF SAEC ENCSR000DXI
M4453_1.02 BCL11A C2H2 ZF GM12878 ENCSR000BHA
M4484_1.02 ZNF143 C2H2 ZF GM12878 ENCSR000DZL
M4454_1.02 BRCA1 EIN3 GM12878 ENCSR000DZS
M4475_1.02 SPI1 Ets GM12878 ENCSR000BGQ
M4461_1.02 ETS1 Ets GM12878 ENCSR000BKA
M4462_1.02 GABPA Ets GM12878 ENCSR331HPA
M4595_1.02 GATA2 GATA HUVEC ENCSR000EVW
M4473_1.02 PBX3 Homeodomain GM12878 ENCSR000BGR
M4463_1.02 IRF4 IRF GM12878 ENCSR000BGY
M4466_1.02 MEF2A MADS box GM12878 ENCSR000BKB
M4467_1.02 MEF2C MADS box GM12878 ENCSR000BNG
M4477_1.02 SRF MADS box GM12878 ENCSR000BGE
M4512_1.02 SRF MADS box H1-hESC ENCSR000BIV
M4511_1.02 RXRA Nuclear receptor H1-hESC ENCSR000BJW
M4468_1.02 RELA Rel GM12878 ENCSR000EAG




Table 4.1 ChIP-seq experiments downloaded from ENCODE. 
Differential binding events were calculated by comparing the motif score of each 
SNV to its reference allele. Thresholds of two types were generated for gain/disruption of 
TFBSs to determine their ability to predict ChIP-seq allelic imbalance: 1) when only the 
reference or alternate allele pass the binding threshold for the motif determined by TFMp-
value (Touzet and Varré 2007), or 2) when at least one allele passed the motif binding 
threshold and the difference in score between alleles (Dallele score) is above a certain value 
ranging from 0 to 7. To benchmark our predictions, for each TF, we used SNVs in allelic 
imbalance in ChIP-seq as true positives and those not in allelic imbalance as true negatives, 
and compared to predicted gain/loss of TFBSs in the same direction as the allelic imbalance. 
F-values and relative accuracies were calculated for all thresholds (Figure 4.1). We further 
selected the first threshold, and motif score differences of two and three from the second 





Figure 4.1. ChIP-seq allelic imbalance F-scores versus Dallele score threshold. Arrows show 
selected thresholds. 
Processing of PCAWG mutational data 
 
We identified coding regions by filtering “coding_regions” of the GENCODE v19 
(Harrow et al. 2012) (Jun 14 2018) annotation. Promoters were defined as regions between 
-2 kb to +250 bp from the transcription start site (TSS) from any protein coding region. In 
the case of overlapping alternative promoters, we merged the regions to prevent over 
counting. We used the R package IRanges (M. Lawrence et al. 2013) to determine the 
promoter coordinates and BEDTools (Quinlan and Hall 2010) was used to remove 
promoter coordinates overlapping with coding regions (e.g., in cases with genes with 
alternative promoters). We downloaded VCF files of 2,654 samples of the PCAWG cohort 
(Campbell et al. 2020) from the ICGC portal (Hudson et al. 2010) (Jan 23 2019) and 
BEDTools intersection command (Quinlan and Hall 2010) was used to identify SNVs in 
promoter regions. 
Generation and use of the TF-aware burden test 
 
We designed the TF-aware burden test to determine whether the number of 
observed SNVs in promoter B that lead to gain (or loss) of a binding site for PWM A is 
more than expected by chance given the total number of mutations observed in promoter 
B across samples within a certain cancer type. The number of promoter SNVs that create 
(or disrupt) a binding site for PWM A in promoter B follows a binomial distribution P(n, 
p), where n is number of SNVs in promoter B across patients, and p is the probability that 
an SNV in B creates (or disrupts) a binding site for PWM A. 










changing the reference base at position i in promoter B to the mutated base Mj, C(PWM 
A, Bi, Mj) is 1 if mutating Bi to Mj leads the creation (or distruption) of a binding site for 
PWM A and 0 otherwise, and L is the nucleotide length of promoter B. F(Bi, Mj) was 
calculated based on the genome-wide mutational frequencies in a cancer type, whereas 
C(PWM A, Bi, Mj) was determined by calculating the motif score difference between the 
sequence surrounding position i for the reference and alternate alleles. These motif scores 
were obtained by querying the altered TFBS database. We used thresholds obtained from 
TFMp-value algorithm (Touzet and Varré 2007) to determine whether a motif score is 
significant, and the three different thresholds selected from the ChIP-seq allelic imbalance 
analysis. For a given set of SNV samples, we calculated P(n, p) for each PWM- promoter 
pair and each of these three thresholds independently and corrected for multiple hypothesis 
testing using FDR. To increase the confidence in our predictions, only PWM-promoter 
associations that are significant with an FDR < 0.01 using all three Dscore thresholds were 
considered. Then we selected SNVs from the PCAWG samples (Campbell et al. 2020) 
located in the significant promoters that were associated with differential score of the 
corresponding PWM. For predicted driver SNVs, we used the union of significant 
associated PWM from any of the three thresholds. We used the TFABT for each of the 20 
cancer types sample set and a pan-cancer analysis to identify predict driver SNVs. 





To determine the pathways associated with the 813 genes with predicted driver 
NCVs, we used Metascape “Express Analysis” (Zhou et al. 2019) function on this gene set 
to identify its significantly enriched pathways. In addition, to determine if the 813 genes 
are enriched in known cancer associated genes, we downloaded the Cancer Gene Census 
(CGC) list of genes from the COSMIC database (Sondka et al. 2018) (Aug 2 2018) and 
calculated the odds ratio (OR) for enrichment of the 813 genes in CGC. We also filtered 
the CGC gene list by the 741 TFs used in this study, to obtain a list of known cancer 
associated TFs. We determined the enrichment of known cancer associated TF in the 404 
TF predicted to be associated with altered binding site (creation/disruption) by the TFABT 
predicted driver NCVs.  
To determine whether our list of predicted driver genes in enriched in essential 
genes, we used the list essential genes from cancer cell lines from DepMap (Meyers et al. 
2017) (May 5 2020) and fitness associated genes from Project Score (fitness genes for three 
or more cell lines) (Behan et al. 2019) (May 5 2020). We determined the proportion of the 
813 predicted driver genes, and CGC genes, which are essential or are fitness related and 
compared to that of other protein coding genes using a proportion comparison test.  
Gene expression levels have been associated with cancer prognostics 
(favorably/unfavorably) (The Human Protein Atlas, downloaded April 29 2019) (Uhlen et 
al. 2017). Genes were classified as being associated exclusively with favorable or 
unfavorable prognostics, or a mix (either) of the two. We determined the enrichment of 
prognostic associated (favorable, unfavorable, and either) genes in the 813 driver gene set 




Structural variation has been associated with changes in gene expression. We 
obtained genes associated with changes in gene expression caused by structural variation 
across 21 TCGA cohorts (A. Li et al. 2019) (May 25 2020). We filtered this gene set for 
genes with altered gene expression in more than five cancer types. Similarly, we calculated 
an enrichment of these genes in the 813 driver gene set and in the CGC genes using a 
proportional comparison test. 
MPRA library construction 
 
The MPRA library was constructed as previously described in Tewhey et al. 
(Tewhey et al. 2016). Briefly, oligos were synthesized (Agilent Technologies) as 230 bp 
sequences containing 200 bp of genomic sequences and 15 bp of adaptor sequence on either 
end. Unique 20 bp barcodes were added by PCR along with additional constant sequence 
for subsequent incorporation into a backbone vector by Gibson assembly. The oligo library 
was expanded by electroporation into NEB 10-beta E. coli, and the resulting plasmid 
library was sequenced by Illumina 2 × 150 bp chemistry to acquire oligo-barcode pairings. 
[DB2] The library underwent restriction digestion, and GFP with a minimal TATA 
promoter was inserted by Gibson assembly resulting in the 200 bp oligo.] sequence 
positioned directly upstream of the promoter and the 20 bp barcode falling in the 3’ UTR 
of GFP. After expansion within E. coli the final MPRA plasmid library was sequenced by 
Illumina 1 × 31 bp chemistry to acquire a baseline representation of each oligo-barcode 
pair within the library. 





Jurkat cells were grown in RPMI with 10% FBS to a density 1M cells per mL prior 
to transfection. HT-29 cells were cultured in Mocoy’s 5a media with 10% FBS and SK-
MEL-28 in EMEM supplemented with 10% FBS. Six transfection replicates were 
performed on separate days by collecting 90M cells and splitting across nine 100 uL 
transfections each containing 10 µg of MPRA plasmid. Cells were electroporated with the 
Neon Transfection System (100 µl kit) using 3 pulses at 1550v for 10ms. After transfection 
each replicate was split between two T-175 flasks with 150 mL of culture media for 
recovery. After 48 hours, the cells were pelleted, washed three times with PBS and stored 
at -80 C for later extraction. 
RNA isolation and MPRA RNA-seq library generation 
 
RNA for all cell lines was extracted from frozen cell pellets using the Qiagen 
RNeasy Maxi kit. Half of the isolated total RNA underwent DNase treatment and a mixture 
of 3 GFP-specific biotinylated primers (#120, #123 and #126) were used to capture GFP 
transcripts with Streptavidin C1 Dynabeads (Life Technologies). An additional DNase 
treatment was performed, cDNA synthesized from GFP mRNA using SuperScript III and 
purified with AMPure XP beads. Quantitative PCR using primers specific for the GFP 
transcript (#781 and #782) was used to measure GFP transcript abundance in each sample. 
Replicates within each cell type were diluted to approximately the same concentration 
based on the qPCR results. Illumina sequencing libraries were constructed using a two-step 
amplification process to add sequencing adapters and indices. An initial PCR amplification 
with NEBNext Ultra II Q5 Master Mix and primers 781 and 782 were used to extend 




cycles used in the first amplification was selected based on where linear amplification 
began for each cell type (Jurkat: 10 cycles, SK-MEL-28 & HT-29: 13 cycles).  A second 6 
cycle PCR using NEBNext Ultra II Q5 Master Mix added P7 and P5 indices and flow cell 
adapters. For SK-MEL-28 samples we failed to recover enough product during the first 
amplification and processed the second total RNA aliquot using the same protocol, pooling 
the two preparations prior to sequencing. The resulting MPRA RNA-tag libraries were 
sequenced using Illumina single-end 31 bp chemistry (with 8 bp index read), clustered at 
80-90% maximum density on a NextSeq High Output flow cell. 
 
Table 4.2 (A) Primers used in MPRA experiments and (B) Illumina Adaptor/Index Primers 
for Second PCR. 





Data from the MPRA was analyzed as previously described (Tewhey et al. 2016). 
Briefly, the sum of the barcode counts for each oligo were provided to DESeq2 (Love, 
Huber, and Anders 2014) and replicates were median normalized followed by an additional 
normalization of the RNA samples to center the average RNA/DNA activity distribution 
of the 506 negative control sequences over a log2 fold change of zero. This normalization 
was performed independently for each cell type. Dispersion-mean relationships were 
modeled for each cell type independently and used by DESeq2 in a negative binomial 
distribution to identify oligos showing differential expression relative to the plasmid input. 
Oligos passing a false discovery rate (FDR) threshold of 1% were considered to be active. 
For sequences that displayed significant MPRA activity, a paired t-test was applied on the 
log-transformed RNA/plasmid ratios for each experimental replicate to test whether the 
reference and alternate allele had similar activity. An FDR threshold of 5% was used to 
identify SNPs with a significant skew in MPRA activity between alleles (allelic skew). 
Mutational signatures for MPRA validated drivers 
 
SNVs can be caused by multiple mutational processes such as UV-light or 
APOBEC activities. We used ICGC probabilities for each SNV-donor combination to 
assign them a given mutational process if its probability is greater than 0.5 as described 
(Rheinbay et al. 2020). These processes were used to compare the MPRA validation rate 
difference between SNVs derived and not derived from a given mutational process. We 







BI_COMPOSITE_SNV_SBS75_S and APOBEC related signatures 
BI_COMPOSITE_SNV_SBS2_P, BI_COMPOSITE_SNV_SBS13_P, 
BI_COMPOSITE_SNV_SBS69_P. 
Normalized gene expression analysis 
 
We downloaded aligned BAM files corresponding to 1,366 samples from ICGC. 
BAM files were converted to FASTQ files using the SAMtools fastq (H. Li et al. 2009) 
function. Then, we used Salmon (Patro et al. 2017) to quantify the expression of the human 
transcriptome (Esembl, May 30 2019) in transcripts per million (TPM). We summed the 
expression of each gene transcript to obtain the gene TPM expression. 
We calculated a reference expression value for each gene-cancer type combination 
based on the median TPM expression across donors who do not have any mutation in the 
gene promoter. For each donor and gene with a predicted driver NCV in its promoter, we 
calculated the normalized TPM expression as log10( DE:EFGHI:I	JKL
FIMIFI:NI	HI:IGNO:NIF	PQRI	JKL
)	, where 
values greater than 0 are associated with overexpression and values less than 0 with 
underexpression of genes with predicted driver SNVs. This analysis resulted in a dataset 
of normalized expression values for gene-donor pairs associated with predicted drivers. 
Association of creation and disruption of TFBS with target gene expression 
 
To estimate optimal threshold(s) of motif scores differences for a given PWM 
between a reference al Predicted driver NCVs in gene promoters may alter binding of 




NCVs associated with the creation and disruption of a given TF and calculated the 




We selected TFs that had a log10(ratio) greater than 0.5 in at least two of the three 
cell lines, which will suggest these TFs may act as activators. We determined the 
transcriptional effect of activator TFs by comparing the normalized expression of genes 
with associated driver SNVs leading to a TFBS creation and compared its distribution to a 
µ=0 (no effect) using a Kruskal Wallis test. This determined changes in gene expression 
associated with the presence of SNVs affecting activator TFs. A similar approach was used 
for genes with associated driver NCVs leading to a given TFBS disruption. This analysis 
associated the effect of creation or disruption of a TFBS with the over or underexpression 
of its gene targets respectively. 
Cell culture for CASCADE experiments 
 
The cell lines used for CASCADE experiments were obtained from ATCC. Three 
cell lines were used for the CASCADE experiments: Jurkat (ATCC TIB-152), an acute T 
cell leukemia cell line, SK-MEL28 (ATCC HTB-72), a malignant melanoma cell line, and 
HT-29 (ATCC HTB-38), a colorectal adenocarcinoma cell line.  
Jurkat cells were grown in suspension in RPMI 1640 Glutamax media 
(Thermofisher Scientific, Catalog #72400120) with 10% heat-inactivated fetal bovine 
serum (Thermofisher Scientific, Catalog #11360070) and 1mM sodium pyruvate 




#132903) non-treated flasks were used when culturing JURKAT cells for experiments. 
Cells were grown in 50mL of media when being cultured in T175 flasks. 3 T175 flasks, or 
100 million Jurkat cells, were used for each nuclear extraction.  
SK-MEL28 cells were grown in Eagle’s Minimum Essential Medium (EMEM) 
(ATCC, Catalog #ATCC-30-2003) with 10% heat-inactivated fetal bovine serum. T225 
treated flasks for adherent cells (Corning, Catalog #353138) were used when culturing SK-
MEL28 cells for experiments. Cells were grown in 40mL of media when being cultured in 
T225 flasks. 3 T225 flasks, or 60 million SK-MEL28 cells, were used for each nuclear 
extraction.  
HT-29 cells were grown McCoy’s 5A Medium (EMEM) (ATCC, Catalog #ATCC-
30-2007) with 10% heat-inactivated fetal bovine serum. T225 treated flasks for adherent 
cells (Corning, Catalog #353138) were used when culturing HT-29 cells for experiments. 
Cells were grown in 40mL of media when being cultured in T225 flasks. 3 T225 flasks, or 
60 million HT-29 cells, were used for each nuclear extraction. 
CASCADE protein binding microarray experiments 
 
The nuclear extract protocols are as previously described (P. Zhang et al. 2018). 
Changes to the previously published protocols are detailed. To harvest nuclear extracts 
from Jurkat cells, the cells were collected in falcon tubes. The cells were pelleted by 
centrifugation at 500xg for 5 min at 4°C. The media was aspirated off, taking care to not 
disturb the pellet. The cell pellet was washed once with 1X PBS and 0.1mM Protease 




4°C. The 1X PBS and 0.1mM Protease Inhibitor was aspirated off. The cell pellet was 
placed on ice.  
To harvest nuclear extracts from SK-MEL28 and HT-29 cells, the media was 
aspirated off and the cells were washed once with 1X PBS. Once the 1X PBS used to wash 
the cells was aspirated off, enough 1X PBS was mixed with 0.1mM Protease to cover the 
cells was added to each flask. A cell scraper was then used to dislodge the cells from the 
flask. The cells were collected in a falcon tube and placed on ice. To pellet the cells, the 
cell volume was centrifuged at 500xg for 5 min at 4°C. The cell pellet was placed on ice.  
Once the cells were pelleted, the supernatant was aspirated off. The pellet was 
resuspended in Buffer A and incubated for 10 min on ice (10mM HEPES, pH 7.9, 1.5mM 
MgCl, 10mM KCl, 0.1mM Protease Inhibitor, Phosphatase Inhibitor (Santa-Cruz 
Biotechnology, Catalogue #sc-45044), 0.5mM DTT (Sigma-Aldrich, Catalogue #4315)) to 
lyse the plasma membrane. After the 10 min incubation, a final concentration of 0.1% 
Igepal detergent was added to the cell and Buffer A mixture and vortexed for 10 sec. To 
separate the cytosolic fraction from the isolated nuclei, the sample was centrifuged at 
500xg for 5 min at 4°C. The cytosolic fraction was collected into a separate microcentrifuge 
tube. The pelleted nuclei were then resuspended in Buffer C (20mM HEPES, pH 7.9, 
1.5mM MgCl, 0.2mM EDTA, 0.1mM Protease Inhibitor, Phosphatase Inhibitor, 0.5mM 
DTT, and 420mM NaCl) and then vortexed for 30 sec. The nuclei were incubated in Buffer 
C for 1 h while mixing at 4°C. To separate the nuclear extract from the nuclear debris, the 
mixture was centrifuged at 21,000xg for 20 min at 4°C. The nuclear extract was collected 




desalted using Zeba Spin Desalting Columns (ThermoFisher Scientific, Catalog #89882). 
Prior to flash freezing the nuclear extracts, glycerol was added to the nuclear extracts to 
reach a final concentration of 5%. Nuclear extracts were stored at -80°C until used for 
experiments. 
Microarray DNA double stranding and PBM protocols are as previously described 
(Shi et al. 2016; Valouev et al. 2008a; P. Zhang et al. 2018). Any changes to the previously 
published protocols are detailed. Double-stranded microarrays were pre-wetted in HBS 
(20mM HEPES, 150mM NaCl) containing 0.01% Triton X-100 for 5 min and then de-
wetted in an HBS bath. Next the array was incubated with nuclear extract for 1 h in the 
dark in a binding reaction buffer (20mM HEPES, pH 7.9, 100mM NaCl, 1mM DTT, 
0.2mg/mL BSA, 0.02% Triton X-100, 0.4mg/mL salmon testes DNA (Sigma-Aldrich, 
Catalogue #D7656)). The array was then rinsed in an HBS bath containing 0.1% Tween-
20 and subsequently de-wetted in an HBS bath. After the protein incubation, the array was 
incubated for 20 min in the dark with 20µg/mL primary antibody for the TF or COF of 
interest (Supplementary Table 1). The primary antibody was diluted in 2% milk in HBS. 
After the primary antibody incubation, the array was first rinsed in an HBS bath containing 
0.1% Tween-20 and then de-wetted in an HBS bath. Microarrays were then incubated with 
10µg/mL of either alexa488 or alexa647 conjugated secondary antibody (see 
Supplementary Table 1) for 20 min in the dark. The secondary antibody was diluted in 2% 
milk in HBS. Excess antibody was removed by washing the array twice for 3 min in 0.05% 
Tween-20 in HBS and once for 2 min in HBS in coplin jars as described above. After the 




4400A scanner and fluorescence was quantified using GenePix Pro 7.2. Exported 
fluorescence data were normalized with MicroArray LINEar Regression (Shi et al. 2016). 
CASCADE-based differential COF recruitment microarray design 
 
We obtained matching survival A high-throughput array-based screen was 
designed to profile differential COF recruitment to the 2,555 predicter driver NCVs, and 
500 no predicted binding NCVs in 26-base DNA probe target regions centered at the SNP 
position (relative to + strand: 13 bases + SNV location + 12 bases) were obtained for each 
reference (REF) allele using BEDTools (Quinlan and Hall, 2010). For each REF allele 
probe, a probe with the corresponding SNV allele was also included in the design such that 
each of the comparisons above is represented by a pair of REF and SNV probes. For 1,523 
of the predicted driver NCVs and 767 no predicted binding SNVs (sampled randomly from 
each full category above), additional REF/SNV probes were included by shifting the 
variant position -5 and +5 bases within the target region of the probe such that each of these 
comparisons were represented in three total registers. The 26-base target regions were 
embedded in larger 60-base PBM DNA probes as follows: 
“GCCTAG” 5’ flank – 26-base target region – “CTAG” 3’ flank – 
“GTCTTGATTCGCTTGACGCTGCTG” double-stranding primer  
5 replicates of each probe in both the reference (+) orientation and reverse (-) orientation 
were included in the final design. The microarrays were purchased from Agilent 
Technologies Inc. (AMAID: 085920, format: 8×60K). 





Each REF/SNV pair was screened for differential COF recruitment and 
experimental results were preprocessed as above. Z-scores were obtained for each probe 
as previously described (Bray et al., 2020) against the distribution of fluorescence 
intensities obtained at the set of variant-centered no_predicted_binding probes for a given 
experiment. Differential COF recruitment statistics were computed as previously described 
(Bray et al., 2020). Briefly for each REF and SNV allele pair in the design, a t-test was 
used to compare the fluorescence intensity distributions between the 5 REF probes and 5 
SNP probes for a given COF assayed. To mitigate the influence of probe orientation-
specific effects, t-tests were performed independently for each probe orientation with the 
p-values combined using Fisher’s method. For the select sites included in three registers 
(see above), these t-tests were performed across each orientation and each register shift 
independently with the p-values combined using Fisher’s method as above The Benjamini-
Hochberg method was used to adjust the individual p-values for each REF/SNV pair across 
the total number of to account for multiple hypothesis testing. Differential COF recruitment 
was deemed statistically significant if the adjusted p-value (q-value) was below 0.05. The 
fluorescence intensity z-score difference for a given REF and SNV allele probe pair 
(termed Δz-score) was computed as previously described (Bray et al., 2020). Briefly, Δz-
scores were computed by subtracting the mean REF z-score from the mean SNV z-score 
such that a positive Δz-score represents a gain-of-recruitment introduced by the SNV allele 
and a negative Δz-score represents a loss. 
Results 





We developed a novel TF-aware burden test (TFABT) that identifies gene 
promoters containing higher than expected number of SNVs across patients that create (or 
disrupt) a TFBS for a particular TF (741 TFs were tested). For each TF-promoter (A,B) 
pair, the method uses a binomial distribution P(x, n, p) to calculate the FDR for the 
observed number of SNVs in promoter B creating (or disrupting) interactions with TF A 
(x) given the total number of observed SNVs in promoter B (n) all patient samples from a 
cancer type and the probability that a random SNV in B creates (or disrupts) a binding site 
for TF A (p).  
We applied the TFABT to predict cancer driver NCVs in gene promoters using 
2,654 tumor samples from the PCAWG cohort corresponding to 20 cancer types  
(Campbell et al. 2020). Driver predictions were performed per cancer type and in a pan-
cancer analysis. In total, we predicted 2,555 candidate driver NCVs in the promoters of 
813 genes, which create/disrupt binding sites of 404 TFs. The majority of predicted driver 
NCVs were obtained from skin cancer (Figure 4.2A). This is not only related to skin cancer 
samples having the largest number of NCVs but also to a higher percentage of those NCVs 
being predicted drivers (Figure 4.3). The majority of predicted driver NCVs (76%) are 
associated with the disruption of existing TFBSs. This is likely related to a higher 
probability of disrupting a TFBS over its creation in cis-regulatory regions or to the 





Figure 4.2 Driver NCVs prediction and their association with cancer genes and pathways. (A) 
Number of significant NCVs with predicted gain and/or loss of TF binding per cancer type. (B) 
Genes with the most predicted cancer driver NCVs and the percent of patients affected per cancer 
type. (C) Metascape network showing the intra-cluster and inter-cluster similarities of enriched 
gene ontology terms for genes with significant NCVs. (D) Fraction of essential and fitness related 
genes for genes with predicted NCVs, in CGC, or all protein-coding genes. (E) Fraction of genes 
whose expression has favorable, unfavorable (or either) prognosis in cancer for genes with 
predicted NCVs, in CGC, or all protein-coding genes. 
We identified driver NCVs in multiple genes with reported driver NCVs. For 
example, we identified 16 candidate driver NCVs in the promoter of TERT, which included 




Horn et al. 2013; Huang et al. 2013). A large fraction of bladder (65%), skin (47%), and 
head/neck (17%) cancer samples contain at least one of TERT candidate driver NCV 
(Figure 4.2B). In addition, we predicted eight candidate driver SNVs in the promoter of 
PLEKHS1, including two previously reported mutations in chr10:15511590 C>T and 
chr10:115511593 C>T (Rheinbay et al. 2017). These candidate driver NCVs were found 
in 39% of bladder cancer samples, with no other cancer type having more than a 5% 
frequency (Figure 4.2B). Furthermore, the TFABT identified previously known drivers in 
ALDOA, DPH3, CCDC107, LEPRROTL1, and TBC1D12 (Rheinbay et al. 2017; 
Denisova et al. 2015). Novel driver candidate SNVs in lymphoid cancers were predicted 
in the BCL6 and BCL2 promoters, which were found in 23% and 21% of lymphoid cancer 
samples, respectively. Finally, predicted driver SNVs in RPL13A, C16orf59, CDC20, 
OXNAD1, PES1, and TRMT10C were found in skin cancer samples with frequencies 





Figure 4.3. Number of predicted cancer driver NCVs and number of SNVs by cancer type. 
We found multiple lines of evidence showing our predicted driver gene set is 
associated with known cancer related genes, pathways, and functions. First, our predicted 
driver gene set is enriched in gene ontologies associated with general and cancer related 
cellular processes such as cell cycle, TP53 regulation, Wnt signaling, epithelial-
mesenchymal transition, and mitochondrial apoptosis (Figure 4.2C). Second, we found a 
significant enrichment of genes from the Cancer Gene Census (CGC) (Sondka et al. 2018) 
genes in the 813 promoter genes (OR=1.54, p=0.008) and their 404 associated TFs 
(OR=2.3, p=2x10-4). Third, we found a significant enrichment of our predicted driver 




4.2D) (Behan et al. 2019), and genes whose expression has been associated with favorable 
or unfavorable cancer prognosis (Uhlen et al. 2017), comparable to those of CGC genes 
(Figure 4.2E). Finally, we identified a significant overlap of predicted driver genes and a 
set of genes whose somatic copy number variation are associated with changes in their 
expression in multiple cancer types (OR=1.42, p=0.007) (A. Li et al. 2019). These results 
suggest that our predicted drivers are likely to be functional. 
TF-aware driver candidate NCVs lead to altered transcriptional activity 
 
To investigate the effect of the predicted driver NCVs on transcriptional activity, 
we used MPRAs (Tewhey et al. 2016) to systematically test the 2,555 predicted driver 
NCVs and control NCV sets in HT-29 (colorectal), Jurkat (lymphoma) and SK-MEL-28 
(melanoma) cell lines. Since only a subset of DNA regions show MPRA activity for either 
NCV allele, we calculated the validation rate as the ratio of NCVs displaying allelic skew 
over the total number of active DNA regions for each NCV category. For the TF-aware 
predicted driver NCVs, we obtained validation rates of 33%, 53% and 27% for HT-29, 
Jurkat, and SK-MEL-28, respectively, higher than the percentage of NCVs with no 
predicted differential TF binding or no predicted TF binding that display allelic skew 
(Figure 4.4A, Supplementary Figure 4.5A-B). Further, 235 predicted drivers were 
validated across the three cell lines, and 21, 320 and 12 predicted drivers were validated 
exclusively in HT-29, Jurkat and SK-MEL-28 cell lines (Supplementary Figure 4.6). The 
high validation rates from the predicted driver NCVs are similar to experimentally 
characterized driver NCVs in promoters (literature), NCVs leading to allelic imbalance in 




gene expression and cause differential TF binding (germline) (Figure 4.4A). This shows 
that the TFABT can prioritize functional NCVs.  
 
Figure 4.4 Predicted driver NCVs can alter transcriptional acitvity. (A) Validation rate versus 
q-value threshold in SK-MEL-28 for predicted driver NCVs, ChIP-seq allelic imbalance, known 
drivers, MPRA positive controls, germline NCVs, literature genes, no significant differential 
binding, no differential binding. (B) Validation rate vs q-value in SK-MEL-28 for predicted NCVs 
based on whether NCV caused gain, loss of TFBS or both. (C) Fraction of NCVs per frequency in 
patient samples. (D) Fraction of MPRA validated NCVs for genes with at least four 




We validated NCVs associated with both gain and loss of TFBSs. However, we 
observed a higher validation rate for NCVs that loose TFBSs than for NCVs that gain 
TFBSs or bifunctional NCVs (Figure 4.4B). This difference may be related to a higher 
likelihood of affecting expression by disrupting an existing TFBS in a regulatory region 
than by creating a TFBS that may not be in the appropriate regulatory region context or 
distance/orientation to other TFBSs to affect transcriptional activity. Importantly, we found 
that the validation rate for predicted driver NCVs is similar regardless of the NCV 
frequency across cancer samples (Figure 4.4C). This suggests that NCVs with low 
mutation frequency, such as those private to particular tumor samples, can also lead to 
altered transcriptional activity.  
 
Figure 4.5 MPRA validation rate. Validation rates versus q-value for (A) Jurkat and (B) HT-29 




Multiple NCVs in a gene promoter often lead to the same transcriptional effect 
(over or underexpression). For example, all validated NCVs in the TERT promoter lead to 
increased transcriptional activity, consistent previously characterized TERT promoter 
drivers associated with TERT overexpression (Susanne Horn et al. 2013; Huang et al. 
2013). Conversely, two MPRA validated predicted driver NCVs in the RNF20 promoter 
(chr9:104296044 C>T and chr9:104296134 G>A) display reduced transcriptional activity 
(Figure 4.4D). RNF20 underexpression due to promoter hypermethylation has been 
previously associated with genome instability in multiple cancer types (Guppy and 
McManus 2017; Nakamura et al. 2011; Shema et al. 2008). Our results suggest that reduced 
RNF20 promoter activity resulting from NCVs constitutes another potential cancer 
mechanism (Figure 4.4D). Other examples include skin cancer associated genes PARS2, 
GOSR2, and MBD3L1 whose promoter SNVs lead to reduced transcriptional activity 





Figure 4.6. Three-way Venn diagram displaying the number of MPRA validated NCVs for HT-
29, Jurkat and SK-MEL-28 cell lines 
Diver NCVs outside core promoter may affect transcriptional activity  
 
Most driver NCVs have been identified and characterized in core promoter regions 
(-250bp to +250bp from the TSS) (Rheinbay et al. 2017; 2020). Here, we used extended 
promoter regions of -2kb to +250bp from the TSS, expanding the current landscape of 
analysis. Although the fraction of NCVs in PCAWG is mostly homogenous throughout the 
extended promoter region, we observed an enrichment of predicted driver NCVs in the 
core promoter, even though our model did not incorporate any additional information 
beyond TF specificities and promoter sequence (Figure 4.7A). This suggests, that 
considering core promoter regions likely identifies most driver NCVs in gene promoters. 
Nevertheless, we detected MPRA-validated NCVs beyond the core promoter (upstream of 




lymphoid cancer associated NCV chr18:60988772 A>G in the BCL2 promoter is located 
at -1441bp from the TSS and leads increase transcriptional activity in Jurkat cells. In 
addition, we identified the chr5:137799888 G>C NCV located at position -1291 from the 
EGR1 TSS that causes reduced transcriptional activity. Underexpression of the tumor 
suppressor gene EGR1 has been previously reported in multiple cancer types (Baron et al. 
2006; Ferraro et al. 2005). Further, overexpression of USP37 has been previously 
associated with higher mortality rate in breast cancer (Qin et al. 2018) , the chr2:219365001 
located at position -1865 from its TSS was shown to cause increased transcriptional activity 
in Jurkat cells. These results suggest that NCVs located further from the commonly studied 






Figure 4.7 NCV validation rate by TSS distance and mutational signature type. (A) Validation 
rate of predicted driver NCVs in SK-MEL-28 by genomic distance to TSS, and fraction of NCVs 
per 100 bp for predicted driver NCVs, MPRA active NCVs and SNVs in the PCAWG cohort. (B) 
Validation rate for NCVs associated or not with APOBEC mutational processes for the three cell 
lines. (C) Validation rate of predicted driver NCVs associated or not with UV-light mutational 
signature in SK-MEL-28. 
NCVs derived from mutational processes can affect transcriptional activity 
 
Somatic mutations in cancer are caused by endogenous and exogenous mutational 
processes, that differ between patients and cancer types leading to different mutational 
signatures (Alexandrov et al. 2013; 2020). We analyzed the transcriptional activity of 




mutational burden tests: 1) defective apolipoprotein B messenger RNA-editing enzyme 
catalytic (APOBEC) cytidine deaminases that share a common mutational context of C>G 
or C>T at TCT and TCA (Alexandrov et al. 2020), and 2) UV-light associated mutational 
signatures consisting mainly of C>T at TCN and C>T at CCN (Alexandrov et al. 2020). 
We found no significant difference between the validation rate in MPRAs between 
APOBEC+ and APOBEC- NCVs (Figure 4.7B). Importantly, UV-light+ predicted driver 
NCVs validate in MPRAs in SK-MEL-28 cells at a higher rate than UV-light- NCVs (29% 
versus 17%, p=0.003) (Figure 4.7C). This is particularly important given that 86% of the 
predicted driver NCVs in MPRA-active regions in SK-MEL-28 cells are derived from the 
UV-light+ signature. Even though previous studies have filtered out NCVs derived from 
cancer associated mutational processes such as APOBEC and UV-light to increase 
statistical power of their analysis (Rheinbay et al. 2017; 2020), the similar or higher MPRA 
validation rate of predicted driver NCVs suggest that a significant fraction of these NCVs 
have functional activity. 
Transcription factors and their effect in transcriptional activity 
 
We further analyzed the 404 TFs involved in the predicted altered TF binding 
caused by the 2,555 candidate driver NCVs. We found that in the majority of cancer types 
four TF families are mainly involved (Figure 4.8A). Predicted driver NCVs in skin, 
head/neck, kidney, bone/soft tissue and pancreas cancers affect the binding sites of Ets 
factors, a TF family that has been largely associated with multiple cancer types (Bell et al. 
2016; 2015; Yinghui Li et al. 2015). In contrast, predicted driver NCVs in cervix, uterus, 




lung, and prostate cancer NCVs affect Homeodomain binding sites. These differences are 
likely related to the different mutational signatures between cancer types that result in 
altered binding of different TF families. Interestingly, we observed a higher validation rate 
in MPRAs for predicted driver SNVs altering binding sites of TF from the nuclear receptors 
(NR), Ets, and BHLH families (Figure 4.8B). Whether this reflects what occurs in the 





Figure 4.8 Transcription factor effect on transcriptional activity. (A) Fraction of TF families 
with altered TFBS caused by predicted driver NCVs by cancer type. (B) MPRA validation rate in 
SK-MEL-28 versus q-value for TF families. (C) Normalized TPM of genes with predicted driver 
NCVs by TFs associated with gain/overexpression and loss/underexpression. 
TFs can activate or repress target gene expression, with some TFs acting mainly as 
activators and others mainly as repressors. To investigate the effect of predicted driver 
NCVs on their target gene expression, we normalized the expression levels of genes from 
donors with a predicted driver NCV to the median expression of those without any NCV 
in the corresponding gene promoter. This analysis identified 20 TFs whose gain of binding 
sites are associated with increased transcriptional activity and whose disruption of binding 
site is associated with reduced transcriptional activity (Figure 4.8C). Interestingly, we 
identified ten Ets, one nuclear receptor, and one STAT TFs whose creation of binding sites 
is associated with a significant increase of their target genes expression in patient samples. 
In contrast, we did not find any significant association of TFBS disruption and 
underexpression of target genes. This lack of significance may result from a lack of 
sensitivity due to gene expression for the wild type allele or due to compensatory 
mechanisms. In total, we identified 319 genes containing predicted driver NCVs that create 
or disrupt Ets binding sites. Changes in expression, alternative isoforms, or gene fusions 
involving multiple Ets factors have been associated with cancer. The creation or disrution 
of Ets TFBSs likely constitutes another widespread cancer mechanism that can also be 
modulated by the previously reported changes in Ets activities. 
Predicted driver NCVs lead to differential cofactor recruitment 
 
To determine the effect of our predicted driver NCVs on differential cofactor (COF) 




microarray-based method that allows for high-throughput profiling of COF recruitment on 
reference and mutant NCV pairs using nuclear extracts. We used CASCADE to study the 
effect of NCVs in two specifications: 1) single register, where the reference/mutant NCV 
alleles are located in the middle of the probe, and 2) triple register, where the 
reference/mutant NCV alleles are tested in the top, center and bottom of the probe. We 
tested the predicted drivers and controls in a single register array in SK-MEL-28 cells for 
differential recruitment of p300, P300 + peptides, SMARCA4 TBL1XR1, HDAC1, 
HDAC3, RBBP5, SKP2, and GCN5. Overall, we observed a similar or higher validation 
rate for predicted driver NCVs compared to other positive controls such as known driver 
NCVs and ChIP-seq allelic imbalance, and we found a low validation rate for negative 
controls such as NCVs with no predicted or no differential TF binding.  These results show 
that the predicted driver NCVs are associated with differential cofactor recruitment.  
After filtering for reference or mutant NCV alleles above background fluorescent 
intensity (z-score > 2), we observed a high validation rate of 49% of predicted driver NCVs 
for differential recruitment of TBL1XR1 in SK-MEL-28 (Fig 4.9A). These validated NCVs 
show a trend to disrupt TBL1XR1 recruitment. However, the handful of driver NCVs 
showing a gain of TBL1XR1 recruitment are associated with fifteen cancer types may serve 
as therapeutics candidates. Interestingly, vorinostat has been shown to inhibit TBL1XR1, 
it has been approved to treat cutaneous T-cell lymphoma , and clinical trial are active for 
breast and skin cancer types (Munster et al. 2011; Haas et al. 2014). This raises the 
possibility of using vorinostat as a therapeutic opportunity to treat patients carrying these 




P300+peptides in SK-MEL-28 (Fig 4.9B). Similarly, P300 inhibitor, A-485, has been 
shown to inhibit tumor growth in multiple lineage-specific tumors including hematological 
malignancies and androgen receptor-positive prostate cancer (Lasko et al. 2017), and 
upregulates apoptosis in non-small-cell lung carcinoma cells in combination with TRAIL 
(B. Zhang et al. 2020). 
 
Figure 4.9 Predicted drivers cause differential COF recruitment. Differential COF recruitment 
for predicted driver NCVs and no predicted binding NCVs (validation rate) showed as Dz-score 
versus -log10(q-value) in SK-MEL-28 for (A) TBL1XR1 and (B) P300 + peptides, where dotted 
line on y-axis represents significance threshold and on x-axis no differential COF recruitment (0 
Dz-score). Significance values, -log10(q-value), for 3 register versus 1 register array for predicted 
driver NCVs and no predicted binding (validation rate) for (C) TBL1XR1, (D) P300 + peptides, 




Furthermore, we used 3-register probes for 768 randomly selected predicted drivers 
and 384 NCVs with no predicted TFBS. Interestingly, we observed an increase in 
validation rate of 3X and 4X for TBL1XR1 and p300 + peptides recruitment (Figures 4.9C-
D), respectively. Moreover, the 3-register probes were able to validate 5.2% and 2.9% of 
predicted drivers for SKP2 and p300, COFs that show less than 0.5% or no validation rate 
in the 1-register probes (Figures 4.9E-F). This is because NCVs location and orientation in 
the array probes may have distinct effects of TF and COF binding, and using three registers 
increase the likelihood of detecting altered COF recruitment. Importantly, NCVs with no 
predicted TFBS showed validation rates no greater than 1% in the 3-register probes. These 
results support the use of 3-register probes to boost the validation rate for predicted driver 
NCVs without leading to high false positives for negative controls. 
Discussion 
 
In this study, we developed a novel TFABT based on the hypothesis that creating 
(or disrupting) a TFBS at different positions within a gene promoter is likely to lead to 
similar effects on target gene expression. The TFABT identifies gene promoters containing 
higher than expected number of NCVs across patients that create (or disrupt) a TFBS for a 
particular TF based on a binomial test. We applied the TFABT to predict cancer driver 
SNVs in gene promoters using 2,654 tumor samples from the PCAWG cohort 
corresponding to 20 cancer types. Driver predictions were performed per cancer type and 
in a pan-cancer analysis. In total, we predicted 2,555 driver candidates in the promoters of 
813 genes, which create/disrupt binding sites for 404 TFs. These genes included known 




Further, we showed multiple lines of evidence suggesting that the predicted genes and 
associated with known cancer related genes/TF, pathways and gene functions. 
By testing the predicted driver NCVs in MPRAs in three cell lines, we found a 
validation rate similar or greater that known cancer driver NCVs in promoters, ChIP-seq 
allelic imbalance NCVs and germline NCVs associated with altered gene expression and 
TF binding. These results show that the TFABT can prioritize transcription perturbing 
NCVs. Moreover, we show that NCVs private to one sample, which constitute the majority 
of NCVs in the PCAWG cohort, are similarly likely to alter transcriptional activity as 
recurrent NCVs. These MPRA validated cancer driver NCVs greatly expand the current 
known drivers in literature. However, the effect of multiple NCVs located in the same 
regulatory region (i.e promoters, enhancers) remains to be studied. We showed that most 
predicted driver NCVs are located in the core promoter of a gene, which suggests that 
considering the core promoter regions as most other studies have done, likely identifies 
most drivers NCVs in promoters. Conversely, predicted driver NCVs derived from 
APOBEC and UV-light mutational processes show transcriptional perturbing activity, even 
though multiple studies filter out these types of NCVs. Further, UV-light predicted driver 
NCVs validate at a higher rate in MPRAs compared to non UV-light predicted driver 
NCVs. This suggests that excluding NCVs from burden tests based on mutational 
signatures may not be warranted.  
Our validation using MPRAs shows that many of the potential driver NCVs 
identified alter transcriptional activity in an episomal construct. Whether, these NCVs alter 




associated with cancer phenotypes (e.g., increase proliferation, reduced apoptosis, etc.) 
remains to be determined. As NCV drivers have low mutational frequency, available 
cohorts, in most cases, lack statistical power to determine the link between NCVs and its 
target gene expression. Therefore, larger studies cohorts integrating WGS and RNA-seq 
will allow in-vivo validation of NCV drivers. 
We observed a higher validation rate for NCVs associated with differential binding 
of nuclear receptors and Ets factors. These is consistent with the known role of Ets factors 
in cancer initiation and progression (Bell et al. 2016; 2015; Yinghui Li et al. 2015). Even 
though only a small fraction of predicted driver NCVs affect nuclear receptor binding sites, 
we validated driver NCVs associated with NR1I3 and VDR in lymphoma, and NR2C2 in 
skin cancer, which have known antagonists and agonists. These druggable TFs as well as 
the cofactors found to be differentially recruited to the NCVs using CASCADE provide a 
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Chapter 5. Conclusions 
 
In this dissertation, I have discussed the application of literature curation and novel 
bioinformatics algorithms to study transcriptional regulation in health and disease. 
Specifically, in chapter 2 I demonstrated how mining three decades of knowledge can be 
used to generate a comprehensive mouse and human cytokine GRN, CytReg, with 2-3-fold 
more TF-cytokine gene interactions than other available databases. CytReg was 
implemented as a user-friendly database (https://cytreg.bu.edu) where PDIs can be easily 
browsed by TF, cytokine, species, assay type, and TF expression pattern, then visualized 
as a table or an interactive network. The integrative analysis of the cytokine GRN and other 
functional datasets provided insight into the general principles governing cytokine 
regulation, such as a correlation between TF connectivity in the cytokine GRN and immune 
phenotype. By characterizing the TFs and cytokines studied in the last three decades, we 
found biases towards specific TFs/cytokines in the literature and highlight the 
incompleteness of the cytokine GRN. Further, by using cytokine co-expression data and 
TF motif analysis, we predicted novel TF-cytokine promoter interactions that were 
validated with eY1H assays. This exemplifies how the integrative analysis of CytReg can 
be used to prioritize interaction candidates to validate experimentally. Ultimately, the 
integration of different high-throughput and unbiased approaches, population-wide studies 




will lead to a more comprehensive picture of cytokine regulation in different cell types, 
conditions, and individuals. 
In chapter 3, I discussed the predicted genome-wide effects of SNVs on TFBS.  We 
created a database of altered TFBS (aTFBS-DB) by calculating the effect (gain/loss) of all 
possible SNVs across the human genome for 741 TFs. The aTFBS-DB was used to 
determine “gainability” and “disruptability” scores for each TF in gene regulatory regions. 
We established that TFBS for bZIP, C2H2 ZF, nuclear receptors and T-box families are 
less likely to be altered by SNVs, whereas forkhead and homeodomain families show 
higher rewiring potential by their higher gainability and disruptability scores. However, 
whether in vivo binding site occupancy for these TFs is actually rewired across evolution 
or between individuals in the human population remains to be determined. By calculating 
gainability and disruptability scores for functional cis-eQTL SNVs and common SNVs in 
the human population, we determined that cis-eQTL are more likely to perturb TFBS. 
Altogether, this database provides a blueprint to study the impact of SNVs on genetic 
variation. 
In chapter 4, I described how we used the aTFBS-DB to develop the TFABT, a 
novel algorithm to predict cancer driver NCVs in promoters. We applied the TFABT to a 
the PCAWG cohort of 2,654 samples across 20 cancer types and predicted 2,555 driver 
NCV candidates located in 813 genes that alter the binding of 404 TFs. Importantly, we 
identified known drivers in TERT, ALDOA, CCDC107, LEPRROLT1, and TBC1D1 and 
presented multiple lines of evidence suggesting the predicted genes are associated with 




drivers using MPRAs in three cell lines, we achieved a validation rate of transcriptional 
activity similar to or greater than known cancer driver NCVs in promoters, ChIP-seq allelic 
imbalance NCVs, and germline NCVs associated with altered gene expression and TF 
binding, showing that the TFABT can prioritize transcription perturbing NCVs. Moreover, 
we establish that NCVs unique to one sample, which constitute the majority of NCVs in 
the PCAWG cohort, are similarly likely to alter transcriptional activity as recurrent NCVs. 
We further identified differential COF recruitment caused by the predicted drivers using 
CASCADE. The study in this chapter demonstrates the functional and biophysical impact 
of driver NCVs and can be used as the foundation to develop novel methodologies to 
predict the functional impact of NCVs in distal regulatory elements. 
Taken together, this thesis provides a framework to study transcriptional 
mechanisms in cellular processes, such as cytokine expression, and the effects of their 






Aerts, Stein, Peter Van Loo, Gert Thijs, Herbert Mayer, Rainer de Martin, Yves Moreau, 
and Bart De Moor. 2005. “TOUCAN 2: The All-Inclusive Open Source Workbench 
for Regulatory Sequence Analysis.” Nucleic Acids Research 33 (SUPPL. 2). 
https://doi.org/10.1093/nar/gki354. 
Aguet, François, Andrew A. Brown, Stephane E. Castel, Joe R. Davis, Yuan He, Brian 
Jo, Pejman Mohammadi, et al. 2017. “Genetic Effects on Gene Expression across 
Human Tissues.” Nature 550 (7675): 204–13. https://doi.org/10.1038/nature24277. 
Al-Yahya, Suhad, Linah Mahmoud, Fahad Al-Zoghaibi, Abdullah Al-Tuhami, Haithem 
Amer, Fahad N. Almajhdi, Stephen J. Polyak, and Khalid S. A. Khabar. 2015. 
“Human Cytokinome Analysis for Interferon Response.” Journal of Virology 89 
(14): 7108–19. https://doi.org/10.1128/jvi.03729-14. 
Alexandrov, Ludmil B., Jaegil Kim, Nicholas J. Haradhvala, Mi Ni Huang, Alvin Wei 
Tian Ng, Yang Wu, Arnoud Boot, et al. 2020. “The Repertoire of Mutational 
Signatures in Human Cancer.” Nature 578 (7793): 94–101. 
https://doi.org/10.1038/s41586-020-1943-3. 
Alexandrov, Ludmil B., Serena Nik-Zainal, David C. Wedge, Samuel A.J.R. Aparicio, 
Sam Behjati, Andrew V. Biankin, Graham R. Bignell, et al. 2013. “Signatures of 
Mutational Processes in Human Cancer.” Nature 500 (7463): 415–21. 
https://doi.org/10.1038/nature12477. 
Alioto, Tyler S., Ivo Buchhalter, Sophia Derdak, Barbara Hutter, Matthew D. Eldridge, 
Eivind Hovig, Lawrence E. Heisler, et al. 2015. “A Comprehensive Assessment of 
Somatic Mutation Detection in Cancer Using Whole-Genome Sequencing.” Nature 
Communications 6 (December). https://doi.org/10.1038/ncomms10001. 
Andersson, Robin, Claudia Gebhard, Irene Miguel-Escalada, Ilka Hoof, Jette Bornholdt, 
Mette Boyd, Yun Chen, et al. 2014. “An Atlas of Active Enhancers across Human 
Cell Types and Tissues.” Nature 507 (7493): 455–61. 
https://doi.org/10.1038/nature12787. 
Araya, Carlos L., Can Cenik, Jason A. Reuter, Gert Kiss, Vijay S. Pande, Michael P. 
Snyder, and William J. Greenleaf. 2016a. “Identification of Significantly Mutated 
Regions across Cancer Types Highlights a Rich Landscape of Functional Molecular 
Alterations.” Nature Genetics 48 (2): 117–25. https://doi.org/10.1038/ng.3471. 
Araya, Carlos L, Can Cenik, Jason A Reuter, Gert Kiss, Vijay S Pande, Michael P 
Snyder, and William J Greenleaf. 2016b. “Identification of Significantly Mutated 
Regions across Cancer Types Highlights a Rich Landscape of Functional Molecular 




Arend, William P., and Jean-Michel -M Dayer. 1995. “Inhibition of the Production and 
Effects of Interleukins-1 and Tumor Necrosis Factor α in Rheumatoid Arthritis.” 
Arthritis & Rheumatism 38 (2): 151–60. https://doi.org/10.1002/art.1780380202. 
Auton, Adam, Gonçalo R. Abecasis, David M. Altshuler, Richard M. Durbin, David R. 
Bentley, Aravinda Chakravarti, Andrew G. Clark, et al. 2015. “A Global Reference 
for Human Genetic Variation.” Nature. Nature Publishing Group. 
https://doi.org/10.1038/nature15393. 
Baron, V., E. D. Adamson, A. Calogero, G. Ragona, and D. Mercola. 2006. “The 
Transcription Factor Egr1 Is a Direct Regulator of Multiple Tumor Suppressors 
Including TGFβ1, PTEN, P53, and Fibronectin.” Cancer Gene Therapy. Cancer 
Gene Ther. https://doi.org/10.1038/sj.cgt.7700896. 
Barrera, David, Nancy Noyola-Martínez, Euclides Avila, Ali Halhali, Fernando Larrea, 
and Lorenza Díaz. 2012. “Calcitriol Inhibits Interleukin-10 Expression in Cultured 
Human Trophoblasts under Normal and Inflammatory Conditions.” Cytokine 57 (3): 
316–21. https://doi.org/10.1016/j.cyto.2011.11.020. 
Batmanov, Kirill, Wei Wang, Magnar Bjørås, Jan Delabie, and Junbai Wang. 2017. 
“Integrative Whole-Genome Sequence Analysis Reveals Roles of Regulatory 
Mutations in BCL6 and BCL2 in Follicular Lymphoma.” Scientific Reports 7 (1): 
7040. https://doi.org/10.1038/s41598-017-07226-4. 
Behan, Fiona M., Francesco Iorio, Gabriele Picco, Emanuel Gonçalves, Charlotte M. 
Beaver, Giorgia Migliardi, Rita Santos, et al. 2019. “Prioritization of Cancer 
Therapeutic Targets Using CRISPR–Cas9 Screens.” Nature 568 (7753): 511–16. 
https://doi.org/10.1038/s41586-019-1103-9. 
Bell, Robert J.A., H. Tomas Rube, Alex Kreig, Andrew Mancini, Shaun D. Fouse, 
Raman P. Nagarajan, Serah Choi, et al. 2015. “The Transcription Factor GABP 
Selectively Binds and Activates the Mutant TERT Promoter in Cancer.” Science 348 
(6238): 1036–39. https://doi.org/10.1126/science.aab0015. 
Bell, Robert J.A., H. Tomas Rube, Ana Xavier-Magalhães, Bruno M. Costa, Andrew 
Mancini, Jun S. Song, and Joseph F. Costello. 2016. “Understanding TERT 
Promoter Mutations: A Common Path to Immortality.” Molecular Cancer Research. 
American Association for Cancer Research Inc. https://doi.org/10.1158/1541-
7786.MCR-16-0003. 
Belperio, J A, M P Keane, D A Arenberg, C L Addison, J E Ehlert, M D Burdick, and R 
M Strieter. 2000. “CXC Chemokines in Angiogenesis.” Journal of Leukocyte 
Biology 68 (1): 1–8. 




W. Estep, and Martha L. Bulyk. 2006. “Compact, Universal DNA Microarrays to 
Comprehensively Determine Transcription-Factor Binding Site Specificities.” 
Nature Biotechnology 24 (11): 1429–35. https://doi.org/10.1038/nbt1246. 
Berghe, Wim Vanden, Karolien De Bosscher, Elke Boone, Stéphane Plaisance, and Guy 
Haegeman. 1999. “The Nuclear Factor-ΚB Engages CBP/P300 and Histone 
Acetyltransferase Activity for Transcriptional Activation of the Interleukin-6 Gene 
Promoter.” Journal of Biological Chemistry 274 (45): 32091–98. 
https://doi.org/10.1074/jbc.274.45.32091. 
Bernardini, G, G Spinetti, D Ribatti, G Camarda, L Morbidelli, M Ziche, A Santoni, M C 
Capogrossi, and M Napolitano. 2000. “I-309 Binds to and Activates Endothelial Cell 
Functions and Acts as an Angiogenic  Molecule in Vivo.” Blood 96 (13): 4039–45. 
Bessa Garcia, Simone Aparecida de, Mafalda Araújo, Tiago Pereira, João Mouta, and 
Renata Freitas. 2020. “HOX Genes Function in Breast Cancer Development.” 
Biochimica et Biophysica Acta - Reviews on Cancer. Elsevier B.V. 
https://doi.org/10.1016/j.bbcan.2020.188358. 
Boyle, Alan P., Eurie L. Hong, Manoj Hariharan, Yong Cheng, Marc A. Schaub, Maya 
Kasowski, Konrad J. Karczewski, et al. 2012. “Annotation of Functional Variation 
in Personal Genomes Using RegulomeDB.” Genome Research 22 (9): 1790–97. 
https://doi.org/10.1101/gr.137323.112. 
Brattsand, R., and M. Linden. 1996. “Cytokine Modulation by Glucocorticoids: 
Mechanisms and Actions in Cellular Studies.” In Alimentary Pharmacology and 
Therapeutics, Supplement, 10:81–90. Aliment Pharmacol Ther. 
https://doi.org/10.1046/j.1365-2036.1996.22164025.x. 
Bray, David, Heather Hook, Rose Zhao, Jessica L Keenan, Ashley Penvose, Yemi 
Osayame, Nima Mohaghegh, and Trevor Siggers. 2020. “Customizable High-
Throughput Platform for Profiling Cofactor Recruitment to DNA to Characterize 
Cis-Regulatory Elements and Screen Non-Coding Single-Nucleotide 
Polymorphisms.” BioRxiv, April, 2020.04.21.053710. 
https://doi.org/10.1101/2020.04.21.053710. 
Breuer, Karin, Amir K Foroushani, Matthew R Laird, Carol Chen, Anastasia Sribnaia, 
Raymond Lo, Geoffrey L Winsor, Robert E W Hancock, Fiona S L Brinkman, and 
David J Lynn. 2013. “InnateDB: Systems Biology of Innate Immunity and beyond--
Recent Updates and  Continuing Curation.” Nucleic Acids Research 41 (Database 
issue): D1228-33. https://doi.org/10.1093/nar/gks1147. 
Brewster, Brooke L., Francesca Rossiello, Juliet D. French, Stacey L. Edwards, Ming 
Wong, Ania Wronski, Phillip Whiley, et al. 2012. “Identification of Fifteen Novel 




That Introduces a Functional MiR-103 Target Site.” Human Mutation 33 (12): 
1665–75. https://doi.org/10.1002/humu.22159. 
Brown, Andrew Anand, Ana Viñuela, Olivier Delaneau, Tim D. Spector, Kerrin S. Small, 
and Emmanouil T. Dermitzakis. 2017. “Predicting Causal Variants Affecting 
Expression by Using Whole-Genome Sequencing and RNA-Seq from Multiple 
Human Tissues.” Nature Genetics 49 (12): 1747–51. 
https://doi.org/10.1038/ng.3979. 
Browne, Edward P., and Thomas Shenk. 2003. “Human Cytomegalovirus UL83-Coded 
Pp65 Virion Protein Inhibits Antiviral Gene Expression in Infected Cells.” 
Proceedings of the National Academy of Sciences of the United States of America 
100 (20): 11439–44. https://doi.org/10.1073/pnas.1534570100. 
Campbell, Peter J., Gad Getz, Jan O. Korbel, Joshua M. Stuart, Jennifer L. Jennings, 
Lincoln D. Stein, Marc D. Perry, et al. 2020. “Pan-Cancer Analysis of Whole 
Genomes.” Nature 578 (7793): 82–93. https://doi.org/10.1038/s41586-020-1969-6. 
Carrasco Pro, Sebastian, Alvaro Dafonte Imedio, Clarissa Stephanie Santoso, Kok Ann 
Gan, Jared Allan Sewell, Melissa Martinez, Rebecca Sereda, Shivani Mehta, and 
Juan Ignacio Fuxman Bass. 2018. “Global Landscape of Mouse and Human 
Cytokine Transcriptional Regulation.” Nucleic Acids Research 46 (18): 9321–37. 
https://doi.org/10.1093/nar/gky787. 
Carter, Scott L., Kristian Cibulskis, Elena Helman, Aaron McKenna, Hui Shen, Travis 
Zack, Peter W. Laird, et al. 2012. “Absolute Quantification of Somatic DNA 
Alterations in Human Cancer.” Nature Biotechnology 30 (5): 413–21. 
https://doi.org/10.1038/nbt.2203. 
Cavelier, Lucia, Adam Ameur, Susana Häggqvist, Ida Höijer, Nicola Cahill, Ulla Olsson-
Strömberg, and Monica Hermanson. 2015. “Clonal Distribution of BCR-ABL1 
Mutations and Splice Isoforms by Single-Molecule Long-Read RNA Sequencing.” 
BMC Cancer 15 (1). https://doi.org/10.1186/s12885-015-1046-y. 
Chadwick, Lisa Helbling. 2012. “The NIH Roadmap Epigenomics Program Data 
Resource.” Epigenomics. Epigenomics. https://doi.org/10.2217/epi.12.18. 
Chan, Andrew C., and Paul J. Carter. 2010. “Therapeutic Antibodies for Autoimmunity 
and Inflammation.” Nature Reviews Immunology. Nat Rev Immunol. 
https://doi.org/10.1038/nri2761. 
Cibulskis, Kristian, Michael S Lawrence, Scott L Carter, Andrey Sivachenko, David 
Jaffe, Carrie Sougnez, Stacey Gabriel, Matthew Meyerson, Eric S Lander, and Gad 
Getz. 2013. “Sensitive Detection of Somatic Point Mutations in Impure and 





Claeys, Marleen, Valerie Storms, Hong Sun, Tom Michoel, and Kathleen Marchal. 2012. 
“Motifsuite: Workflow for Probabilistic Motif Detection and Assessment.” 
Bioinformatics 28 (14): 1931–32. https://doi.org/10.1093/bioinformatics/bts293. 
Claussnitzer, Melina, Simon N. Dankel, Bernward Klocke, Harald Grallert, Viktoria 
Glunk, Tea Berulava, Heekyoung Lee, et al. 2014. “Leveraging Cross-Species 
Transcription Factor Binding Site Patterns: From Diabetes Risk Loci to Disease 
Mechanisms.” Cell 156 (1–2): 343–58. https://doi.org/10.1016/j.cell.2013.10.058. 
Coetzee, Simon G., Gerhard A. Coetzee, and Dennis J. Hazelett. 2015. “MotifbreakR: An 
R/Bioconductor Package for Predicting Variant Effects at Transcription Factor 
Binding Sites.” Bioinformatics 31 (23): 3847–49. 
https://doi.org/10.1093/bioinformatics/btv470. 
Davis, Carrie A, Benjamin C Hitz, Cricket A Sloan, Esther T Chan, Jean M Davidson, 
Idan Gabdank, Jason A Hilton, et al. 2018. “The Encyclopedia of DNA Elements 
(ENCODE): Data Portal Update.” Nucleic Acids Research 46 (D1): D794–801. 
https://doi.org/10.1093/nar/gkx1081. 
Denisova, Evgeniya, Barbara Heidenreich, Eduardo Nagore, P. Sivaramakrishna 
Rachakonda, Ismail Hosen, Ivana Akrap, Víctor Traves, et al. 2015. “Frequent 
DPH3 Promoter Mutations in Skin Cancers.” Oncotarget 6 (34): 35922–30. 
https://doi.org/10.18632/oncotarget.5771. 
Deplancke, Bart, Arnab Mukhopadhyay, Wanyuan Ao, Ahmed M. Elewa, Christian A. 
Grove, Natalia J. Martinez, Reynaldo Sequerra, et al. 2006. “A Gene-Centered C. 
Elegans Protein-DNA Interaction Network.” Cell 125 (6): 1193–1205. 
https://doi.org/10.1016/j.cell.2006.04.038. 
Depristo, Mark A., Eric Banks, Ryan Poplin, Kiran V. Garimella, Jared R. Maguire, 
Christopher Hartl, Anthony A. Philippakis, et al. 2011. “A Framework for Variation 
Discovery and Genotyping Using Next-Generation DNA Sequencing Data.” Nature 
Genetics 43 (5): 491–501. https://doi.org/10.1038/ng.806. 
Ding, Li, Matthew H. Bailey, Eduard Porta-Pardo, Vesteinn Thorsson, Antonio 
Colaprico, Denis Bertrand, David L. Gibbs, et al. 2018. “Perspective on Oncogenic 
Processes at the End of the Beginning of Cancer Genomics.” Cell 173 (2): 305-
320.e10. https://doi.org/10.1016/j.cell.2018.03.033. 
Dunham, Ian, Anshul Kundaje, Shelley F. Aldred, Patrick J. Collins, Carrie A. Davis, 
Francis Doyle, Charles B. Epstein, et al. 2012. “An Integrated Encyclopedia of DNA 





Eirew, Peter, Adi Steif, Jaswinder Khattra, Gavin Ha, Damian Yap, Hossein Farahani, 
Karen Gelmon, et al. 2015. “Dynamics of Genomic Clones in Breast Cancer Patient 
Xenografts at Single-Cell Resolution.” Nature 518 (7539): 422–26. 
https://doi.org/10.1038/nature13952. 
Elkon, Ran, and Reuven Agami. 2017. “Characterization of Noncoding Regulatory DNA 
in the Human Genome.” Nature Biotechnology. Nature Publishing Group. 
https://doi.org/10.1038/nbt.3863. 
Eppig, Janan T., Cynthia L. Smith, Judith A. Blake, Martin Ringwald, James A. Kadin, 
Joel E. Richardson, and Carol J. Bult. 2017. “Mouse Genome Informatics (MGI): 
Resources for Mining Mouse Genetic, Genomic, and Biological Data in Support of 
Primary and Translational Research.” In Methods in Molecular Biology, 1488:47–
73. Humana Press Inc. https://doi.org/10.1007/978-1-4939-6427-7_3. 
Ferraro, Bernadette, Gerald Bepler, Swati Sharma, Alan Cantor, and Eric B. Haura. 2005. 
“EGR1 Predicts PTEN and Survival in Patients with Non-Small-Cell Lung Cancer.” 
Journal of Clinical Oncology 23 (9): 1921–26. 
https://doi.org/10.1200/JCO.2005.08.127. 
Fredriksson, Nils J, Lars Ny, Jonas A Nilsson, and Erik Larsson. 2014. “Systematic 
Analysis of Noncoding Somatic Mutations and Gene Expression Alterations across 
14 Tumor Types.” Nature Genetics 46 (12): 1258–63. 
https://doi.org/10.1038/ng.3141. 
Freedman, Steven J., Zhen Yu J. Sun, Florence Poy, Andrew L. Kung, David M. 
Livingston, Gerhard Wagner, and Michael J. Eck. 2002. “Structural Basis for 
Recruitment of CBP/P300 by Hypoxia-Inducible Factor-1α.” Proceedings of the 
National Academy of Sciences of the United States of America 99 (8): 5367–72. 
https://doi.org/10.1073/pnas.082117899. 
Frith, Martin C, Yutao Fu, Liqun Yu, Jiang-Fan Chen, Ulla Hansen, and Zhiping Weng. 
2004. “Detection of Functional DNA Motifs via Statistical Over-Representation.” 
Nucleic Acids Research 32 (4): 1372–81. https://doi.org/10.1093/nar/gkh299. 
Fu, Yao, Zhu Liu, Shaoke Lou, Jason Bedford, Xinmeng J.asmine Mu, Kevin Y. Yip, 
Ekta Khurana, and Mark Gerstein. 2014. “FunSeq2: A Framework for Prioritizing 
Noncoding Regulatory Variants in Cancer.” Genome Biology 15 (10): 480. 
https://doi.org/10.1186/s13059-014-0480-5. 
Fujimoto, Akihiro, Mayuko Furuta, Yasushi Totoki, Tatsuhiko Tsunoda, Mamoru Kato, 
Yuichi Shiraishi, Hiroko Tanaka, et al. 2016. “Whole-Genome Mutational 
Landscape and Characterization of Noncoding and Structural Mutations in Liver 




Futreal, P. Andrew, Lachlan Coin, Mhairi Marshall, Thomas Down, Timothy Hubbard, 
Richard Wooster, Nazneen Rahman, and Michael R. Stratton. 2004. “A Census of 
Human Cancer Genes.” Nature Reviews Cancer. Nature Publishing Group. 
https://doi.org/10.1038/nrc1299. 
Fuxman Bass, Juan I., John S. Reece-Hoyes, and Albertha J.M. Walhout. 2016a. “Gene-
Centered Yeast One-Hybrid Assays.” Cold Spring Harbor Protocols 2016 (12): 
1039–43. https://doi.org/10.1101/pdb.top077669. 
———. 2016b. “Generating Bait Strains for Yeast One-Hybrid Assays.” Cold Spring 
Harbor Protocols 2016 (12): 1097–1103. https://doi.org/10.1101/pdb.prot088948. 
Fuxman Bass, Juan I., Nidhi Sahni, Shaleen Shrestha, Aurian Garcia-Gonzalez, Akihiro 
Mori, Numana Bhat, Song Yi, David E. Hill, Marc Vidal, and Albertha J.M. 
Walhout. 2015. “Human Gene-Centered Transcription Factor Networks for 
Enhancers and Disease Variants.” Cell 161 (3): 661–73. 
https://doi.org/10.1016/j.cell.2015.03.003. 
Gaildrat, Pascaline, Audrey Killian, Alexandra Martins, Isabelle Tournier, Thierry 
Frébourg, and Mario Tosi. 2010. “Use of Splicing Reporter Minigene Assay to 
Evaluate the Effect on Splicing of Unclassified Genetic Variants.” Methods in 
Molecular Biology (Clifton, N.J.). Methods Mol Biol. https://doi.org/10.1007/978-1-
60761-759-4_15. 
Gan, Kok A., Sebastian Carrasco Pro, Jared A. Sewell, and Juan I. Fuxman Bass. 2018. 
“Identification of Single Nucleotide Non-Coding Driver Mutations in Cancer.” 
Frontiers in Genetics 9 (FEB): 16. https://doi.org/10.3389/fgene.2018.00016. 
Gao, Zhuanglei, Zhaoxia Li, Yuelin Liu, and Zhonghao Liu. 2019. “Forkhead Box O3 
Promotes Colon Cancer Proliferation and Drug Resistance by Activating MDR1 
Expression.” Molecular Genetics and Genomic Medicine 7 (3). 
https://doi.org/10.1002/mgg3.554. 
Gerstein, Mark B., Anshul Kundaje, Manoj Hariharan, Stephen G. Landt, Koon Kiu Yan, 
Chao Cheng, Xinmeng Jasmine Mu, et al. 2012. “Architecture of the Human 
Regulatory Network Derived from ENCODE Data.” Nature 489 (7414): 91–100. 
https://doi.org/10.1038/nature11245. 
Gilmore, T. D., and M. Herscovitch. 2006. “Inhibitors of NF-ΚB Signaling: 785 and 
Counting.” Oncogene. Oncogene. https://doi.org/10.1038/sj.onc.1209982. 
Gilmore, Thomas D., and Steve Gerondakis. 2011. “The C-Rel Transcription Factor in 





Goettel, Jeremy A., Roopali Gandhi, Jessica E. Kenison, Ada Yeste, Gopal Murugaiyan, 
Sharmila Sambanthamoorthy, Alexandra E. Griffith, et al. 2016. “AHR Activation Is 
Protective against Colitis Driven by T Cells in Humanized Mice.” Cell Reports 17 
(5): 1318–29. https://doi.org/10.1016/j.celrep.2016.09.082. 
Goh, Kwang Il, Michael E. Cusick, David Valle, Barton Childs, Marc Vidal, and Albert 
László Barabási. 2007. “The Human Disease Network.” Proceedings of the National 
Academy of Sciences of the United States of America 104 (21): 8685–90. 
https://doi.org/10.1073/pnas.0701361104. 
Goodman, W. A., S. Omenetti, D. Date, L. Di Martino, C. De Salvo, G. D. Kim, S. 
Chowdhry, et al. 2016. “KLF6 Contributes to Myeloid Cell Plasticity in the 
Pathogenesis of Intestinal Inflammation.” Mucosal Immunology 9 (5): 1250–62. 
https://doi.org/10.1038/mi.2016.1. 
Goutagny, Stéphane, Jean C. Nault, Maxime Mallet, Dominique Henin, Jessica Z. Rossi, 
and Michel Kalamarides. 2014. “High Incidence of Activating TERT Promoter 
Mutations in Meningiomas Undergoing Malignant Progression.” Brain Pathology 
24 (2): 184–89. https://doi.org/10.1111/bpa.12110. 
Grant, Charles E., Timothy L. Bailey, and William Stafford Noble. 2011. “FIMO: 
Scanning for Occurrences of a given Motif.” Bioinformatics 27 (7): 1017–18. 
https://doi.org/10.1093/bioinformatics/btr064. 
Griffith, Jason W., Caroline L. Sokol, and Andrew D. Luster. 2014. “Chemokines and 
Chemokine Receptors: Positioning Cells for Host Defense and Immunity.” Annual 
Review of Immunology 32 (1): 659–702. https://doi.org/10.1146/annurev-immunol-
032713-120145. 
Gu, Zuguang, Roland Eils, and Matthias Schlesner. 2016. “Complex Heatmaps Reveal 
Patterns and Correlations in Multidimensional Genomic Data.” Bioinformatics 
(Oxford, England) 32 (18): 2847–49. https://doi.org/10.1093/bioinformatics/btw313. 
Guppy, Brent J., and Kirk J. McManus. 2017. “Synthetic Lethal Targeting of RNF20 
through PARP1 Silencing and Inhibition.” Cellular Oncology 40 (3): 281–92. 
https://doi.org/10.1007/s13402-017-0323-y. 
Haas, N. B., I. Quirt, S. Hotte, E. McWhirter, R. Polintan, S. Litwin, P. D. Adams, et al. 
2014. “Phase II Trial of Vorinostat in Advanced Melanoma.” Investigational New 
Drugs 32 (3): 526–34. https://doi.org/10.1007/s10637-014-0066-9. 
Han, Heonjong, Hongseok Shim, Donghyun Shin, Jung Eun Shim, Yunhee Ko, Junha 
Shin, Hanhae Kim, et al. 2015. “TRRUST: A Reference Database of Human 





Harrow, J., A. Frankish, J. M. Gonzalez, E. Tapanari, M. Diekhans, F. Kokocinski, B. L. 
Aken, et al. 2012. “GENCODE: The Reference Human Genome Annotation for The 
ENCODE Project.” Genome Research 22 (9): 1760–74. 
https://doi.org/10.1101/gr.135350.111. 
Helleday, Thomas, Saeed Eshtad, and Serena Nik-Zainal. 2014a. “Mechanisms 
Underlying Mutational Signatures in Human Cancers.” Nature Reviews Genetics. 
Nature Publishing Group. https://doi.org/10.1038/nrg3729. 
———. 2014b. “Mechanisms Underlying Mutational Signatures in Human Cancers.” 
Nature Reviews Genetics 15 (9): 585–98. https://doi.org/10.1038/nrg3729. 
Hindorff, Lucia A., Praveen Sethupathy, Heather A. Junkins, Erin M. Ramos, Jayashri P. 
Mehta, Francis S. Collins, and Teri A. Manolio. 2009. “Potential Etiologic and 
Functional Implications of Genome-Wide Association Loci for Human Diseases and 
Traits.” Proceedings of the National Academy of Sciences of the United States of 
America 106 (23): 9362–67. https://doi.org/10.1073/pnas.0903103106. 
Hirota, Keiji, Hiroyuki Yoshitomi, Motomu Hashimoto, Shinji Maeda, Shin Teradaira, 
Naoshi Sugimoto, Tomoyuki Yamaguchi, et al. 2007. “Preferential Recruitment of 
CCR6-Expressing Th17 Cells to Inflamed Joints via CCL20 in Rheumatoid Arthritis 
and Its Animal Model.” Journal of Experimental Medicine 204 (12): 2803–12. 
https://doi.org/10.1084/jem.20071397. 
Holloway, A. F., S. Rao, and M. F. Shannon. 2002. “Regulation of Cytokine Gene 
Transcription in the Immune System.” Molecular Immunology. Mol Immunol. 
https://doi.org/10.1016/S0161-5890(01)00094-3. 
Holmes, C., C. Cunningham, E. Zotova, J. Woolford, C. Dean, S. Kerr, D. Culliford, and 
V. H. Perry. 2009. “Systemic Inflammation and Disease Progression in Alzheimer 
Disease.” Neurology 73 (10): 768–74. 
https://doi.org/10.1212/WNL.0b013e3181b6bb95. 
Homey, Bernhard, Anja Müller, and Albert Zlotnik. 2002. “Chemokines: Agents for the 
Immunotherapy of Cancer?” Nature Reviews Immunology. European Association for 
Cardio-Thoracic Surgery. https://doi.org/10.1038/nri748. 
Horn, S., A. Figl, P. S. Rachakonda, C. Fischer, A. Sucker, A. Gast, S. Kadel, et al. 2013. 
“TERT Promoter Mutations in Familial and Sporadic Melanoma.” Science 339 
(6122): 959–61. https://doi.org/10.1126/science.1230062. 
Horn, Susanne, Adina Figl, P. Sivaramakrishna Rachakonda, Christine Fischer, Antje 
Sucker, Andreas Gast, Stephanie Kadel, et al. 2013. “TERT Promoter Mutations in 





Hornshøj, Henrik, Morten Muhlig Nielsen, Nicholas A. Sinnott-Armstrong, Michał P. 
Świtnicki, Malene Juul, Tobias Madsen, Richard Sallari, et al. 2018. “Pan-Cancer 
Screen for Mutations in Non-Coding Elements with Conservation and Cancer 
Specificity Reveals Correlations with Expression and Survival /631/67/69 /631/114 
Article.” Npj Genomic Medicine 3 (1). https://doi.org/10.1038/s41525-017-0040-5. 
Hottiger, Michael O., and Gary J. Nabel. 2000. “Viral Replication and the Coactivators 
P300 and CBP.” Trends in Microbiology. Trends Microbiol. 
https://doi.org/10.1016/S0966-842X(00)01874-6. 
Hsu, Yu Chin, Yu Ting Hsiao, Tzu Yuan Kao, Jan Gowth Chang, and Grace S. Shieh. 
2017. “Detection of Somatic Mutations in Exome Sequencing of Tumor-Only 
Samples.” Scientific Reports 7 (1). https://doi.org/10.1038/s41598-017-14896-7. 
Huang, F. W., E. Hodis, M. J. Xu, G. V. Kryukov, L. Chin, and L. A. Garraway. 2013. 
“Highly Recurrent TERT Promoter Mutations in Human Melanoma.” Science 339 
(6122): 957–59. https://doi.org/10.1126/science.1229259. 
Hudson, Thomas J., Warwick Anderson, Axel Aretz, Anna D. Barker, Cindy Bell, Rosa 
R. Bernabé, M. K. Bhan, et al. 2010. “International Network of Cancer Genome 
Projects.” Nature. Nature. https://doi.org/10.1038/nature08987. 
Hume, Maxwell A., Luis A. Barrera, Stephen S. Gisselbrecht, and Martha L. Bulyk. 
2015. “UniPROBE, Update 2015: New Tools and Content for the Online Database 
of Protein-Binding Microarray Data on Protein-DNA Interactions.” Nucleic Acids 
Research 43 (D1): D117–22. https://doi.org/10.1093/nar/gku1045. 
Ivanov, Ivaylo I., Brent S. McKenzie, Liang Zhou, Carlos E. Tadokoro, Alice Lepelley, 
Juan J. Lafaille, Daniel J. Cua, and Dan R. Littman. 2006. “The Orphan Nuclear 
Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T 
Helper Cells.” Cell 126 (6): 1121–33. https://doi.org/10.1016/j.cell.2006.07.035. 
Jacob, Chaim O., Song Zang, Lily Li, Voicu Ciobanu, Frank Quismorio, Akiei Mizutani, 
Minoru Satoh, and Michael Koss. 2003. “Pivotal Role of Stat4 and Stat6 in the 
Pathogenesis of the Lupus-Like Disease in the New Zealand Mixed 2328 Mice.” 
The Journal of Immunology 171 (3): 1564–71. 
https://doi.org/10.4049/jimmunol.171.3.1564. 
Johnson, P F, and S L McKnight. 1989. “Eukaryotic Transcriptional Regulatory 
Proteins.” Annual Review of Biochemistry 58 (1): 799–839. 
https://doi.org/10.1146/annurev.bi.58.070189.004055. 
Jolma, Arttu, Jian Yan, Thomas Whitington, Jarkko Toivonen, Kazuhiro R. Nitta, Pasi 
Rastas, Ekaterina Morgunova, et al. 2013. “DNA-Binding Specificities of Human 





Jung, Hyunchul, Donghoon Lee, Jongkeun Lee, Donghyun Park, Yeon Jeong Kim, 
Woong Yang Park, Dongwan Hong, Peter J. Park, and Eunjung Lee. 2015. “Intron 
Retention Is a Widespread Mechanism of Tumor-Suppressor Inactivation.” Nature 
Genetics 47 (11): 1242–48. https://doi.org/10.1038/ng.3414. 
Juul, Malene, Johanna Bertl, Qianyun Guo, Morten Muhlig Nielsen, Michał Świtnicki, 
Henrik Hornshøj, Tobias Madsen, Asger Hobolth, and Jakob Skou Pedersen. 2017. 
“Non-Coding Cancer Driver Candidates Identified with a Sample- and Position-
Specific Model of the Somatic Mutation Rate.” ELife 6 (March). 
https://doi.org/10.7554/eLife.21778. 
Kalender Atak, Zeynep, Hana Imrichova, Dmitry Svetlichnyy, Gert Hulselmans, Valerie 
Christiaens, Joke Reumers, Hugo Ceulemans, and Stein Aerts. 2017. “Identification 
of Cis-Regulatory Mutations Generating de Novo Edges in Personalized Cancer 
Gene Regulatory Networks.” Genome Medicine 9 (1). 
https://doi.org/10.1186/s13073-017-0464-7. 
Karin, Nathan, and Hila Razon. 2018. “Chemokines beyond Chemo-Attraction: CXCL10 
and Its Significant Role in Cancer and Autoimmunity.” Cytokine 109 (September): 
24–28. https://doi.org/10.1016/j.cyto.2018.02.012. 
Kaser, Arthur, Ann Hwee Lee, Andre Franke, Jonathan N. Glickman, Sebastian Zeissig, 
Herbert Tilg, Edward E.S. Nieuwenhuis, et al. 2008. “XBP1 Links ER Stress to 
Intestinal Inflammation and Confers Genetic Risk for Human Inflammatory Bowel 
Disease.” Cell 134 (5): 743–56. https://doi.org/10.1016/j.cell.2008.07.021. 
Katainen, Riku, Kashyap Dave, Esa Pitkänen, Kimmo Palin, Teemu Kivioja, Niko 
Välimäki, Alexandra E. Gylfe, et al. 2015. “CTCF/Cohesin-Binding Sites Are 
Frequently Mutated in Cancer.” Nature Genetics 47 (7): 818–21. 
https://doi.org/10.1038/ng.3335. 
Kawaguchi, Yasushi, Masako Hara, and Timothy M. Wright. 1999. “Endogenous IL-1α 
from Systemic Sclerosis Fibroblasts Induces IL-6 and PDGF-A.” Journal of Clinical 
Investigation 103 (9): 1253–60. https://doi.org/10.1172/JCI4304. 
Keilwagen, Jens, Stefan Posch, and Jan Grau. 2019. “Accurate Prediction of Cell Type-
Specific Transcription Factor Binding.” Genome Biology 20 (1). 
https://doi.org/10.1186/s13059-018-1614-y. 
Khan, Aziz, Oriol Fornes, Arnaud Stigliani, Marius Gheorghe, Jaime A Castro-
Mondragon, Robin van der Lee, Adrien Bessy, et al. 2018. “JASPAR 2018: Update 
of the Open-Access Database of Transcription Factor Binding Profiles and Its Web 





Khurana, Ekta, Yao Fu, Dimple Chakravarty, Francesca Demichelis, Mark A. Rubin, and 
Mark Gerstein. 2016. “Role of Non-Coding Sequence Variants in Cancer.” Nature 
Reviews Genetics 17 (2): 93–108. https://doi.org/10.1038/nrg.2015.17. 
Kim, Kyoung S., Vikram Rajagopal, Caryn Gonsalves, Cage Johnson, and Vijay K. 
Kalra. 2006. “A Novel Role of Hypoxia-Inducible Factor in Cobalt Chloride- and 
Hypoxia-Mediated Expression of IL-8 Chemokine in Human Endothelial Cells.” 
The Journal of Immunology 177 (10): 7211–24. 
https://doi.org/10.4049/jimmunol.177.10.7211. 
Klein, Robyn S., Leonid Izikson, Terry Means, Hilary D. Gibson, Eugene Lin, Raymond 
A. Sobel, Howard L. Weiner, and Andrew D. Luster. 2004. “IFN-Inducible Protein 
10/CXC Chemokine Ligand 10-Independent Induction of Experimental 
Autoimmune Encephalomyelitis.” The Journal of Immunology 172 (1): 550–59. 
https://doi.org/10.4049/jimmunol.172.1.550. 
Knight, Julian C., Irina Udalova, Adrian V.S. Hill, Brian M. Greenwood, Norbert Peshu, 
Kevin Marsh, and Dominic Kwiatkowski. 1999. “A Polymorphism That Affects 
OCT-1 Binding to the TNF Promoter Region Is Associated with Severe Malaria.” 
Nature Genetics 22 (2): 145–50. https://doi.org/10.1038/9649. 
Koboldt, Daniel C., Ken Chen, Todd Wylie, David E. Larson, Michael D. McLellan, 
Elaine R. Mardis, George M. Weinstock, Richard K. Wilson, and Li Ding. 2009. 
“VarScan: Variant Detection in Massively Parallel Sequencing of Individual and 
Pooled Samples.” Bioinformatics 25 (17): 2283–85. 
https://doi.org/10.1093/bioinformatics/btp373. 
Koboldt, Daniel C, Qunyuan Zhang, David E Larson, Dong Shen, Michael D McLellan, 
Ling Lin, Christopher A Miller, Elaine R Mardis, Li Ding, and Richard K Wilson. 
2012. “VarScan 2: Somatic Mutation and Copy Number Alteration Discovery in 
Cancer by Exome  Sequencing.” Genome Research 22 (3): 568–76. 
https://doi.org/10.1101/gr.129684.111. 
Kucab, Jill E., Xueqing Zou, Sandro Morganella, Madeleine Joel, A. Scott Nanda, Eszter 
Nagy, Celine Gomez, et al. 2019. “A Compendium of Mutational Signatures of 
Environmental Agents.” Cell 177 (4): 821-836.e16. 
https://doi.org/10.1016/j.cell.2019.03.001. 
Kumar, Sunil, Giovanna Ambrosini, and Philipp Bucher. 2017. “SNP2TFBS - a Database 
of Regulatory SNPs Affecting Predicted Transcription Factor  Binding Site 





Kutchko, Katrina M., Wes Sanders, Ben Ziehr, Gabriela Phillips, Amanda Solem, 
Matthew Halvorsen, Kevin M. Weeks, Nathaniel M, Nathaniel Moorman, and Alain 
Laederach. 2015. “Multiple Conformations Are a Conserved and Regulatory Feature 
of the RB1 5’ UTR.” RNA 21 (7): 1274–85. https://doi.org/10.1261/rna.049221.114. 
Kveler, Ksenya, Elina Starosvetsky, Amit Ziv-Kenet, Yuval Kalugny, Yuri Gorelik, Gali 
Shalev-Malul, Netta Aizenbud-Reshef, et al. 2018. “Immune-Centric Network of 
Cytokines and Cells in Disease Context Identified by Computational Mining of 
PubMed.” Nature Biotechnology 36 (7): 651–59. https://doi.org/10.1038/nbt.4152. 
Lambert, Samuel A., Arttu Jolma, Laura F. Campitelli, Pratyush K. Das, Yimeng Yin, 
Mihai Albu, Xiaoting Chen, Jussi Taipale, Timothy R. Hughes, and Matthew T. 
Weirauch. 2018. “The Human Transcription Factors.” Cell. Cell Press. 
https://doi.org/10.1016/j.cell.2018.01.029. 
Lanzós, Andrés, Joana Carlevaro-Fita, Loris Mularoni, Ferran Reverter, Emilio Palumbo, 
Roderic Guigó, and Rory Johnson. 2017. “Discovery of Cancer Driver Long 
Noncoding RNAs across 1112 Tumour Genomes: New Candidates and 
Distinguishing Features.” Scientific Reports 7 (January). 
https://doi.org/10.1038/srep41544. 
Lasko, Loren M., Clarissa G. Jakob, Rohinton P. Edalji, Wei Qiu, Debra Montgomery, 
Enrico L. Digiammarino, T. Matt Hansen, et al. 2017. “Discovery of a Selective 
Catalytic P300/CBP Inhibitor That Targets Lineage-Specific Tumours.” Nature 550 
(7674): 128–32. https://doi.org/10.1038/nature24028. 
Law, Philip J., Maria Timofeeva, Ceres Fernandez-Rozadilla, Peter Broderick, James 
Studd, Juan Fernandez-Tajes, Susan Farrington, et al. 2019. “Association Analyses 
Identify 31 New Risk Loci for Colorectal Cancer Susceptibility.” Nature 
Communications 10 (1). https://doi.org/10.1038/s41467-019-09775-w. 
Lawrence, Michael, Wolfgang Huber, Hervé Pagès, Patrick Aboyoun, Marc Carlson, 
Robert Gentleman, Martin T. Morgan, and Vincent J. Carey. 2013. “Software for 
Computing and Annotating Genomic Ranges.” PLoS Computational Biology 9 (8). 
https://doi.org/10.1371/journal.pcbi.1003118. 
Lawrence, Michael S., Petar Stojanov, Craig H. Mermel, James T. Robinson, Levi A. 
Garraway, Todd R. Golub, Matthew Meyerson, Stacey B. Gabriel, Eric S. Lander, 
and Gad Getz. 2014. “Discovery and Saturation Analysis of Cancer Genes across 21 
Tumour Types.” Nature 505 (7484): 495–501. https://doi.org/10.1038/nature12912. 
Lawrence, Michael S., Petar Stojanov, Paz Polak, Gregory V. Kryukov, Kristian 
Cibulskis, Andrey Sivachenko, Scott L. Carter, et al. 2013. “Mutational 
Heterogeneity in Cancer and the Search for New Cancer-Associated Genes.” Nature 




Le, Vu Thuy Khanh, Mirko Trilling, Albert Zimmermann, and Hartmut Hengel. 2008. 
“Mouse Cytomegalovirus Inhibits Beta Interferon(IFN-β) Gene Expression and 
Controls Activation Pathways of the IFN-β Enhanceosome.” Journal of General 
Virology 89 (5): 1131–41. https://doi.org/10.1099/vir.0.83538-0. 
Li, Amy, Bjoern Chapuy, Xaralabos Varelas, Paola Sebastiani, and Stefano Monti. 2019. 
“Identification of Candidate Cancer Drivers by Integrative Epi-DNA and Gene 
Expression (IEDGE) Data Analysis.” Scientific Reports 9 (1). 
https://doi.org/10.1038/s41598-019-52886-z. 
Li, Guoliang, Xiaoan Ruan, Raymond K. Auerbach, Kuljeet Singh Sandhu, Meizhen 
Zheng, Ping Wang, Huay Mei Poh, et al. 2012. “Extensive Promoter-Centered 
Chromatin Interactions Provide a Topological Basis for Transcription Regulation.” 
Cell 148 (1–2): 84–98. https://doi.org/10.1016/j.cell.2011.12.014. 
Li, Heng. 2011. “A Statistical Framework for SNP Calling, Mutation Discovery, 
Association Mapping and  Population Genetical Parameter Estimation from 
Sequencing Data.” Bioinformatics (Oxford, England) 27 (21): 2987–93. 
https://doi.org/10.1093/bioinformatics/btr509. 
Li, Heng, and Richard Durbin. 2009. “Fast and Accurate Short Read Alignment with 
Burrows-Wheeler Transform.” Bioinformatics (Oxford, England) 25 (14): 1754–60. 
https://doi.org/10.1093/bioinformatics/btp324. 
Li, Heng, Bob Handsaker, Alec Wysoker, Tim Fennell, Jue Ruan, Nils Homer, Gabor 
Marth, Goncalo Abecasis, and Richard Durbin. 2009. “The Sequence 
Alignment/Map Format and SAMtools.” Bioinformatics (Oxford, England) 25 (16): 
2078–79. https://doi.org/10.1093/bioinformatics/btp352. 
Li, Yinghui, Qi Ling Zhou, Wenjie Sun, Prashant Chandrasekharan, Hui Shan Cheng, 
Zhe Ying, Manikandan Lakshmanan, et al. 2015. “Non-Canonical NF-ΚB 
Signalling and ETS1/2 Cooperatively Drive C250T Mutant TERT Promoter 
Activation.” Nature Cell Biology 17 (10): 1327–38. 
https://doi.org/10.1038/ncb3240. 
Li, Yongsheng, Nidhi Sahni, Rita Pancsa, Daniel J. McGrail, Juan Xu, Xu Hua, Jasmin 
Coulombe-Huntington, et al. 2017. “Revealing the Determinants of Widespread 
Alternative Splicing Perturbation in Cancer.” Cell Reports 21 (3): 798–812. 
https://doi.org/10.1016/j.celrep.2017.09.071. 
Lieberman-Aiden, Erez, Nynke L. Van Berkum, Louise Williams, Maxim Imakaev, 
Tobias Ragoczy, Agnes Telling, Ido Amit, et al. 2009. “Comprehensive Mapping of 
Long-Range Interactions Reveals Folding Principles of the Human Genome.” 




Liu, Kuiliang, Jianghao Fan, and Jing Wu. 2017. “Forkhead Box Protein J1 (FOXJ1) Is 
Overexpressed in Colorectal Cancer and Promotes Nuclear Translocation of β-
Catenin in SW620 Cells.” Medical Science Monitor 23 (February): 856–66. 
https://doi.org/10.12659/MSM.902906. 
Liu, T., N. Wang, J. Cao, A. Sofiadis, A. Dinets, J. Zedenius, C. Larsson, and D. Xu. 
2014. “The Age-and Shorter Telomere-Dependent Tert Promoter Mutation in 
Follicular Thyroid Cell-Derived Carcinomas.” Oncogene 33 (42): 4978–84. 
https://doi.org/10.1038/onc.2013.446. 
Liu, Xue Song, Matthew D. Genet, Jenna E. Haines, Elie K. Mehanna, Shaowei Wu, 
Hung I.Harry Chen, Yidong Chen, et al. 2015. “Zbtb7a Suppresses Melanoma 
Metastasis by Transcriptionally Repressing Mcam.” Molecular Cancer Research 13 
(8): 1206–17. https://doi.org/10.1158/1541-7786.MCR-15-0169. 
Lochovsky, Lucas, Jing Zhang, Yao Fu, Ekta Khurana, and Mark Gerstein. 2015. 
“LARVA: An Integrative Framework for Large-Scale Analysis of Recurrent 
Variants in Noncoding Annotations.” Nucleic Acids Research 43 (17): 8123–34. 
https://doi.org/10.1093/nar/gkv803. 
Lonsdale, John, Jeffrey Thomas, Mike Salvatore, Rebecca Phillips, Edmund Lo, Saboor 
Shad, Richard Hasz, et al. 2013. “The Genotype-Tissue Expression (GTEx) 
Project.” Nature Genetics. Nat Genet. https://doi.org/10.1038/ng.2653. 
Love, Michael I., Wolfgang Huber, and Simon Anders. 2014. “Moderated Estimation of 
Fold Change and Dispersion for RNA-Seq Data with DESeq2.” Genome Biology 15 
(12). https://doi.org/10.1186/s13059-014-0550-8. 
Luscombe, Nicholas M., M. Madan Babu, Haiyuan Yu, Michael Snyder, Sarah A. 
Teichmann, and Mark Gerstein. 2004. “Genomic Analysis of Regulatory Network 
Dynamics Reveals Large Topological Changes.” Nature 431 (7006): 308–12. 
https://doi.org/10.1038/nature02782. 
MacArthur, Jacqueline, Emily Bowler, Maria Cerezo, Laurent Gil, Peggy Hall, Emma 
Hastings, Heather Junkins, et al. 2017. “The New NHGRI-EBI Catalog of Published 
Genome-Wide Association Studies (GWAS Catalog).” Nucleic Acids Research 45 
(D1): D896–901. https://doi.org/10.1093/nar/gkw1133. 
MacEwan, David J. 2002. “TNF Receptor Subtype Signalling: Differences and Cellular 
Consequences.” Cellular Signalling. Cell Signal. https://doi.org/10.1016/S0898-
6568(01)00262-5. 
Manel, Nicolas, Derya Unutmaz, and Dan R. Littman. 2008. “The Differentiation of 
Human TH-17 Cells Requires Transforming Growth Factor-β and Induction of the 





Marco, Antonio, Charlotte Konikoff, Timothy L Karr, and Sudhir Kumar. 2009. 
“Relationship between Gene Co-Expression and Sharing of Transcription Factor 
Binding  Sites in Drosophila Melanogaster.” Bioinformatics (Oxford, England) 25 
(19): 2473–77. https://doi.org/10.1093/bioinformatics/btp462. 
Martincorena, Iñigo, Keiran M. Raine, Moritz Gerstung, Kevin J. Dawson, Kerstin 
Haase, Peter Van Loo, Helen Davies, Michael R. Stratton, and Peter J. Campbell. 
2017. “Universal Patterns of Selection in Cancer and Somatic Tissues.” Cell 171 (5): 
1029-1041.e21. https://doi.org/10.1016/j.cell.2017.09.042. 
Martinez, Natalia J., Maria C. Ow, M. Inmaculada Barrasa, Molly Hammell, Reynaldo 
Sequerra, Lynn Doucette-Stamm, Frederick P. Roth, Victor R. Ambros, and 
Albertha J.M. Walhout. 2008. “A C. Elegans Genome-Scale MicroRNA Network 
Contains Composite Feedback Motifs with High Flux Capacity.” Genes and 
Development 22 (18): 2535–49. https://doi.org/10.1101/gad.1678608. 
Matys, V., E. Fricke, R. Geffers, E. Gößling, M. Haubrock, R. Hehl, K. Hornischer, et al. 
2003. “TRANSFAC®: Transcriptional Regulation, from Patterns to Profiles.” 
Nucleic Acids Research. https://doi.org/10.1093/nar/gkg108. 
Maurano, Matthew T., Eric Haugen, Richard Sandstrom, Jeff Vierstra, Anthony Shafer, 
Rajinder Kaul, and John A. Stamatoyannopoulos. 2015. “Large-Scale Identification 
of Sequence Variants Influencing Human Transcription Factor Occupancy in Vivo.” 
Nature Genetics 47 (12): 1393–1401. https://doi.org/10.1038/ng.3432. 
Maurano, Matthew T., Richard Humbert, Eric Rynes, Robert E. Thurman, Eric Haugen, 
Hao Wang, Alex P. Reynolds, et al. 2012. “Systematic Localization of Common 
Disease-Associated Variation in Regulatory DNA.” Science 337 (6099): 1190–95. 
https://doi.org/10.1126/science.1222794. 
McCarthy, S A, D Chen, B S Yang, J J Garcia Ramirez, H Cherwinski, X R Chen, M 
Klagsbrun, C A Hauser, M C Ostrowski, and M McMahon. 1997. “Rapid 
Phosphorylation of Ets-2 Accompanies Mitogen-Activated Protein Kinase 
Activation and the Induction of Heparin-Binding Epidermal Growth Factor Gene 
Expression by Oncogenic Raf-1.” Molecular and Cellular Biology 17 (5): 2401–12. 
https://doi.org/10.1128/mcb.17.5.2401. 
McLendon, Roger, Allan Friedman, Darrell Bigner, Erwin G. Van Meir, Daniel J. Brat, 
Gena M. Mastrogianakis, Jeffrey J. Olson, et al. 2008. “Comprehensive Genomic 
Characterization Defines Human Glioblastoma Genes and Core Pathways.” Nature 
455 (7216): 1061–68. https://doi.org/10.1038/nature07385. 




Gilbert, Qing Sheng Mi, Pere Santamaria, Gregory A. Dekaban, and Terry L. 
Delovitch. 2007. “CCL4 Protects from Type 1 Diabetes by Altering Islet β-Cell-
Targeted Inflammatory Responses.” Diabetes 56 (3): 809–17. 
https://doi.org/10.2337/db06-0619. 
Medoff, Benjamin D., Alain Sauty, Andrew M. Tager, James A. Maclean, R. Neal Smith, 
Anuja Mathew, Jennifer H. Dufour, and Andrew D. Luster. 2002. “IFN-γ-Inducible 
Protein 10 (CXCL10) Contributes to Airway Hyperreactivity and Airway 
Inflammation in a Mouse Model of Asthma.” The Journal of Immunology 168 (10): 
5278–86. https://doi.org/10.4049/jimmunol.168.10.5278. 
Medzhitov, Ruslan, and Tiffany Horng. 2009. “Transcriptional Control of the 
Inflammatory Response.” Nature Reviews Immunology. Nat Rev Immunol. 
https://doi.org/10.1038/nri2634. 
Melnikov, Alexandre, Anand Murugan, Xiaolan Zhang, Tiberiu Tesileanu, Li Wang, 
Peter Rogov, Soheil Feizi, et al. 2012. “Systematic Dissection and Optimization of 
Inducible Enhancers in Human Cells Using a Massively Parallel Reporter Assay.” 
Nature Biotechnology 30 (3): 271–77. https://doi.org/10.1038/nbt.2137. 
Melton, Collin, Jason A. Reuter, Damek V. Spacek, and Michael Snyder. 2015. 
“Recurrent Somatic Mutations in Regulatory Regions of Human Cancer Genomes.” 
Nature Genetics 47 (7): 710–16. https://doi.org/10.1038/ng.3332. 
Meng, Xiangdong, Michael H. Brodsky, and Scot A. Wolfe. 2005. “A Bacterial One-
Hybrid System for Determining the DNA-Binding Specificity of Transcription 
Factors.” Nature Biotechnology 23 (8): 988–94. https://doi.org/10.1038/nbt1120. 
Meyers, Robin M., Jordan G. Bryan, James M. McFarland, Barbara A. Weir, Ann E. 
Sizemore, Han Xu, Neekesh V. Dharia, et al. 2017. “Computational Correction of 
Copy Number Effect Improves Specificity of CRISPR-Cas9 Essentiality Screens in 
Cancer Cells.” Nature Genetics 49 (12): 1779–84. https://doi.org/10.1038/ng.3984. 
Miotto, Deborah, Pota Christodoulopoulos, Ron Olivenstein, Rame Taha, Lisa Cameron, 
Anne Tsicopoulos, A. B. Tonnel, et al. 2001. “Expression of IFN-γ-Inducible 
Protein; Monocyte Chemotactic Proteins 1 3 and 4; and Eotaxin in TH1- and TH2-
Mediated Lung Diseases.” Journal of Allergy and Clinical Immunology 107 (4): 
664–70. https://doi.org/10.1067/mai.2001.113524. 
Miyamoto, Megumi, Yukihiro Shimizu, Kazuhiko Okada, Yoshiro Kashii, Kiyohiro 
Higuchi, and Akiharu Watanabe. 1998. “Effect of Interleukin-8 on Production of 
Tumor-Associated Substances and Autocrine Growth of Human Liver and 





Mogi, Makio, Minoru Harada, Peter Riederer, Hirotaro Narabayashi, Keisuke Fujita, and 
Toshiharu Nagatsu. 1994. “Tumor Necrosis Factor-α (TNF-α) Increases Both in the 
Brain and in the Cerebrospinal Fluid from Parkinsonian Patients.” Neuroscience 
Letters 165 (1–2): 208–10. https://doi.org/10.1016/0304-3940(94)90746-3. 
Mogno, Ilaria, Jamie C. Kwasnieski, and Barak A. Cohen. 2013. “Massively Parallel 
Synthetic Promoter Assays Reveal the in Vivo Effects of Binding Site Variants.” 
Genome Research 23 (11): 1908–15. https://doi.org/10.1101/gr.157891.113. 
Movva, Rajiv, Peyton Greenside, Georgi K. Marinov, Surag Nair, Avanti Shrikumar, and 
Anshul Kundaje. 2019. “Deciphering Regulatory DNA Sequences and Noncoding 
Genetic Variants Using Neural Network Models of Massively Parallel Reporter 
Assays.” PLoS ONE 14 (6). https://doi.org/10.1371/journal.pone.0218073. 
Müller, Anja, Bernhard Homey, Hortensia Soto, Nianfeng Ge, Daniel Catron, Matthew E. 
Buchanan, Terri McClanahan, et al. 2001. “Involvement of Chemokine Receptors in 
Breast Cancer Metastasis.” Nature 410 (6824): 50–56. 
https://doi.org/10.1038/35065016. 
Munster, P. N., K. T. Thurn, S. Thomas, P. Raha, M. Lacevic, A. Miller, M. Melisko, et 
al. 2011. “A Phase II Study of the Histone Deacetylase Inhibitor Vorinostat 
Combined with Tamoxifen for the Treatment of Patients with Hormone Therapy-
Resistant Breast Cancer.” British Journal of Cancer 104 (12): 1828–35. 
https://doi.org/10.1038/bjc.2011.156. 
Murphy, Kenneth M., and Steven L. Reiner. 2002. “The Lineage Decisions of Helper T 
Cells.” Nature Reviews Immunology. Nat Rev Immunol. 
https://doi.org/10.1038/nri954. 
Nakamura, Kyosuke, Akihiro Kato, Junya Kobayashi, Hiromi Yanagihara, Shuichi 
Sakamoto, Douglas V.N.P. Oliveira, Mikio Shimada, et al. 2011. “Regulation of 
Homologous Recombination by RNF20-Dependent H2B Ubiquitination.” Molecular 
Cell 41 (5): 515–28. https://doi.org/10.1016/j.molcel.2011.02.002. 
Navarro, Lorena, Kerri Mowen, Steven Rodems, Brian Weaver, Nancy Reich, Deborah 
Spector, and Michael David. 1998. “Cytomegalovirus Activates Interferon 
Immediate-Early Response Gene Expression and an Interferon Regulatory Factor 3-
Containing Interferon-Stimulated Response Element-Binding Complex.” Molecular 
and Cellular Biology 18 (7): 3796–3802. https://doi.org/10.1128/mcb.18.7.3796. 
Navin, Nicholas, Jude Kendall, Jennifer Troge, Peter Andrews, Linda Rodgers, Jeanne 
McIndoo, Kerry Cook, et al. 2011. “Tumour Evolution Inferred by Single-Cell 
Sequencing.” Nature 472 (7341): 90–95. https://doi.org/10.1038/nature09807. 




2003. “Proinflammatory Cytokines and Sepsis Syndrome: Not Enough, or Too 
Much of a Good Thing?” Trends in Immunology. Elsevier Ltd. 
https://doi.org/10.1016/S1471-4906(03)00079-6. 
Neurath, Markus F. 2014. “Cytokines in Inflammatory Bowel Disease.” Nature Reviews 
Immunology. Nature Publishing Group. https://doi.org/10.1038/nri3661. 
Nickel, Renate G., Vincenzo Casolaro, Ulrich Wahn, Kirsten Beyer, Kathleen C. Barnes, 
Beverly S. Plunkett, Linda R. Freidhoff, et al. 2000. “Atopic Dermatitis Is 
Associated with a Functional Mutation in the Promoter of the C-C Chemokine 
RANTES.” The Journal of Immunology 164 (3): 1612–16. 
https://doi.org/10.4049/jimmunol.164.3.1612. 
Nik-Zainal, Serena, Ludmil B. Alexandrov, David C. Wedge, Peter Van Loo, Christopher 
D. Greenman, Keiran Raine, David Jones, et al. 2012. “Mutational Processes 
Molding the Genomes of 21 Breast Cancers.” Cell 149 (5): 979–93. 
https://doi.org/10.1016/j.cell.2012.04.024. 
Nik-Zainal, Serena, Helen Davies, Johan Staaf, Manasa Ramakrishna, Dominik Glodzik, 
Xueqing Zou, Inigo Martincorena, et al. 2016. “Landscape of Somatic Mutations in 
560 Breast Cancer Whole-Genome Sequences.” Nature 534 (7605): 47–54. 
https://doi.org/10.1038/nature17676. 
Nik-Zainal, Serena, Peter Van Loo, David C. Wedge, Ludmil B. Alexandrov, Christopher 
D. Greenman, King Wai Lau, Keiran Raine, et al. 2012. “The Life History of 21 
Breast Cancers.” Cell 149 (5): 994–1007. https://doi.org/10.1016/j.cell.2012.04.023. 
Noyes, Marcus B., Ryan G. Christensen, Atsuya Wakabayashi, Gary D. Stormo, Michael 
H. Brodsky, and Scot A. Wolfe. 2008. “Analysis of Homeodomain Specificities 
Allows the Family-Wide Prediction of Preferred Recognition Sites.” Cell 133 (7): 
1277–89. https://doi.org/10.1016/j.cell.2008.05.023. 
O’Keefe, Stephen J., Jun’Ichi Tamura, Randall L. Kincaid, Michael J. Tocci, and Edward 
A. O’Neill. 1992. “FK-506- and CsA-Sensitive Activation of the Interleukin-2 
Promoter by Calcineurin.” Nature 357 (6380): 692–94. 
https://doi.org/10.1038/357692a0. 
O’Shea, John J., Averil Ma, and Peter Lipsky. 2002. “Cytokines and Autoimmunity.” 
Nature Reviews Immunology. European Association for Cardio-Thoracic Surgery. 
https://doi.org/10.1038/nri702. 
Patro, Rob, Geet Duggal, Michael I. Love, Rafael A. Irizarry, and Carl Kingsford. 2017. 
“Salmon Provides Fast and Bias-Aware Quantification of Transcript Expression.” 




Peltz, Gary. 1997. “Transcription Factors in Immune-Mediated Disease.” Current 
Opinion in Biotechnology 8 (4): 467–73. https://doi.org/10.1016/S0958-
1669(97)80070-5. 
Piraino, Scott W., and Simon J. Furney. 2017. “Identification of Coding and Non-Coding 
Mutational Hotspots in Cancer Genomes.” BMC Genomics 18 (1): 17. 
https://doi.org/10.1186/s12864-016-3420-9. 
Pon, Julia R., and Marco A. Marra. 2015. “Driver and Passenger Mutations in Cancer.” 
Annual Review of Pathology: Mechanisms of Disease 10 (1): 25–50. 
https://doi.org/10.1146/annurev-pathol-012414-040312. 
Qin, Tao, Bai Li, Xiaoyue Feng, Shujun Fan, Lei Liu, Dandan Liu, Jun Mao, et al. 2018. 
“Abnormally Elevated USP37 Expression in Breast Cancer Stem Cells Regulates 
Stemness, Epithelial-Mesenchymal Transition and Cisplatin Sensitivity.” Journal of 
Experimental and Clinical Cancer Research 37 (1). https://doi.org/10.1186/s13046-
018-0934-9. 
Quang, Daniel, and Xiaohui Xie. 2019. “FactorNet: A Deep Learning Framework for 
Predicting Cell Type Specific Transcription Factor Binding from Nucleotide-
Resolution Sequential Data.” Methods 166 (August): 40–47. 
https://doi.org/10.1016/j.ymeth.2019.03.020. 
Quinlan, Aaron R, and Ira M Hall. 2010. “BEDTools: A Flexible Suite of Utilities for 
Comparing Genomic Features.” Bioinformatics (Oxford, England) 26 (6): 841–42. 
https://doi.org/10.1093/bioinformatics/btq033. 
Rao, Anjana, Chun Luo, and Patrick G. Hogan. 1997. “TRANSCRIPTION FACTORS 
OF THE NFAT FAMILY:Regulation and Function.” Annual Review of Immunology 
15 (1): 707–47. https://doi.org/10.1146/annurev.immunol.15.1.707. 
Ravasi, T., H. Suzuki, C. V. Cannistraci, S. Katayama, V. B. Bajic, K. Tan, A. Akalin, et 
al. 2010. “An Atlas of Combinatorial Transcriptional Regulation in Mouse and 
Man.” Cell 140 (5): 744–52. https://doi.org/10.1016/j.cell.2010.01.044. 
Reece-Hoyes, John S., A. Rasim Barutcu, Rachel Patton McCord, Jun Seop Jeong, Lizhi 
Jiang, Andrew MacWilliams, Xinping Yang, et al. 2011. “Yeast One-Hybrid Assays 
for Gene-Centered Human Gene Regulatory Network Mapping.” Nature Methods 8 
(12): 1050–54. https://doi.org/10.1038/nmeth.1764. 
Reece-Hoyes, John S., Alos Diallo, Bryan Lajoie, Amanda Kent, Shaleen Shrestha, 
Sreenath Kadreppa, Colin Pesyna, Job Dekker, Chad L. Myers, and Albertha J.M. 
Walhout. 2011. “Enhanced Yeast One-Hybrid Assays for High-Throughput Gene-





Rentzsch, Philipp, Daniela Witten, Gregory M Cooper, Jay Shendure, and Martin 
Kircher. 2019. “CADD: Predicting the Deleteriousness of Variants throughout the 
Human Genome.” Nucleic Acids Research 47 (D1): D886–94. 
https://doi.org/10.1093/nar/gky1016. 
Rheinbay, Esther, Morten Muhlig Nielsen, Federico Abascal, Jeremiah A. Wala, Ofer 
Shapira, Grace Tiao, Henrik Hornshøj, et al. 2020. “Analyses of Non-Coding 
Somatic Drivers in 2,658 Cancer Whole Genomes.” Nature 578 (7793): 102–11. 
https://doi.org/10.1038/s41586-020-1965-x. 
Rheinbay, Esther, Prasanna Parasuraman, Jonna Grimsby, Grace Tiao, Jesse M. Engreitz, 
Jaegil Kim, Michael S. Lawrence, et al. 2017a. “Recurrent and Functional 
Regulatory Mutations in Breast Cancer.” Nature 547 (7661): 55–60. 
https://doi.org/10.1038/nature22992. 
———. 2017b. “Recurrent and Functional Regulatory Mutations in Breast Cancer.” 
Nature 547 (7661): 55–60. https://doi.org/10.1038/nature22992. 
Roadmap Epigenomics Consortium, Anshul Kundaje, Wouter Meuleman, Jason Ernst, 
Misha Bilenky, Angela Yen, Alireza Heravi-Moussavi, et al. 2015. “Integrative 
Analysis of 111 Reference Human Epigenomes.” Nature 518 (7539): 317–29. 
https://doi.org/10.1038/nature14248. 
Roberts, Steven A., Michael S. Lawrence, Leszek J. Klimczak, Sara A. Grimm, David 
Fargo, Petar Stojanov, Adam Kiezun, et al. 2013. “An APOBEC Cytidine 
Deaminase Mutagenesis Pattern Is Widespread in Human Cancers.” Nature Genetics 
45 (9): 970–76. https://doi.org/10.1038/ng.2702. 
Rolland, Thomas, Murat Taşan, Benoit Charloteaux, Samuel J. Pevzner, Quan Zhong, 
Nidhi Sahni, Song Yi, et al. 2014. “A Proteome-Scale Map of the Human 
Interactome Network.” Cell 159 (5): 1212–26. 
https://doi.org/10.1016/j.cell.2014.10.050. 
Rosa, Jaime S., Rebecca L. Flores, Stacy R. Oliver, Andria M. Pontello, Frank P. 
Zaldivar, and Pietro R. Galassetti. 2008. “Sustained IL-1α, IL-4, and IL-6 Elevations 
Following Correction of Hyperglycemia in Children with Type 1 Diabetes 
Mellitus.” Pediatric Diabetes 9 (1): 9–16. https://doi.org/10.1111/j.1399-
5448.2007.00243.x. 
Rosenberg, Alexander B., Rupali P. Patwardhan, Jay Shendure, and Georg Seelig. 2015. 
“Learning the Sequence Determinants of Alternative Splicing from Millions of 
Random Sequences.” Cell 163 (3): 698–711. 
https://doi.org/10.1016/j.cell.2015.09.054. 




Kleinman, William J. Murphy, and Joost J. Oppenheim. 2001. “ Eotaxin (CCL11) 
Induces In Vivo Angiogenic Responses by Human CCR3 + Endothelial Cells .” The 
Journal of Immunology 166 (12): 7571–78. 
https://doi.org/10.4049/jimmunol.166.12.7571. 
Salton, Maayan, Wojciech K. Kasprzak, Ty Voss, Bruce A. Shapiro, Poulikos I. 
Poulikakos, and Tom Misteli. 2015. “Inhibition of Vemurafenib-Resistant 
Melanoma by Interference with Pre-MRNA Splicing.” Nature Communications 6 
(May). https://doi.org/10.1038/ncomms8103. 
Sánchez, Elena, Rogelio J. Palomino-Morales, Norberto Ortego-Centeno, Juan Jiménez-
Alonso, Miguel A. González-Gay, Miguel A. López-Nevot, Julio Sánchez-Román, 
et al. 2009. “Identification of a New Putative Functional IL18 Gene Variant through 
an Association Study in Systemic Lupus Erythematosus.” Human Molecular 
Genetics 18 (19): 3739–48. https://doi.org/10.1093/hmg/ddp301. 
Saunders, Christopher T., Wendy S.W. Wong, Sajani Swamy, Jennifer Becq, Lisa J. 
Murray, and R. Keira Cheetham. 2012. “Strelka: Accurate Somatic Small-Variant 
Calling from Sequenced Tumor-Normal Sample Pairs.” Bioinformatics 28 (14): 
1811–17. https://doi.org/10.1093/bioinformatics/bts271. 
Schadendorf, Möller, Algermissen, Worm, Sticherling, and Czarnetzki. 1994. “IL-8 
Produced by Human Malignant Melanoma Cells in Vitro Is an Essential Autocrine  
Growth Factor.” Journal of Immunology (Baltimore, Md. : 1950). United States. 
Schaub, Marc A., Alan P. Boyle, Anshul Kundaje, Serafim Batzoglou, and Michael 
Snyder. 2012. “Linking Disease Associations with Regulatory Information in the 
Human Genome.” Genome Research 22 (9): 1748–59. 
https://doi.org/10.1101/gr.136127.111. 
Schmidt, Dominic, Michael D. Wilson, Benoit Ballester, Petra C. Schwalie, Gordon D. 
Brown, Aileen Marshall, Claudia Kutter, et al. 2010. “Five-Vertebrate ChlP-Seq 
Reveals the Evolutionary Dynamics of Transcription Factor Binding.” Science 328 
(5981): 1036–40. https://doi.org/10.1126/science.1186176. 
Sewell, Jared A., and Juan I. Fuxman Bass. 2017. “Cellular Network Perturbations by 
Disease-Associated Variants.” Current Opinion in Systems Biology. Elsevier Ltd. 
https://doi.org/10.1016/j.coisb.2017.04.009. 
Shema, Efrat, Itay Tirosh, Yael Aylon, Jing Huang, Chaoyang Ye, Neta Moskovits, Nina 
Raver-Shapira, et al. 2008. “The Histone H2B-Specific Ubiquitin Ligase 
RNF20/HBREl Acts as a Putative Tumor Suppressor through Selective Regulation 





Shepherd, Jonathan H., Ivan P. Uray, Abhijit Mazumdar, Anna Tsimelzon, Michelle 
Savage, Susan G. Hilsenbeck, and Powel H. Brown. 2016. “The SOX11 
Transcription Factor Is a Critical Regulator of Basal-like Breast Cancer Growth, 
Invasion, and Basal-like Gene Expression.” Oncotarget 7 (11): 13106–21. 
https://doi.org/10.18632/oncotarget.7437. 
Shi, Wenqiang, Oriol Fornes, Anthony Mathelier, and Wyeth W Wasserman. 2016. 
“Evaluating the Impact of Single Nucleotide Variants on Transcription Factor 
Binding.” Nucleic Acids Research 44 (21): 10106–16. 
https://doi.org/10.1093/nar/gkw691. 
Shin, Sunyoung, Rebecca Hudson, Christopher Harrison, Mark Craven, and Sündüz 
Keleş. 2019. “AtSNP Search: A Web Resource for Statistically Evaluating Influence 
of Human Genetic  Variation on Transcription Factor Binding.” Bioinformatics 
(Oxford, England) 35 (15): 2657–59. 
https://doi.org/10.1093/bioinformatics/bty1010. 
Shiraishi, Yuichi, Yusuke Sato, Kenichi Chiba, Yusuke Okuno, Yasunobu Nagata, 
Kenichi Yoshida, Norio Shiba, et al. 2013. “An Empirical Bayesian Framework for 
Somatic Mutation Detection from Cancer Genome Sequencing Data.” Nucleic Acids 
Research 41 (7). https://doi.org/10.1093/nar/gkt126. 
Shlyueva, Daria, Gerald Stampfel, and Alexander Stark. 2014. “Transcriptional 
Enhancers: From Properties to Genome-Wide Predictions.” Nature Reviews 
Genetics. Nature Publishing Group. https://doi.org/10.1038/nrg3682. 
Shrestha, Shaleen, Jared Allan Sewell, Clarissa Stephanie Santoso, Elena Forchielli, 
Sebastian Carrasco Pro, Melissa Martinez, and Juan Ignacio Fuxman Bass. 2019. 
“Discovering Human Transcription Factor Physical Interactions with Genetic 
Variants, Novel DNA Motifs, and Repetitive Elements Using Enhanced Yeast One-
Hybrid Assays.” Genome Research 29 (9): 1533–44. 
https://doi.org/10.1101/gr.248823.119. 
Shuai, Shimin, Federico Abascal, Samirkumar B. Amin, Gary D. Bader, Pratiti 
Bandopadhayay, Jonathan Barenboim, Rameen Beroukhim, et al. 2020. “Combined 
Burden and Functional Impact Tests for Cancer Driver Discovery Using 
DriverPower.” Nature Communications 11 (1). https://doi.org/10.1038/s41467-019-
13929-1. 
Signori, Emanuela, Claudia Bagni, Sara Papa, Beatrice Primerano, Monica Rinaldi, 
Francesco Amaldi, and Vito Michele Fazio. 2001. “A Somatic Mutation in the 
5′UTR of BRCA1 Gene in Sporadic Breast Cancer Causes Down-Modulation of 





Singh, Ram Raj, Vijay Saxena, Song Zang, Lily Li, Fred D. Finkelman, David P. Witte, 
and Chaim O. Jacob. 2003. “Differential Contribution of IL-4 and STAT6 vs 
STAT4 to the Development of Lupus Nephritis.” The Journal of Immunology 170 
(9): 4818–25. https://doi.org/10.4049/jimmunol.170.9.4818. 
Smith, Robin P., Leila Taher, Rupali P. Patwardhan, Mee J. Kim, Fumitaka Inoue, Jay 
Shendure, Ivan Ovcharenko, and Nadav Ahituv. 2013. “Massively Parallel 
Decoding of Mammalian Regulatory Sequences Supports a Flexible Organizational 
Model.” Nature Genetics 45 (9): 1021–28. https://doi.org/10.1038/ng.2713. 
Sondka, Zbyslaw, Sally Bamford, Charlotte G. Cole, Sari A. Ward, Ian Dunham, and 
Simon A. Forbes. 2018. “The COSMIC Cancer Gene Census: Describing Genetic 
Dysfunction across All Human Cancers.” Nature Reviews Cancer. Nature 
Publishing Group. https://doi.org/10.1038/s41568-018-0060-1. 
Spitz, François, and Eileen E.M. Furlong. 2012. “Transcription Factors: From Enhancer 
Binding to Developmental Control.” Nature Reviews Genetics. Nat Rev Genet. 
https://doi.org/10.1038/nrg3207. 
Stenson, Peter D., Matthew Mort, Edward V. Ball, Katy Howells, Andrew D. Phillips, 
David N. Cooper, and Nick S.T. Thomas. 2009. “The Human Gene Mutation 
Database: 2008 Update.” Genome Medicine. Genome Med. 
https://doi.org/10.1186/gm13. 
Stenson, Peter D., Matthew Mort, Edward V. Ball, Katy Shaw, Andrew D. Phillips, and 
David N. Cooper. 2014. “The Human Gene Mutation Database: Building a 
Comprehensive Mutation Repository for Clinical and Molecular Genetics, 
Diagnostic Testing and Personalized Genomic Medicine.” Human Genetics. Hum 
Genet. https://doi.org/10.1007/s00439-013-1358-4. 
Stephen-Victor, Emmanuel, Helmut Fickenscher, and Jagadeesh Bayry. 2016. “IL-26: An 
Emerging Proinflammatory Member of the IL-10 Cytokine Family with 
Multifaceted Actions in Antiviral, Antimicrobial, and Autoimmune Responses.” 
PLoS Pathogens. Public Library of Science. 
https://doi.org/10.1371/journal.ppat.1005624. 
Stunnenberg, Hendrik G., Sergio Abrignani, David Adams, Melanie de Almeida, Lucia 
Altucci, Viren Amin, Ido Amit, et al. 2016. “The International Human Epigenome 
Consortium: A Blueprint for Scientific Collaboration and Discovery.” Cell. Cell 
Press. https://doi.org/10.1016/j.cell.2016.11.007. 
Supek, Fran, Belén Miñana, Juan Valcárcel, Toni Gabaldón, and Ben Lehner. 2014. 
“Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers.” 




Tak, Yu Gyoung, and Peggy J. Farnham. 2015. “Making Sense of GWAS: Using 
Epigenomics and Genome Engineering to Understand the Functional Relevance of 
SNPs in Non-Coding Regions of the Human Genome.” Epigenetics and Chromatin. 
BioMed Central Ltd. https://doi.org/10.1186/s13072-015-0050-4. 
Tanaka, Ken Ichiro, Takushi Namba, Yasuhiro Arai, Mitsuaki Fujimoto, Hiroaki Adachi, 
Gen Sobue, Koji Takeuchi, Akira Nakai, and Tohru Mizushima. 2007. “Genetic 
Evidence for a Protective Role for Heat Shock Factor 1 and Heat Shock Protein 70 
against Colitis.” Journal of Biological Chemistry 282 (32): 23240–52. 
https://doi.org/10.1074/jbc.M704081200. 
Taniguchi, Tadatsugu, Kouetsu Ogasawara, Akinori Takaoka, and Nobuyuki Tanaka. 
2001. “ IRF F AMILY OF T RANSCRIPTION F ACTORS AS R EGULATORS 
OF H OST D EFENSE .” Annual Review of Immunology 19 (1): 623–55. 
https://doi.org/10.1146/annurev.immunol.19.1.623. 
Tewhey, Ryan, Dylan Kotliar, Daniel S Park, Brandon Liu, Sarah Winnicki, Steven K 
Reilly, Kristian G Andersen, et al. 2016. “Direct Identification of Hundreds of 
Expression-Modulating Variants Using a Multiplexed Reporter Assay.” Cell 165 
(6): 1519–29. https://doi.org/10.1016/j.cell.2016.04.027. 
Thanos, Dimitris, and Tom Maniatis. 1995. “Virus Induction of Human IFNβ Gene 
Expression Requires the Assembly of an Enhanceosome.” Cell 83 (7): 1091–1100. 
https://doi.org/10.1016/0092-8674(95)90136-1. 
Thomas-Chollier, Morgane, Matthieu Defrance, Alejandra Medina-Rivera, Olivier Sand, 
Carl Herrmann, Denis Thieffry, and Jacques van Helden. 2011. “RSAT 2011: 
Regulatory Sequence Analysis Tools.” Nucleic Acids Research 39 (Web Server 
issue): W86-91. https://doi.org/10.1093/nar/gkr377. 
Thomas, Mary C., and Cheng Ming Chiang. 2006. “The General Transcription 
Machinery and General Cofactors.” Critical Reviews in Biochemistry and Molecular 
Biology. Crit Rev Biochem Mol Biol. https://doi.org/10.1080/10409230600648736. 
Touzet, Hélène, and Jean-Stéphane Varré. 2007a. “Efficient and Accurate P-Value 
Computation for Position Weight Matrices.” Algorithms for Molecular Biology 2 
(1): 15. https://doi.org/10.1186/1748-7188-2-15. 
Touzet, Hélène, and Jean Stéphane Varré. 2007b. “Efficient and Accurate P-Value 
Computation for Position Weight Matrices.” Algorithms for Molecular Biology 2 
(1). https://doi.org/10.1186/1748-7188-2-15. 
Tsai, Eunice Y., James V. Falvo, Alla V. Tsytsykova, Amy K. Barczak, Andreas M. 
Reimold, Laurie H. Glimcher, Matthew J. Fenton, David C. Gordon, Ian F. Dunn, 




Involving Ets, Elk-1, Sp1, and CREB Binding Protein and P300 Is Recruited to the 
Tumor Necrosis Factor Alpha Promoter In Vivo.” Molecular and Cellular Biology 
20 (16): 6084–94. https://doi.org/10.1128/mcb.20.16.6084-6094.2000. 
Tsytsykova, Alla V., and Anne E. Goldfeld. 2002. “Inducer-Specific Enhanceosome 
Formation Controls Tumor Necrosis Factor Alpha Gene Expression in T 
Lymphocytes.” Molecular and Cellular Biology 22 (8): 2620–31. 
https://doi.org/10.1128/mcb.22.8.2620-2631.2002. 
Tu, Xin, Shaofang Nie, Yuhua Liao, Hongsong Zhang, Qian Fan, Chengqi Xu, Ying Bai, 
et al. 2013. “The IL-33-ST2L Pathway Is Associated with Coronary Artery Disease 
in a Chinese Han Population.” American Journal of Human Genetics 93 (4): 652–
60. https://doi.org/10.1016/j.ajhg.2013.08.009. 
Turner, Mark D., Belinda Nedjai, Tara Hurst, and Daniel J. Pennington. 2014. “Cytokines 
and Chemokines: At the Crossroads of Cell Signalling and Inflammatory Disease.” 
Biochimica et Biophysica Acta - Molecular Cell Research. Elsevier. 
https://doi.org/10.1016/j.bbamcr.2014.05.014. 
Uhlen, Mathias, Cheng Zhang, Sunjae Lee, Evelina Sjöstedt, Linn Fagerberg, 
Gholamreza Bidkhori, Rui Benfeitas, et al. 2017. “A Pathology Atlas of the Human 
Cancer Transcriptome.” Science 357 (6352). 
https://doi.org/10.1126/science.aan2507. 
Ulirsch, Jacob C., Satish K. Nandakumar, Li Wang, Felix C. Giani, Xiaolan Zhang, Peter 
Rogov, Alexandre Melnikov, et al. 2016. “Systematic Functional Dissection of 
Common Genetic Variation Affecting Red Blood Cell Traits.” Cell 165 (6): 1530–
45. https://doi.org/10.1016/j.cell.2016.04.048. 
Valouev, Anton, David S. Johnson, Andreas Sundquist, Catherine Medina, Elizabeth 
Anton, Serafim Batzoglou, Richard M. Myers, and Arend Sidow. 2008a. “Genome-
Wide Analysis of Transcription Factor Binding Sites Based on ChIP-Seq Data.” 
Nature Methods 5 (9): 829–34. https://doi.org/10.1038/nmeth.1246. 
Valouev, Anton, David S Johnson, Andreas Sundquist, Catherine Medina, Elizabeth 
Anton, Serafim Batzoglou, Richard M Myers, and Arend Sidow. 2008b. “Genome-
Wide Analysis of Transcription Factor Binding Sites Based on ChIP-Seq Data.” 
Nature Methods 5 (9): 829–34. https://doi.org/10.1038/nmeth.1246. 
Vaquerizas, Juan M., Sarah K. Kummerfeld, Sarah A. Teichmann, and Nicholas M. 
Luscombe. 2009. “A Census of Human Transcription Factors: Function, Expression 
and Evolution.” Nature Reviews Genetics. Nat Rev Genet. 
https://doi.org/10.1038/nrg2538. 




Diaz, and Kenneth W. Kinzler. 2013. “Cancer Genome Landscapes.” Science. 
American Association for the Advancement of Science. 
https://doi.org/10.1126/science.1235122. 
Wang, J., C. Lu, D. Min, Z. Wang, and X. Ma. 2007. “A Mutation in the 5′ Untranslated 
Region of the BRCA1 Gene in Sporadic Breast Cancer Causes Downregulation of 
Translation Efficiency.” Journal of International Medical Research 35 (4): 564–73. 
https://doi.org/10.1177/147323000703500417. 
Wei, Sheng, Jiangong Niu, Hui Zhao, Zhensheng Liu, Li E. Wang, Younghun Han, Wei 
V. Chen, et al. 2011. “Association of a Novel Functional Promoter Variant 
(Rs2075533 C>T) in the Apoptosis Gene TNFSF8 with Risk of Lung Cancer-a 
Finding from Texas Lung Cancer Genome-Wide Association Study.” 
Carcinogenesis 32 (4): 507–15. https://doi.org/10.1093/carcin/bgr014. 
Weinhold, Nils, Anders Jacobsen, Nikolaus Schultz, Chris Sander, and William Lee. 
2014. “Genome-Wide Analysis of Noncoding Regulatory Mutations in Cancer.” 
Nature Genetics 46 (11): 1160–65. https://doi.org/10.1038/ng.3101. 
Weinstein, John N., Eric A. Collisson, Gordon B. Mills, Kenna R.Mills Shaw, Brad A. 
Ozenberger, Kyle Ellrott, Chris Sander, et al. 2013. “The Cancer Genome Atlas Pan-
Cancer Analysis Project.” Nature Genetics. Nature Publishing Group. 
https://doi.org/10.1038/ng.2764. 
Weirauch, Matthew T., Ally Yang, Mihai Albu, Atina G. Cote, Alejandro Montenegro-
Montero, Philipp Drewe, Hamed S. Najafabadi, et al. 2014. “Determination and 
Inference of Eukaryotic Transcription Factor Sequence Specificity.” Cell 158 (6): 
1431–43. https://doi.org/10.1016/j.cell.2014.08.009. 
Wen, Xiaoquan, Roger Pique-Regi, and Francesca Luca. 2017. “Integrating Molecular 
QTL Data into Genome-Wide Genetic Association Analysis: Probabilistic 
Assessment of Enrichment and Colocalization.” PLoS Genetics 13 (3). 
https://doi.org/10.1371/journal.pgen.1006646. 
Wishart, David S., Yannick D. Feunang, An C. Guo, Elvis J. Lo, Ana Marcu, Jason R. 
Grant, Tanvir Sajed, et al. 2018. “DrugBank 5.0: A Major Update to the DrugBank 
Database for 2018.” Nucleic Acids Research 46 (D1): D1074–82. 
https://doi.org/10.1093/nar/gkx1037. 
Wong, Henry Sung Ching, Che Mai Chang, Xiao Liu, Wan Chen Huang, and Wei Chiao 
Chang. 2016. “Characterization of Cytokinome Landscape for Clinical Responses in 
Human Cancers.” OncoImmunology 5 (11). 
https://doi.org/10.1080/2162402X.2016.1214789. 




“BioGPS: Building Your Own Mash-up of Gene Annotations and Expression 
Profiles.” Nucleic Acids Research 44 (D1): D313–16. 
https://doi.org/10.1093/nar/gkv1104. 
Wu, Ren Chin, Ayse Ayhan, Daichi Maeda, Kyu Rae Kim, Blaise A. Clarke, Patricia 
Shaw, Michael Herman Chui, Barry Rosen, Ie Ming Shih, and Tian Li Wang. 2014. 
“Frequent Somatic Mutations of the Telomerase Reverse Transcriptase Promoter in 
Ovarian Clear Cell Carcinoma but Not in Other Major Types of Gynaecological 
Malignancy.” Journal of Pathology 232 (4): 473–81. 
https://doi.org/10.1002/path.4315. 
Wunderlich, Zeba, and Leonid A. Mirny. 2009. “Different Gene Regulation Strategies 
Revealed by Analysis of Binding Motifs.” Trends in Genetics. Trends Genet. 
https://doi.org/10.1016/j.tig.2009.08.003. 
Xiao, T., J. J. Zhu, S. Huang, C. Peng, S. He, J. Du, R. Hong, et al. 2017. 
“Phosphorylation of NFAT3 by CDK3 Induces Cell Transformation and Promotes 
Tumor Growth in Skin Cancer.” Oncogene 36 (20): 2835–45. 
https://doi.org/10.1038/onc.2016.434. 
Xie, Shanhai, Janet E. Price, Mario Luca, Didier Jean, Zeèv Ronai, and Menashe Bar-Eli. 
1997. “Dominant-Negative CREB Inhibits Tumor Growth and Metastasis of Human 
Melanoma Cells.” Oncogene 15 (17): 2069–75. 
https://doi.org/10.1038/sj.onc.1201358. 
Xu, Zongli, and Jack A Taylor. 2009. “SNPinfo: Integrating GWAS and Candidate Gene 
Information into Functional SNP  Selection for Genetic Association Studies.” 
Nucleic Acids Research 37 (Web Server issue): W600-5. 
https://doi.org/10.1093/nar/gkp290. 
Yang, Seoyeon, Ji Yeon Lee, Ho Hur, Ji Hoon Oh, and Myoung Hee Kim. 2018. “Up-
Regulation of HOXB Cluster Genes Are Epigenetically Regulated in Tamoxifen-
Resistant MCF7 Breast Cancer Cells.” BMB Reports 51 (9): 450–55. 
https://doi.org/10.5483/BMBRep.2018.51.9.020. 
Yang, Xuexian O., Bhanu P. Pappu, Roza Nurieva, Askar Akimzhanov, Hong Soon 
Kang, Yeonseok Chung, Li Ma, et al. 2008. “T Helper 17 Lineage Differentiation Is 
Programmed by Orphan Nuclear Receptors RORα and RORγ.” Immunity 28 (1): 
29–39. https://doi.org/10.1016/j.immuni.2007.11.016. 
Yi, Woelsung, Sanjay Gupta, Edd Ricker, Michela Manni, Rolf Jessberger, Yurii 
Chinenov, Henrik Molina, and Alessandra B. Pernis. 2017. “The MTORC1-4E-BP-
EIF4E Axis Controls de Novo Bcl6 Protein Synthesis in T Cells and Systemic 





Yiu Chan, Calvin Wing, Zuguang Gu, Matthias Bieg, Roland Eils, and Carl Herrmann. 
2019. “Impact of Cancer Mutational Signatures on Transcription Factor Motifs in 
the Human Genome.” BMC Medical Genomics 12 (1). 
https://doi.org/10.1186/s12920-019-0525-4. 
Yu, H. H., P. H. Liu, Y. C. Lin, W. J. Chen, J. H. Lee, L. C. Wang, Y. H. Yang, and B. L. 
Chiang. 2010. “Interleukin 4 and STAT6 Gene Polymorphisms Are Associated with 
Systemic Lupus Erythematosus in Chinese Patients.” Lupus 19 (10): 1219–28. 
https://doi.org/10.1177/0961203310371152. 
Zajac-Kaye, Maria, Edward P. Gelmann, and David Levens. 1988. “A Point Mutation in 
the C-Myc Locus of a Burkitt Lymphoma Abolishes Binding of a Nuclear Protein.” 
Science 240 (4860): 1776–80. https://doi.org/10.1126/science.2454510. 
Zhang, Baojie, Deng Chen, Bin Liu, Frank J. Dekker, and Wim J. Quax. 2020. “A Novel 
Histone Acetyltransferase Inhibitor A485 Improves Sensitivity of Non-Small-Cell 
Lung Carcinoma Cells to TRAIL.” Biochemical Pharmacology 175 (May). 
https://doi.org/10.1016/j.bcp.2020.113914. 
Zhang, Jun Ming, and Jianxiong An. 2007. “Cytokines, Inflammation, and Pain.” 
International Anesthesiology Clinics. NIH Public Access. 
https://doi.org/10.1097/AIA.0b013e318034194e. 
Zhang, Peng, Ji Han Xia, Jing Zhu, Ping Gao, Yi Jun Tian, Meijun Du, Yong Chen Guo, 
et al. 2018. “High-Throughput Screening of Prostate Cancer Risk Loci by Single 
Nucleotide Polymorphisms Sequencing.” Nature Communications 9 (1). 
https://doi.org/10.1038/s41467-018-04451-x. 
Zhang, Xianxiang, Guangwei Liu, Lei Ding, Tao Jiang, Shihong Shao, Yuan Gao, and 
Yun Lu. 2018. “HOXA3 Promotes Tumor Growth of Human Colon Cancer through 
Activating EGFR/Ras/Raf/MEK/ERK Signaling Pathway.” Journal of Cellular 
Biochemistry 119 (3): 2864–74. https://doi.org/10.1002/jcb.26461. 
Zhao, Wenxue, Joshua L. Pollack, Denitza P. Blagev, Noah Zaitlen, Michael T. 
McManus, and David J. Erle. 2014. “Massively Parallel Functional Annotation of 3’ 
Untranslated Regions.” Nature Biotechnology 32 (4): 387–91. 
https://doi.org/10.1038/nbt.2851. 
Zhou, Yingyao, Bin Zhou, Lars Pache, Max Chang, Alireza Hadj Khodabakhshi, Olga 
Tanaseichuk, Christopher Benner, and Sumit K. Chanda. 2019. “Metascape Provides 
a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets.” Nature 
Communications 10 (1). https://doi.org/10.1038/s41467-019-09234-6. 
Zhu, Fangjie, Lucas Farnung, Eevi Kaasinen, Biswajyoti Sahu, Yimeng Yin, Bei Wei, 
Svetlana O. Dodonova, et al. 2018. “The Interaction Landscape between 
165 
Transcription Factors and the Nucleosome.” Nature 562 (7725): 76–81. 
https://doi.org/10.1038/s41586-018-0549-5. 
Zhu, Min, Joanne S. Allard, Yongqing Zhang, Evelyn Perez, Edward L. Spangler, Kevin 
G. Becker, and Peter R. Rapp. 2014. “Age-Related Brain Expression and Regulation
of the Chemokine CCL4/MIP-1β in APP/PS1 Double-Transgenic Mice.” Journal of
Neuropathology and Experimental Neurology 73 (4): 362–74.
https://doi.org/10.1097/NEN.0000000000000060.
Zhu, Qian, Aaron K. Wong, Arjun Krishnan, Miriam R. Aure, Alicja Tadych, Ran Zhang, 
David C. Corney, et al. 2015. “Targeted Exploration and Analysis of Large Cross-
Platform Human Transcriptomic Compendia.” Nature Methods 12 (3): 211–14. 
https://doi.org/10.1038/nmeth.3249. 
Zia, Amin, and Alan M. Moses. 2012. “Towards a Theoretical Understanding of False 
Positives in DNA Motif Finding.” BMC Bioinformatics 13 (1): 151. 
https://doi.org/10.1186/1471-2105-13-151. 
Zong, Chenghang, Sijia Lu, Alec R. Chapman, and X. Sunney Xie. 2012. “Genome-Wide 
Detection of Single-Nucleotide and Copy-Number Variations of a Single Human 
Cell.” Science 338 (6114): 1622–26. https://doi.org/10.1126/science.1229164. 
166 
CURRICULUM VITAE 
167 
168 
169 
170 
